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vWHAT IS A WITNESS SEMINAR?
The Witness Seminar is a specialized form of oral history, where several 
individuals associated with a particular set of circumstances or events are invited 
to meet together to discuss, debate, and agree or disagree about their memories. 
The meeting is recorded, transcribed and edited for publication. 
This format was first devised and used by the Wellcome Trust’s History of 
Twentieth Century Medicine Group in 1993 to address issues associated with 
the discovery of monoclonal antibodies. We developed this approach after 
holding a conventional seminar, given by a medical historian, on the discovery 
of interferon. Many members of the invited audience were scientists or others 
involved in that work, and the detailed and revealing discussion session 
afterwards alerted us to the importance of recording ‘communal’ eyewitness 
testimonies. We learned that the Institute for Contemporary British History 
held meetings to examine modern political, diplomatic and economic history, 
which they called Witness Seminars, and this seemed a suitable title for us to 
use also. 
The unexpected success of our first Witness Seminar, as assessed by the 
willingness of the participants to attend, speak frankly, agree and disagree, and 
also by many requests for its transcript, encouraged us to develop the Witness 
Seminar model into a full programme, and since then more than 50 meetings 
have been held and published on a wide array of biomedical topics.1 These 
seminars have proved an ideal way to bring together clinicians, scientists, and 
others interested in contemporary medical history to share their memories. We 
are not seeking a consensus, but are providing the opportunity to hear an array 
of voices, many little known, of individuals who were ‘there at the time’ and 
thus able to question, ratify or disagree with others’ accounts – a form of open 
peer-review. The material records of the meeting also create archival sources for 
present and future use.
The History of Twentieth Century Medicine Group became a part of the 
Wellcome Trust’s Centre for the History of Medicine at UCL from October 
2000 to September 2010. It has been part of the School of History, Queen 
Mary, University of London, since October 2010, as the History of Modern 
Biomedicine Research Group, which the Wellcome Trust funds principally 
1  See pages 137–142 for a full list of Witness Seminars held, details of the published volumes and other 
related publications.
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under a Strategic Award entitled ‘The Makers of Modern Biomedicine’. The 
Witness Seminar format continues to be a major part of that programme, 
although now the subjects are largely focused on areas of strategic importance to 
the Wellcome Trust, including the neurosciences, clinical genetics, and medical 
technology.2
Once an appropriate topic has been agreed, usually after discussion with 
a specialist adviser, suitable participants are identified and invited. As the 
organization of the seminar progresses and the participants’ list is compiled, a 
flexible outline plan for the meeting is devised, with assistance from the meeting’s 
designated chairman/moderator. Each participant is sent an attendance list and 
a copy of this programme before the meeting.  Seminars last for about four 
hours; occasionally full-day meetings have been held. After each meeting the 
raw transcript is sent to every participant, each of whom is asked to check his or 
her own contribution and to provide brief biographical details for an appendix. 
The editors incorporate participants’ minor corrections and turn the transcript 
into readable text, with footnotes, appendices, a glossary and a bibliography. 
Extensive research and liaison with the participants is conducted to produce 
the final script, which is then sent to every contributor for approval and to 
assign copyright to the Wellcome Trust. Copies of the original, and edited, 
transcripts and additional correspondence generated by the editorial process are 
all deposited with the records of each meeting in the Wellcome Library, London 
(archival reference GC/253) and are available for study.
For all our volumes, we hope that, even if the precise details of the more 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable to all readers. Our aim is that the volumes 
inform those with a general interest in the history of modern medicine and 
medical science; provide historians with new insights, fresh material for study, 
and further themes for research; and emphasize to the participants that their 
own working lives are of proper and necessary concern to historians.
2  See our Group’s website at http://www.history.qmul.ac.uk/research/modbiomed (visited 8 April 2014). 
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INTRODUCTION
Fifty years of migraine
My first memory of migraine is from the 1970s. My childhood friend’s mother 
would simply disappear for a couple of days at a time, and I was told this 
was because she had migraine. I wondered what on earth could do this to a 
person. But attempts at treatment came before understanding when as a newly 
qualified doctor in 1981, I saw a young woman with migraine who had quite a 
taste for chocolate and the treatment seemed so obvious to me. Later I learned 
that pizotifen could be used and as this was the only treatment I knew, other 
than analgesia, I was stumped when a patient had already tried pizotifen. CT 
scans were new then and offered a way of appearing to do something, though 
now simply imaging the patient is a strategy I disparage. Around that time, a 
leaflet from the City of London Migraine Clinic advised regular naproxen in 
place of as-required frequent analgesia, a strategy I still use. As a neurology 
registrar in the early 1980s I recall a patient who appeared to be describing 
a condition I’d only ever read about: cluster headache. I asked my boss who 
told me he had never seen a case! The next decade brought two great advances: 
firstly attending the International Headache Society Meeting and beginning to 
understand Medication Overuse Headache; secondly, triptans were discovered 
and licensed. Suddenly we had a specific and highly effective acute rescue, and 
prophylaxis seemed very out of date.  I had written my thesis on a rare disorder 
of neuromuscular transmission (the Lambert Eaton Myasthenic Syndrome) and 
then realised I needed to be expert in a common disease, so chose headache as 
my sub-specialty. To my great surprise, in the last couple of years, the use of 
Botox as prophylaxis for chronic migraine has brought me back to synaptic 
transmission, in the context of headache. Moving forward, triptans are coming 
off patent and it is increasingly clear that their overuse is as harmful as overuse 
of any other short-term rescue medication. The new therapies now are devices 
to alter nerve function in the head. If we can find a device that aborts headache, 
will overuse bring the same difficulties of rebound and tolerance, as with 
medications? We have treatment, but do we have understanding?
The concept of ‘hemicrania’, that is half head pain, gives us the word migraine; 
yet nowadays we have a separate group of disorders in which a pure hemicrania, 
such as cluster headache, is considered by most to be separate from migraine. 
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Can we now be sure whether migraine is one disease or many? If we start from a 
position of existing knowledge and travel a line of enquiry in migraine, we tend 
to return to the starting point, but facing in a different direction.
Over the last half-century the genesis of migraine knowledge and therapeutics is a 
microcosm of medicine. In 1960 the leading academic neurology unit in the UK 
would study disorders only of the peripheral nervous system, because only when 
those could be understood, can one move to a more complex area such as the central 
nervous system.1 Then, migraine was a psychoneurotic disorder with predisposition 
arising from lack of a Y chromosome. Establishment of migraine as an organic 
disorder arose from understanding migraine aura. Thereafter it becomes clear that 
the absence of aura does not deny the organic nature of the disease. Once we are sure 
that migraine is ‘real’, it becomes worthy of scientific study.
Next, we need a definition. In the absence of a verifiable organic substrate that 
can be demonstrated independently of history (examination and investigation 
being normal), definition is operational rather than pathological. Meaningful 
definition is the essential prerequisite for scientific study. Therefore the 
classification of migraine and of other headache disorders has been the catalyst 
for the therapeutic advances in migraine over the last 50 years.2 This Witness 
Seminar shows how in fact these moved hand-in-hand, rather than stepwise, 
with the development of specific effective migraine therapeutics. 
The location of migraine’s molecular pathology has had a long journey around 
the body – in blood platelets, female pelvic organs, lung, heart, neck, immune 
system, psyche, arteries, or nerves. The strong consensus is now that migraine 
is a disorder of the nerves; within the central nervous system. That’s agreed, 
but where, within the central nervous system? The strongest contender is the 
trigeminal nucleus in the brainstem, though there remains a school of thought 
that the cerebral cortex contains the underlying migraine generator.
Migraine is a disorder of the central nervous system, and relates closely to under-
activity of the neurotransmitter 5-HT (serotonin).3 The development of 5-HT 
agonists, that is triptan drugs, has revolutionized the management of migraine.4 
1  ie the Institute of Neurology, Queen Square. 
2  For discussion on the classification of headaches, see pages 11–15. 
3  For consistency the term ‘5-HT’ has been used throughout and in most cases the term ‘serotonin’ has 
been changed to 5-HT.
4  See pages 33–8 and 42–5. 
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The specificity of triptans for migraine therapy provides support for the headache 
classification, because triptan response is highly specific for migraine compared 
with other headaches. Just don’t mention the fact that cluster headache, one of 
the hemicranias, responds very well to triptans, as does tension type headache 
(in people who also have migraine). But the classification tells us that cluster 
and tension type headache are different disorders from migraine; or could it 
be that migraine is in fact a spectrum disorder, rather than a single illness, in 
which a person with the underlying predisposition to migraine is vulnerable 
also to other types of headache? Still, we have a unifying hypothesis: 5-HT 
deficiency. Yet the cause of that deficiency remains elusive, appearing to result 
from a range of genetic triggers that may act through ion channel dysfunction. 
And are we sure that this is truly a disorder of the central nervous system and 
not the peripheral nervous system?
The advances of the last half-century have led to many effective therapies, the 
very large majority being 5-HT drugs.5 This Witness Seminar describes how 
the older agents, nowadays considered by many to be archaic, actually work 
quite well but the key point was being very careful in how to use these agents 
correctly. Current migraine practitioners still struggle with encouraging patients 
to use the new drugs at the right time and at the right dose. We hear from 
those active in the field decades ago, about the difficulties of delivering drugs 
through the stomach at a time of migraine-related gastric stasis. As triptans go 
off patent and over-the-counter migraine treatment moves away from systemic 
oral medications towards ‘treating the head’, so we start to think about Botox 
injections in and around the head which may provide the same step change in 
therapy for the current decade, as triptans did 20 years ago. The consensus view 
appears to be that Botox is a treatment for peripheral, not central, nociceptors.6
Fifty years of science has established migraine as an organic disease of the 
nervous system. Those who have achieved this can agree about much, but 
not about everything. To the outsider, much of what has been achieved might 
seem obvious. Trying to define migraine is like trying to define a dog: it’s so 
obvious when you see it, do you really need a definition? But once the definition 
is agreed, can we be sure it is not self-fulfilling? Do we really know that the 
migraine definition has excluded wolves and foxes that corrupt the purity of 
the concept? Having established a hard-core of patients whom all experts would 
5  For further discussion on 5-HT drugs, see the Witness Seminar ‘Drugs affecting 5-HT systems’, (Overy 
and Tansey (eds) (2013)).
6  For discussions on the use of Botox, see pages 48 and 57. 
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agree have migraine, we see that these patients have a range of other sorts of 
headache, including tension type headache and primary stabbing headache, 
which by definition are different from migraine. The Witness Seminar draws 
appropriate attention to the great advances in therapeutics of migraine, and to 
the key importance of treatment specificity. Yet what has become clear in recent 
years, as we swing from enthusiasm for acute rescue away from prophylaxis, and 
then back again, is that the biggest problem with migraine treatment is that 
frequent use of short-term medications tends to make migraine attacks occur 
more often. Arguably the key biological difference between migraine and the 
hemicranias, including cluster headache, is that the former are worsened by 
frequent medication, whereas the latter are not.
This Witness Seminar takes us through half a century of clinical science and 
therapeutics that have beyond doubt changed the lives of many people for the 
better; though there have been steps both forwards and backwards, there are 
fortunately more of the former. We hear from those who were there at the 
start, and others who joined later, enthusiastic to take further forward both 
knowledge and palliation.  Those of us who aspire to stand on the shoulders of 
giants should try to do so without causing too many headaches.
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Professor Tilli Tansey:  Welcome everyone to this Witness Seminar on migraine 
over the past 40 or 50 years. Let me begin by telling you what a Witness Seminar 
is although I know there are quite a few people who have been to previous 
meetings. What we hope to do at these meetings is to get stories from those of 
you who were there at the time, about what happened or perhaps sometimes what 
didn’t happen, who the supporters were, what the drivers were, what the brakes 
were in the process of improvements in treatment, diagnosis, and understanding 
of migraine. Everyone is free to contribute as and when they feel able to. We 
record the meetings and then we publish them with suitable footnotes and 
bibliographies. You will be asked to assign copyright to the Wellcome Trust but 
nothing you say will be published without your permission. This meeting on 
migraine came about largely because we had a meeting on drugs affecting 5-HT 
systems a few months ago.1 That in itself had come about because we’d had a 
meeting on platinum compounds in chemotherapy, which finished off with the 
development of the 5-HT receptor antagonists.2 We had so much on 5-HT and 
the different drugs affecting 5-HT systems that we didn’t have the proper place or 
time to develop the story of the triptans or to put that development into the wider 
context of clinical, especially neurological, research. So we hope to correct that 
deficiency today. As with any of our meetings it depends a great deal on who will 
attend and our chairman. We’re delighted that you’ve all accepted our invitation 
and particularly pleased that Mark Weatherall has accepted the invitation to chair 
this meeting. I’m sure most of you know Mark, he’s a Consultant Neurologist at 
1  Overy and Tansey (eds) (2013). 
2  Christie and Tansey (eds) (2007). 
Figure 1: Dr Mark Weatherall and Professor Tilli Tansey 
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Charing Cross. What many of you may not know is he’s also a medical historian 
(see Appendix 1); he intercalated to do a BSc and then a PhD in the history of 
medicine when he was a medical student at Cambridge so he’s doubly qualified 
and very welcome to chair this meeting. Thank you very much Mark.  
Dr Mark Weatherall:  Thank you very much, Tilli, and a very belated thank 
you for being so kind to me in my PhD viva all those years ago. [Laughter] So, 
yes, it’s a real pleasure to see you all here. Some of you I know personally and 
those whom I don’t know personally I know by reputation, so it’s an honour 
and a delight to be able to chair this meeting. Migraine is a common, important 
neurological disorder. I don’t think anyone in this room would quarrel with that 
statement. But had that statement been made 50 years ago then there might 
have been quite a number of people that would have been prepared to put 
their hand up and disagree with me, quite forcefully. I’m sure there are still a 
few who would be prepared to do that now. One of the things we’d really like 
to explore today is how migraine has come to take its place alongside other 
common important neurological disorders in the worlds of science and of 
clinical medicine (Table 1). We’re going to do that by going back to the period 
at which some of those present started to work in the field to talk about what 
it was like to be interested in migraine, maybe to have migraine, in the 1960s 
and early 1970s, and then, as Tilli said, to set into that context some of the 
work that was done at the time, both around acute treatments like the triptans 
and also other treatments such as methysergide, pizotifen and so on. I warned 
Michael O’Brien that I might come to him first: Michael, would you be able 
to start us off? You entered the field in the mid to late 1960s – what was the 
attraction of migraine at the time? 
Pre 1990s
Migraine pre 1970s 
From ergotamine etc. to the triptans  
Discovery & impact of the triptans
1990s and beyond
Growth of a sub-specialty : specialized clinics  
: training and networks 
Funding research and treatment
New therapeutics
Table 1: Outline programme for Migraine: Diagnosis,  
Treatment and Understanding c.1960–2010 
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Dr Michael O’Brien:  My interest was in the pathophysiology of cerebral 
circulation, cerebral haemodynamics, cerebral blood flow and metabolism, and 
migraine was one of a number of topics that lent itself to this. It wasn’t migraine 
itself which was my prime interest, it was the measurement of brain circulation 
and I started doing that in 1966. I published a paper in 1967, which I think 
was the first ever report of a measurement of cerebral blood flow in a migraine 
attack.3 At that time migraine was thought to be a biphasic vascular event and 
it was thought that that could explain nearly everything. So the idea was that 
the aura stage was associated with vasoconstriction, which caused the aura, or 
at least triggered it, because Leão’s spreading depression had been reported in 
1944.4 So people knew about it and although it had been demonstrated in 
experimental animals like rabbits, it had never been shown in man. It is only 
very recently that the work of Professor Anthony Strong has shown spreading 
depression in man, particularly in relation to stroke.5 Anyway, at that time it 
was possible that vasoconstriction in some way triggered a Leão-type spreading 
depression. Then the question was ‘what happened in the headache stage?’ 
That was thought to be vasodilation, particularly in the non-cerebral cranial 
circulation, which includes the intracranial non-cerebral circulation. One of 
3  O’Brien (1967). 
4  Leão (1944, 1947). 
5  See, for example, Woitzik et al. (2013). 
Figure 2: Dr Michael O’Brien 
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the big problems with that, of course, was the pallor that most people have in 
the headache stage and, if this was vasodilation, why weren’t they flushed? There 
was quite a lot of speculation as to why that might be.   
Weatherall:  One thing you said quite early on was that as a neurologist you 
were, of course, interested in migraine. Do you think neurologists really were 
all that interested in migraine?
O’Brien:  Well, I think they were because that was one of the commonest forms 
of headache; in fact, I think for many neurologists it’s the commonest outpatient 
referral. So, along with MS and epilepsy and so on, headache jumps out at the 
top of most people’s lists.
Weatherall:  In terms of someone training in neurology in the 1960s, did it 
seem to be an exciting field, an interesting field, to be entering?
O’Brien:  No. [Laughter]
Weatherall:  By way of comparison, what might have been the sort of exciting 
fields to have chosen at that stage?
O’Brien:  I think Parkinson’s disease, for instance, hadn’t really taken off at that 
point and become a major interest. MS of course was, epilepsy to some extent 
was, but it’s interesting that at that time there was no epilepsy service at Queen 
Square in the 1960s. There was no headache service at Queen Square in the 
1960s. The domination there by Gilliatt was on peripheral nerves.6
Weatherall:  Pramod Saxena, you were laughing at Michael’s comment – would 
you like to expand on that for us?
Professor Pramod Saxena:  I was not laughing at Michael, no, no, no; I wouldn’t 
dare do that. No, I just think that in neurology in those days, there was not much 
available as drug treatment. You could diagnose very well, beautifully in fact, and 
part of that’s even true now, but you could not do very much for the patient. But 
things have developed since then, also thanks to our neurologist friends. 
Professor Jes Olesen:  I entered the field in the late 1960s and early 1970s and 
I believe that there was extremely little interest in migraine and that continues 
almost to this day, despite the fact that it’s so common and a big thing in 
neurology practice. It was completely common not to learn anything about 
6  See, for example, Gilliatt (1961); Gilliatt and Willison (1963). Professor Roger Gilliatt (1922–1991) held 
the Chair of Clinical Neurology at the Institute of Neurology, Queen Square, London, from 1962 to 1987.
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migraine or other headaches right up until the 1980s. But also I have to disagree 
with Pramod Saxena, they were not able to make the diagnosis very precisely 
because the classification was extremely poor, the definition of the disorder was 
very poor, and the other thing that made neurologists stay away from headache 
and migraine was the fact that the neurological examination is normal. It’s a 
real nuisance for a neurologist to look at people with a normal neurological 
examination. Furthermore, all our wonderful X-rays, angiograms, and, at that 
time, pneumoencephalographies, and later on scans, all of these are normal. So 
it is for all these reasons that neurologists have been very reluctant to go into 
headache and even today it’s still a much understudied condition. The resources 
spent are completely out of proportion to the socio-economic cost of migraine, 
which we have estimated very precisely within the last ten years.7 
Dr Patrick Humphrey:  I just want to make a short response to Michael’s 
comments, which I recognise very much but he didn’t mention the work of 
Harold Wolff.8 Having read all his papers, I’m a tremendous admirer because 
he was a brilliant medical scientist. I can only tell you that we would never 
have discovered the triptans if Wolff hadn’t written those very elegant papers, 
if he hadn’t pointed to blood vessels and particularly obviously blood vessels 
7  See, for example, Gustavsson et al. (2011); Bloudek et al. (2012); Steiner (2010). See also Steiner et al. 
(2003). 
8  Harold Wolff (1898–1962) was Professor of Medicine (Neurology and Psychiatry) at Cornell University 
Medical College and Director of the Neurological Service of the New York Hospital, New York; for further 
biographical details see page 109.
Figure 3: Professor Jes Olesen  
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in the head.9 It just so happened that the 5-HT receptor that we discovered at 
which triptans are agonists are mainly found in certain cranial blood vessels. So 
I think we mustn’t forget Harold Wolff who was brilliant and his papers are still 
worth reading as exemplars of how to write good medical science papers that 
illuminate; for example, Graham and Wolff (1938).10 Do go and read them; 
that’s how papers should be written.  
Weatherall:  We’ll come back to Wolff. 
Professor Merton Sandler:  I wrote a paper 41 years ago, that was before Pat 
was born, I think, [laughter] entitled ‘Migraine: a pulmonary disease?’11 This 
came about because John Vane had invited me to examine one of his PhD 
students at that time, a girl called Valerie Alabaster, who was working with Mick 
Bakhle.12 A good PhD thesis.13 And it suddenly struck me that what they did was 
perfuse rabbit heart, rabbit atrium with 5-HT or tryptamine and found what 
9  See, for example, Wolff, Marcussen and Kunkle (1948); Marcussen and Wolff (1949).
10  Graham and Wolff (1938).
11  Sandler (1972).
12  Sir John Vane was Professor of Experimental Pharmacology at the Royal College of Surgeons. He was 
jointly awarded (with Sune K. Bergström and Bengt I. Samuelsson) the 1984 Nobel Prize in Physiology 
or Medicine for ‘discoveries concerning prostaglandins and related biologically active substances’. Dr Y S 
(Mick) Bakhle joined the Department of Pharmacology at the Royal College of Surgeons in 1965 where he 
remained for nearly 30 years. He was a participant at the Witness Seminar on drugs affecting 5-HT systems 
(Overy and Tansey (eds) (2013)).
13  Alabaster (1971). 
Figure 4: Dr Patrick Humphrey 
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the effluent was on the other side. The effluent was a funny mixture of all sorts 
of things, very few of which they could actually identify. So I started thinking 
and published this airy-fairy paper in the Lancet, which you know was obviously 
looking for rubbish to pad it out with in those days. Anyway that was one of the 
things that I started. We’d started a year or two before with monoamines when 
Edda Hanington – oh she was lovely, wasn’t she, those who remember her – had 
put tyramine on the map, so we had been thinking about tyramine in any case 
at that time.14 I mustn’t ramble on like this at this stage of the game, but the 
monoamines had come on the scene and funny, possible things had emerged at 
the end of it. One of them I got a bit of a bee in my bonnet about, and I think 
it could even be that it has a real role and that’s nerve growth factor (NGF). I 
consider that NGF has all the qualities of a substance that might produce pain. 
It is, when injected, a profoundly potent pain-producing substance and I think 
we should be aware of it, Mr Chairman.  
Dr Richard Peatfield:  Just one thought going back to Michael’s comments: 
we haven’t accounted for the feud between Lord Brain and the rest of British 
neurology.15 Lord Brain was the founding father of the Migraine Trust. 
He thought migraine was really quite important but he’d fallen out quite 
catastrophically with the rest of the Queen Square establishment who, I think, 
14  See, for example, Hanington (1967); Smith, Kellow and Hanington (1970). See also comments by 
Professor Anne MacGregor on pages 10–11 and note 18. 
15  Walter Russell Brain, 1st Baron Brain (1895–1966) was Consulting Physician to the London Hospital 
and to Maida Vale Hospital for Nervous Diseases. For further biographical details see R A H (1982).
Figure 5: Professor Merton Sandler 
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almost to a man, decided migraine was not important largely because Lord 
Brain thought it was, and not for any other better reason. Lord Brain, I think, 
had written a textbook while a senior registrar, which was rather better than 
anyone else had ever written and he was never spoken to again.16 I exaggerate 
slightly but I think only slightly. 
Weatherall:  Whereabouts did Macdonald Critchley sit in that particular feud?
Peatfield:  Others might know that better than me.
Professor Anne MacGregor:  I don’t know where he sat but I think it’s 
worthwhile noting that he did set up a migraine clinic in 1955 as one of the 
first migraine clinics, which means that somebody must have considered it to 
be interesting at that time.17 However, I’m assuming that was purely clinical 
with little research being done. There is one question I would like to ask my 
colleagues who were doing research during the 1970s and 1980s. I went to visit 
Edda Hanington in the 1980s after she’d retired and she said that much of the 
16  Brain and Strauss (1929).
17  Macdonald Critchley (1900–1997) set up the first headache clinic in Britain in 1955 at King’s College 
Hospital where he was Consulting Neurologist, and the National Hospital, Queen Square where he was 
Consulting Physician. For further biographical details, see page 100.
 Figure 6: Mrs Mary Ayres, Professor Anne MacGregor  
and Professor Merton Sandler 
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research that they did and published on migraine was actually migraine with 
aura and they didn’t include migraine without aura because it wasn’t so easily 
diagnosable.18 I am interested to know whether that was true, since that would 
have quite an impact on understanding of migraine from that time. 
Dr Glyn Volans:  My comment is linked to Lord Brain I think. I’m the only 
person so far who is not a neurologist. I came not studying neurology but as a 
clinical pharmacologist when that had only just about been invented.19 What 
I found was an opening to work at Barts with Paul Turner and with Marcia 
Wilkinson who was heading the migraine clinic, and it was Marcia I think who 
came from the Lord Brain side of things if my memory is correct.20 In fact, I 
saw only a few weeks ago that Marcia died recently, well into her 90s and still 
apparently very active towards the end.21 
What we had available as I came to Barts in 1972 was, firstly, an up-to-date, 
comprehensive international classification for migraine that the clinic was 
working to, and the ability to see the patients acutely at the clinic as well as 
patients referred in the more normal ways.22 So we really had a good place to be 
studying the condition. 
18  See further comments by Professor Anne MacGregor on page 57. Dr Edda Hanington wrote widely 
on migraine and headache; see, for example, Hanington (1974, 1980). She reported on the relationship of 
tyramine to the migraine attack; see comments by Professor Merton Sandler on page 9. 
19  For a discussion of the term ‘clinical pharmacology’, see the Witness Seminar on clinical pharmacology 
in the UK, pages 6–8 (Reynolds and Tansey (eds) (2008a)).
20  Professor Paul Turner (1933–1994) was a Professor of Clinical Pharmacology and Consultant Physician 
at St Bartholomew’s Hospital from 1972 until his retirement in 1993; see Richens (1995). Dr Marcia 
Wilkinson (1919–2013) was a Consultant Neurologist at the Elizabeth Garrett Anderson Hospital in 
London from 1953 until 1984 and was the first Medical Director of the City Migraine Clinic from 1970. 
See comments by Professor Anne MacGregor on pages 15–16 and page 109 for further biographical details.
21  See MacGregor (2013).
22  The definitions of a migraine had been agreed in 1969 at a meeting of the Research Group on Migraine 
and Headache of the World Federation of Neurology, of which Dr Macdonald Critchley was the President. 
Migraine was defined as ‘A familial disorder characterized by recurrent attacks of headache widely variable in 
intensity, frequency and duration. Attacks are commonly unilateral and are usually associated with anorexia, 
nausea and vomiting. In some cases they are preceded by, or associated with, neurological and mood 
disturbances.’ The classification was then divided into those conditions that fall within the above definition 
(either classical migraine or non-classical migraine) and conditions which may fall within the category 
of migraine (cluster headaches, facial ‘migraine’, ophthalmoplegic ‘migraine’ and ‘hemiplegic migraine’). 
World Federation of Neurology (1970).
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Weatherall:  Leading on both from Glyn’s and Anne’s comments, one question 
that I want to ask: in 1962 the American Headache Society Ad Hoc Classification 
Committee came up with a classification for headache disorders (Table 2).23 Was 
this something that people were using at the time, or was it really tangential to 
clinical practice?  
1 Vascular headache of the migraine type
‘Classic’ migraine
‘Common’ migraine
‘Cluster’ headache
 Hemiplegic and ophthalmoplegic migraine
 Lower-half headache
2 Muscle-contraction headache
3 Combined headache: vascular and muscle-contraction
4 Headache of nasal vasomotor reaction
5 Headache of delusional, conversion, or hypochondriacal states
6 Nonmigrainous vascular headaches
7 Traction headache
8 Headache due to overt cranial inflammation
9–13 Headache due to disease of ocular, aural, nasal and sinusal, dental, or 
other cranial or neck structures
14 Cranial neuritides
15 Cranial neuralgias
 Table 2: The classification of headaches (The Ad Hoc Committee on  
Classification of Headache, 1962) 
23  The Ad Hoc Committee on Classification of Headache (1962).
Figure 7: Dr Glyn Volans and Dr Richard Peatfield 
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Olesen:  There was this National Institutes of Health (NIH) classification but 
there was also a classification of the World Federation of Neurology, actually 
spearheaded by I don’t remember who but it was a Brit, and they were quite 
similar but not completely similar.24 I think they were widely used but the 
problem was, of course, that they were completely non-operational, they were 
completely ambiguous if you wish. You could diagnose any kind of headache 
as migraine according to those criteria if you wanted to. That was the reason 
why we had to make the international headache classification much later. In the 
meantime, I think patients were diagnosed according to good clinical practice 
in the place where they came from and not really according to these so-called 
definitions because they were useless.
Humphrey:  When Jes got involved in the international headache classification 
I was so excited and pleased. When we started trying to do clinical trials with 
certainly the forerunner of sumatriptan, which I think was AH25086, the 
methodology for such trials had not been worked out. Initially we had about 
eight patients who had what they thought was severe migraine and seven of 
them were just miraculously cured, or rather the symptoms went. And the last 
one no joy at all, and it turned out later he had a broken jaw, not migraine. That 
just typifies the problems that were around at the time trying to do any proper 
clinical trials, so when we wanted to get into big, credible trials with sumatriptan 
it was imperative that people knew what they were doing. I think Jes led the way 
in doing good clinical trials in this field, with proper diagnosis at the forefront.
Weatherall:  Yes, that’s the importance of the final section of all the operational 
criteria, isn’t it – not attributable to any other disorder.25 While we’re talking 
about classification, I think it would be very helpful if Jes would tell us a little 
bit about the background to the IHS, the first iteration of the IHS criteria, 
because I think again it does form a context for the triptan story.26
Olesen:  Yes, I’m happy to. I went into migraine headache research from studies 
of brain blood flow and had a thorough physiological schooling. I was used to 
thinking in rather scientific ways about things and that didn’t seem to be the 
24  See note 22. Dr Richard Peatfield wrote: ‘The other attempt at a diagnostic definition was by Vahlquist 
(1955).’ Note on draft transcript 24 June 2013. 
25  The final section (section 14) of the IHS Criteria is ‘Other headache disorders’, comprising 14.1 
Headache not elsewhere classified and 14.2 Headache unspecified. (Headache Classification Committee of 
the International Headache Society (IHS) (2013), page 787).
26  For the development and pharmacology of the triptans, see Humphrey, Ferrari and Olesen (eds) (2001).
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case for most of the physicians who practised headache at the time. When I 
started to do clinical work I realised that these criteria were useless because you 
could interpret them in any way you wanted. They were full of words like ‘usual’ 
and ‘sometimes’ and ‘often’ and so on. So I made up my own criteria based on 
the large amount of clinical material we had in Copenhagen. They were more 
unambiguous and we used them for our own research but then I realised this 
is never going anywhere; we have to do it in an international organization and 
almost at the same time the International Headache Society (IHS) had been 
formed.27 
I was organizing the second congress of the International Headache Society 
in Copenhagen in 1985, and so at that congress and during the business 
meeting of the International Headache Society, I suggested that the Society 
should take an initiative to form a classification committee and come up with 
a more unambiguous set of diagnostic criteria and so on. Of course, they 
immediately appointed me chairman of the initiative and gave me a free hand. 
That’s when I started to build up the organization behind the first edition of 
the International Headache Society classification. I don’t know how much 
you want to know but I studied all kinds of disease classifications at that 
time; I realised that the most advanced and the most suitable for the headache 
field was the psychiatric DSM-III classification where they had this system of 
criteria a, b, c, and d and so on you should fulfil.28 It was really very operational. 
Then we put together a committee with the leading scientists from all over the 
world and started the work. We quickly reached a decision about the number 
of chapters and distributed the chairmanship of each chapter. We recruited 
many more people because one of the big tasks from the beginning was clearly 
the problem of acceptance throughout the world by headache experts. That 
was why I wanted to involve as many people as possible because if you’ve 
been part of the work you can’t possibly afterwards say it was bad. We had 
more than 100 people working on this over three years and published the 
27  The IHS is an international charitable organization, set up in 1982 ‘for the benefit of people affected by 
headache disorders. The purpose of IHS is to advance headache science, education, and management, and 
promote headache awareness worldwide.’ See their website at www.ihs-headache.org (visited 28 January 
2014).
28  The Diagnostic and Statistical Manual of Mental Disorders (DSM) was first published in 1952 by the 
American Psychiatric Association. It is the standard classification for mental disorders. DSM-III was 
published in 1980.
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first edition in 1988.29 And very unlike, for example, epilepsy classifications, 
the headache classification met no opposition and was just widely accepted 
throughout the world and translated into many languages.30 So that was very, 
very positive.
Saxena:  I don’t know whether I should bring it up or not but earlier, Mark, 
you asked what one remembers about Macdonald Critchley. What I remember, 
which perhaps I should not say, is a meeting organized by Professor Sicuteri, 
perhaps Jes Olesen was there too, to discuss the formation of the European 
and International Headache Societies.31 This idea was vehemently opposed by 
Macdonald Critchley, so much so that he at the time said, ‘That man Saxena, 
now he’s the ringleader!’ He was right perhaps, perhaps not, but other people 
actually joined hands and they eventually founded the European as well as the 
International Headache Societies.32 This I wanted to say. I thought, well this is a 
meeting where you have got to be candid. So I thought I would be.  
Weatherall:  Thank you very much. I want to move on to talk about treatment 
options. Pramod said quite early on that actually there weren’t that many 
treatment options, but the late 1960s, early 1970s is a period at which some of 
the medications that we still use today, or are about to stop being able to use, 
like methysergide, were available or about to become so. So I wanted to ask, 
having made a diagnosis of migraine, what treatment options were available?
MacGregor:  Having written Marcia Wilkinson’s obituary recently and gone 
back through her entire life, which was absolutely fascinating as a history in 
itself, she set up the migraine clinic at the Elizabeth Garrett Anderson Hospital 
29  Headache Classification Committee of the International Headache Society (1988); the second edition 
was published in 2004 (Headache Classification Subcommittee of the International Headache Society 
(2004)), and online two years later: http://ihs-classification.org/en/ (visited 8 January 2014). The beta 
version of the third edition was published in 2013 (Headache Classification Committee of the International 
Headache Society (IHS) (2013)).
30  For the background to epilepsy classification see the introduction to Engel (2013); see also Berg and 
Scheffer (2011).
31  Professor Federigo Sicuteri (1920–2003) was Professor of Clinical Pharmacology and later Internal 
Medicine at Florence University. In 1976 he founded the Italian Headache Society for the Study of 
Headache; he was a member of the Steering Committee of the International Headache Society and became 
President of the Society from 1991 to 1993.
32  The International Headache Society was founded in 1982 and the European Headache Federation was 
founded in 1992. 
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in the 1960s.33 Her main line of treatment was based on the thesis of Elizabeth 
Garrett Anderson, who had not been able to take her thesis in the UK because 
she was a woman, so she’d gone to Paris and wrote her thesis on migraine.34 
Marcia Wilkinson had then translated it and used it as her premise for treatment 
at the Elizabeth Garrett Anderson Hospital. So it goes back a long way but the 
premise was keeping to a routine: sleep, regular meals, not getting dehydrated, 
and buckets of sweet tea, I think, came into it somewhere along the line.35 Aspirin 
was another strategy. This was something Wilkinson was then still following 
through when she was working at the City Migraine Clinics. Then the aspirin 
studies that Glyn Volans did, very elegant ones, brought aspirin through.36 Just 
to put it into perspective in 1989, she gave a talk to the American Headache 
Society, as it was then, on management of migraine in Britain entitled ‘Three 
aspirin and a sweet cup of tea’.37 So I think from that, you can start talking about 
the rest of the science.
33  MacGregor (2013).
34  Garrett (1870). See Wilkinson and Isler (1999).
35  According to Wilkinson’s translation ‘a small cup of tea towards four or five o’clock in the afternoon is 
beneficial’ (Wilkinson and Isler (1999), page 12).
36  See, for example, Volans (1974, 1975). 
37  Professor Anne MacGregor wrote: ‘The actual publication was less provocative – ‘Treatment of acute 
migraine: the British experience’ (Wilkinson (1990)). I had a copy of the typewritten script which she 
read out, so I know what the presentation title and content were.’ Email to Ms Caroline Overy, 19 
December 2013. 
Figure 8: left to right: Dr Jeffrey Aronson, Mrs Mary Ayres, Professor Pramod Saxena (speaking), 
Professor Anne MacGregor, Dr Alec Oxford, Dr Tom Blackburn 
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Weatherall:  Glyn Volans, since we’re talking about aspirin: aspirin was the great 
invention of Bayer at the beginning of the twentieth century, used very widely 
for a number of pain conditions.38 Tell us a bit about how you got involved in 
looking at aspirin and other substances and where that took you.
Volans:  At that time we had two general purpose analgesics, aspirin and 
paracetamol, which were very effective for headaches in most people. I reviewed 
the literature around both, and found that paracetamol was clinically a little 
more difficult because if you ever have to taste the stuff it’s nauseating in its 
own right. However, the key driving factor as to why I studied the absorption of 
aspirin and not paracetamol was because I could measure it. We had a fluorimeter 
in the department with which I could measure aspirin levels with great accuracy, 
whereas if I had wanted to measure paracetamol at that time I had to go to the 
real experts in the School of Pharmacy. They had these impressive machines for 
high-performance liquid chromatography techniques, with which you could 
measure paracetamol levels if you worked on it with great skill for a day or two 
to get a single result. So it was very clear for me that I should put paracetamol 
out of the picture for the studies on drug absorption. 
We later found that if you work hard enough at paracetamol you can make it 
more acceptable to the patient, and the French pharmaceutical industry, for 
instance, was very capable of producing of pleasant tasting soluble formulations. 
In fact, the aspirin formulation which we gave our patients was advertised on TV 
as a lady drinking it out of a champagne glass saying, ‘It may not be champagne 
but it is good for my headache.’ The same company could make paracetamol 
drinkable; I’m not sure how much that kind of product is used now but it can 
be done. 
Once I had demonstrated the ability to study aspirin absorption accurately in 
volunteers, the other key factor then was the migraine clinic where I was able to 
get patients suffering from acute migraine to volunteer as they came in through 
the door. I could then study them not only in the migraine attacks but also 
when they would come back for their follow-up visits, at which time they also 
agreed to the control studies.39 
38  Acetyl salicylic acid, or aspirin, was synthesized by the German chemist Felix Hoffman, possibly under 
the direction of Arthur Eichengrün, in the laboratories of the German dye manufacturer, Friedrich Bayer 
and Co. in 1897, and was launched following clinical trials from 1899. See Sneader (2000).
39  See Volans (1978), also Volans (1974, 1975).
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That’s how aspirin came to the fore at that time. A question I would ask now, 
and I certainly have the beginnings of an answer, is where does the other major 
non-prescription analgesic fit into current treatment? Is ibuprofen, which has 
been available without prescription since the mid 1980s, just as good as the 
other two drugs or is it just possible it could be even better?40
Weatherall:  Can I ask specifically about aspirin and metoclopramide? I believe 
you studied that combination of an analgesic and an antiemetic. Was that 
combination in widespread use at that stage? 
Volans:  I don’t think it was used widely, but it must be possible that people in 
emergency departments who were looking after patients who were vomiting all 
over the place would have used injectable metoclopramide as a symptomatic 
treatment. 
In the migraine clinic, at that time, the intramuscular preparation of 
metoclopramide was easy to give and, by the time that we got to that phase, 
we’d pretty well convinced ourselves that what was causing the poor absorption 
was delayed gastric emptying and that metoclopramide, from everything we 
knew about its mechanism of action, sounded the right antiemetic to use.41
In contrast, all of the other antiemetics, which worked essentially by 
anticholinergic mechanisms, were very likely to cause gastric stasis or to make it 
worse. Indeed, one of the final drug absorption studies in which I participated, 
was led by a colleague, Gillian Wainscott.42 There we used what was then 
the most popular injectable antiemetic, i.e. prochlorperazine (then called 
thiethylperazine) trade name Stemetil. When we gave that to patients they were 
certainly made no better and just possibly they felt worse.43
Dr Jeffrey Aronson:  I can add a comment on the clinical pharmacology of 
metoclopramide and its use in migraine because of course vomiting is a very 
prominent part. As a sufferer, I find that the intensity of the vomiting is proportional 
to the intensity of the headache, and you can use antiemetics to relieve that. But 
an important factor in the use of a drug like metoclopramide is that its action is 
40  Dr Glyn Volans wrote: ‘This question was not answered directly, at that time, but from the later 
discussions it is clear that nonsteroidal anti-inflammatory drugs (NSAIDs) are now recommended in 
current guidelines.’ Note on draft transcript, 2 July 2013. See pages 48–9. 
41  Volans (1975).
42  See page 20 and note 47.
43  Wainscott, Kaspi and Volans (1976).
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through increasing the speed of gastric emptying, which should also improve the 
rate of absorption of the analgesic that you’re giving, and if you don’t take the 
analgesic soon enough then the reduced speed of absorption means that the drug 
fails. So there is an extra twist to metoclopramide, apart from its native antiemetic 
effect, in enhancing the rate of absorption. I’m not sure, Glyn, if you were on that 
paper that Laurie Prescott published in the BMJ in the 1970s showing the curves 
of absorption of paracetamol with and without metoclopramide?44
Volans:  No, I was not involved in that later work but I was aware of the major 
advances, which gave them the ability to measure paracetamol accurately and 
efficiently. I don’t remember whether they were giving the metoclopramide 
intramuscularly like we were or if they had moved onto studying the oral 
formulation.45
Aronson:  That raises another very interesting point about treatment that you’re 
asking, Mark, and that is that drugs are absorbed primarily in the small bowel, 
not in the stomach, so the speed of gastric emptying is important to deliver the 
drug to the site of absorption. If you give the metoclopramide intramuscularly, 
then you will enhance the rate of contraction of the stomach and thus deliver the 
oral aspirin or paracetamol to the small bowel. But I don’t know what happens 
if you give oral metoclopramide, because that should be subject to the same 
delay in absorption if it’s not absorbed in the stomach. Yet the drug companies 
subsequently issued combinations, oral combinations, Paramax for example, 
which is paracetamol plus Maxolon (metoclopramide), and an equivalent one 
with aspirin and metoclopramide (Migravess). I’ve no idea, if anybody has any 
idea here about trials carried out with those sorts of formulations, whether oral 
metoclopramide is effective? I don’t know.46
44  Nimmo et al. (1973). Professor Laurie Prescott was Professor of Clinical Pharmacology at the University 
of Edinburgh and was a participant at the Witness Seminar on clinical pharmacology (Reynolds and Tansey 
(eds) (2008a)). Dr Jeffrey Aronson added: ‘Glyn Volans also subsequently showed that intramuscular 
metoclopramide increased the speed of absorption of aspirin in migraine (Volans G N (1975)).’ Note on 
draft transcript, 30 July 2013.
45  In the study by Nimmo et al. (see note 44) the absorption of paracetamol in healthy volunteers was 
accelerated by intravenous injection of 10mg of metoclopramide.
46  Dr Jeffrey Aronson wrote: ‘There is a systematic review by Andrew Moore and my erstwhile colleague 
Sheena Derry, showing that oral paracetamol plus metoclopramide is as effective as sumatriptan (Derry and 
Moore (2013)). In one careful study, oral metoclopramide increased the speed and extent of absorption of 
aspirin in subjects with migraine and intramuscular metoclopramide had a bigger effect, but neither completely 
restored the absorption to normal (Ross-Lee et al. (1983)).’ Note on draft transcript, 30 July 2013.
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Volans:  I’d have to do a literature search but I think there was marginal evidence 
that the oral formulations may have improved things and certainly that they 
were not making things any worse. The aforementioned Gill Wainscott, in fact, 
moved from the migraine clinic to work with one of the drug companies at that 
stage in her career, although she subsequently had the sense to leave and become 
a psychiatrist.47 
Peatfield:  A bit later domperidone came in and I do know there is a trial 
showing the action of paracetamol is enhanced by oral domperidone, which we 
like in preference to metoclopramide because of the risk of involuntary facial 
movements in young women.48 
Weatherall:  Michael, can I just go back to you? Working as a general neurologist 
in the 1970s, what might you be advising your patients with migraine to do or 
take?
O’Brien:  Even earlier in the 1960s, there were thought to be three arms really: the 
first was to try and establish whether there were any aggravating or precipitating 
factors because, obviously, if somebody was getting their migraine because of 
red wine or something, if they could avoid it then they did better than anything 
any physician could do. The yield from that is not very great but it’s still worth 
attempting. And the second arm was to treat the acute attack when it happens 
– nobody’s mentioned the ergotamines at this point but we had ergotamine 
by mouth, by injection, and by suppository. We also had dihydroergotamine 
and obviously aspirin and paracetamol but nobody’s mentioned codeine, which 
we also had. So we had a number of preparations for the acute event and, of 
course, we knew at that stage in the 1960s that if you didn’t start treatment 
right at the beginning of the attack, as early as possible, it didn’t work. I’m not 
sure we knew why, until Glyn’s work emerged, but we certainly knew it. And 
then the third possibility was prophylaxis and prophylaxis was just extremely 
limited. Dihydroergotamine was used as prophylaxis. Some people used aspirin 
as prophylaxis, small doses of aspirin (I think that actually came in rather later), 
but the effective prophylaxis didn’t come along until later. I don’t think we even 
used beta blockers at that stage, those came in later as well. So those were the 
three ways in which you tackled patients with migraine.
47  See page 18. Dr Gillian Wainscott is a Consultant Psychiatrist and Clinical Director at Birmingham and 
Solihull Mental Health NHS Foundation Trust.
48  MacGregor, Wilkinson and Bancroft (1993). For the use of metoclopramide and involuntary facial 
movements, see, for example, Melmed and Bank (1975).
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Weatherall:  Merton, could I ask you specifically in terms of advising people in 
how to manage migraine, what sort of things would you be saying to people at 
that time?
Sandler:  Well, I’m not a neurologist; that was not my forte. In fact, can I say at 
this stage that about ten years ago I got fed up with migraine completely but 
before I decided to pass to somewhere else or whatever, I put my thoughts down 
on paper. One or two interesting things emerged at that time as you have been 
talking about. It was my complete conviction that the aura of migraine was just 
another triggering event which was active like any other triggering event that 
we know about. Nobody has cottoned onto this. I published that article, all I 
knew about migraine really, ten years ago in a volume entitled Wine.49 That was 
the wrong place to do it; it just happened to be that Roger Pinder and I were 
publishing this book so it was a convenient place to put it. I’m quite sure that 
it fell completely flat, nobody else has read that article ever since, and that it 
remains in the literature.
Humphrey:  Can I just make a few comments because obviously I’m not a 
clinician, but when I was asked to work on migraine by David Jack at Ware I 
had an empty lab and a young lady (Eira Apperley) that I worked with, and was 
left to ‘get on with it.’50 So the first good thing was that I heard a programme 
on Radio 4 on the trials and tribulations of migraine sufferers, around the time 
that my friends had been saying: ‘Don’t waste time working on migraine, it’s 
just something neurotic women complain about, it’s not a real disease.’ And it 
was neurologists saying that, but I realised it was a real disease and thought I’d 
better go and find out about it. I was lucky enough to talk to Marcia Wilkinson 
and spent quite a lot of time with her and she was a lovely lady, she knew how 
to treat her patients. What did I learn from it? Well, we’ve heard how she treated 
her patients and she treated them as best she could with bed rest and keeping 
them in a dark room and so on and so on. But what she actually made me 
realise was that there were no good treatments for migraine, so it was another 
reason for working on it because it was a serious disease that needed a new 
medicine. The other thing she confirmed to me, which was reassuring, was that 
49  Sandler (2003).
50  Sir David Jack was Head of Research, later Research and Development Director, at the pharmaceutical 
manufacturers Allen & Hanburys (now part of GlaxoSmithKline) in Ware, Hertfordshire. See page 103 for 
further biographical details.
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ergotamine did work.51 It was not a nice drug, she didn’t want to particularly 
use it, but it actually worked in some patients.52 So we had a drug that worked 
– that was another starting point. The other thing that she was not overly keen 
on using were prophylactics because she didn’t think they really worked. I’m 
just amazed that people sell them today and make money out of them because 
if you look at them, every single prophylactic drug for migraine then and now 
gives you a 50 per cent reduction in severity of headache, and 50 per cent 
reduction in number of attacks at best. Okay, if you’re having eight attacks a 
month maybe that helps, but not much. The key there, though, was looking 
at the prophylactics for migraine and trying to understand what they may be 
doing to provide their limited effects. I got much of this from Jim Lance, who 
was another clinician who provided a lot of important information to me. He 
published a paper in the 1970s with Anthony and Somerville, where they looked 
at all the prophylactics that were available then.53 A lot of them were 5-HT 
receptor antagonists, dirty ones like cyproheptadine and later on pizotifen came 
along. But they all provided this less than 50 per cent reduction and were all 
similar, but one stood out a little bit and that was methysergide. Methysergide 
seemed to be slightly better, again as a prophylactic, but there were reasons for 
not taking it, retroperitoneal fibrosis kicking in if using it for too long and so on. 
But again it was another clue. So I had two clues, methysergide and ergotamine, 
and I can tell you a lot more about that later. I was really just making the point 
about what was available in the 1970s: not much. 
Weatherall:  We’ll come back to where you took that patent in a little while if 
we may.
Dr Tom Blackburn:  Can I just ask my clinical colleagues: with regard to trying 
to provoke migraine attacks and the amount of work that went on in the 1960s 
and 1970s with compounds like reserpine, fenfluramine, zimelidine, all agents 
that were able to provoke migraine attacks. How important were they to the 
clinicians with regard to developing the hypothesis that 5-HT was important?  
51  See, for example, Wilkinson (1971). 
52  For a discussion of a randomized trial of ergotamine in 1970, see Ness, Reynolds and Tansey (eds) 
(2002), pages 72–3.
53  Lance, Anthony and Somerville (1970). James Lance was Professor of Neurology at the University of 
New South Wales from 1975 to 1992 and since then, Professor Emeritus. He has published widely on 
headaches and migraine.
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O’Brien:  The answer is ‘not very’ because there was always the concern that a 
provoked attack wasn’t quite the same thing as the naturally occurring attacks; 
that was the big difficulty. Anne asked why these studies, or most of the studies, 
were done in migraine with aura.54 The answer is because then you really knew 
it was migraine and there wasn’t going to be any confusion about any other 
sort of headache. I think that the view was, certainly my view at the time was, 
that probably there was a vasoconstrictive phase in the brain and that probably 
everybody had it, but not in all of them was it eloquent. Then, as I said, even 
if you could measure cerebral blood flow (CBF) before a headache in patients 
without a prodrome they would probably still show some vasoconstriction and 
that was the conclusion that I reached in the 1960s.55  
Professor Trevor Jones:  To return to ergotamine for a while. Before I became 
R&D director at Wellcome I was responsible for Development, and Migril 
(ergotamine) was one of our tablet products (Figure 11). In Dartford, where 
our production factories were, they had planted fields of rye grass and had these 
incredibly large tractors, about ten feet high, that went through the rye fields and 
impregnated the rye ears with ergot (I think there are pictures in the museum). 
The problem with the formulation of Migril – cyclizine, caffeine, and ergotamine 
– was to maintain stability during its shelf life otherwise it would degrade to 
54  See pages 10–11. 
55  See, for example, O’Brien (1967), see page 5. 
Figure 9: Dr Patrick Humphrey and Dr Tom Blackburn 
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lysergic acid (LSD) and although you might feel better, it’s not a good therapy! 
The wheel has turned full circle because I am now on the Board of Allergan in 
the USA and we are just about to launch a product called Levadex, which is 
dihydroergotamine as a unique, breath-actuated aerosol spray with very, very fine 
particles, so you don’t get the side effects that we saw in the early days of Migril.56 
MacGregor:  Just going back to ergotamine. I think it’s actually very interesting 
because it was the only treatment that was available at that level when I first 
came into managing migraine in the late 1980s. If you got the dose right and 
the absorption right, patients really got on with it very well. It’s a shame now 
that these drugs that are still effective are becoming no longer available. You can 
no longer get hold of Cafergot in the UK; methysergide may disappear. Migril 
is still available.57 So there is a return but it doesn’t necessarily mean to say that 
drugs like the ergotamine inhalers should have disappeared just because they 
became too expensive to make because of concerns about chlorofluorocarbons 
(CFCs). So these things do change over time. But ergotamine was a very 
useful drug.
56  Levadex was rejected by the FDA in April 2013 due to concerns about manufacturing. Professor Trevor 
Jones wrote: ‘There were one or two manufacturing issues raised by the US FDA that are now resolved so 
we anticipate final review by US FDA this year.’ Email to Ms Caroline Overy, 5 February 2014.
57  Cafergot, a compound of ergotamine tartrate and caffeine made by Alliance Pharmaceuticals, was 
discontinued in the UK in November 2012. Methysergide, marketed as Deseril, was discontinued in the 
UK in May 2013. Migril, manufactured by Wockhardt, is the brand name of ergotamine tartrate, cyclizine 
hydrochloride, and caffeine hydrate.
Figure 10: Professor Trevor Jones 
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Humphrey:  I agree with you, Anne; you know obviously it works in certain people 
and you have to be clever about how you use it, but I would ask why would you 
use it because I know lots of friends, some pharmacologists, who’ve got migraine, 
and in those days they were using bigger and bigger doses and what happened? 
They got sick. They were violently sick because ergotamine is a dopamine 
agonist. Ergotamine is a potent agonist at a number of different receptor types. 
It’s got lots of other effects and it’s a potent coronary vasoconstrictor. I spent 
ten years of my life trying to defend sumatriptan for its relative safety because 
we did a huge amount of work on coronary vessels and cardiac blood flow; and 
now sumatriptan is available over the counter and yet people are trying to bring 
back ergotamine. It doesn’t make any sense whatsoever.
Figure 11: Wellcome Foundation Ltd advertisement proof:  
Ralph Steadman cartoon for Migril, c.1979.
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Sandler:  The question of what were the first indications of whether 5-HT was 
working in migraine or not arose several speakers back. I always remember 
an absolutely fascinating case in the literature of a patient with migraine who 
developed carcinoid tumour and once his tumour started to pump 5-HT into 
his circulation he was right as rain, his migraine was gone.58
Saxena:  I recall that paper as well, so Merton I will support you. A couple of 
points, well more than a couple of points, I’d like to make, if I may? I started 
with 5-HT in 1962, when I passed medicine and joined the Pharmacology 
Department at King George’s Medical College, Lucknow. Lucknow perhaps 
may be known to you in England – it was the place where, according to you, 
the Indian Mutiny took place. 
Jones:  Birthplace of Cliff Richard. [Laughter]
Saxena:  Indeed, and that’s where I come from, Lucknow. We call your ‘Indian 
Mutiny’ the first war of independence, but that’s an aside. [Laughter] I landed 
up working there with 5-HT during my MD after my MBBS. Then, in 1966, 
when I joined Organon International at Oss in the Netherlands, they were 
trying to develop mianserin, a 5-HT antagonist, as an anti-migraine drug. 
Why? Because, like methysergide, mianserin was able to block the rat uterus 
contraction elicited by 5-HT and we all know now that this is a 5-HT
2 
receptor-
mediated response. In those days, the 5-HT
2
 receptor used to be called the D 
receptor. So I was asked by the management: ‘Okay, here is mianserin; prove 
in your animal experiments whether it would work in migraine.’ So in 1966 I 
thought: ‘Well, what is migraine?’ The first paper, as Pat said earlier, that came 
to my mind, and I was most impressed, was by Graham and Wolff, published in 
1938.59 It reached India in 1939, I think; I was in utero. During the headache, 
temporal artery pulsations are high and when you give ergotamine both 
headache and pulsations decrease at the same time. So I thought that firstly, 
there is definitively involvement of head blood vessels here, and secondly, I 
knew that the effective drugs at that time were ergotamine, dihydroergotamine, 
methysergide, pizotifen, and they all had something to do with 5-HT, so 
that said to me also: ‘Yes, 5-HT is important’. Thirdly, a report in 1960 by 
Kimball, Freidman, and Vallejo mentioned that if you give reserpine you can 
elicit migraine-like attacks in migraine patients, and when you give 5-HT 
intravenously, of course, because it’s not absorbed, you can abort those migraine 
58  Hopf, Johnson and Gutmann (1992). 
59  Graham and Wolff (1938).
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attacks.60 Lastly, Sicuteri, Testi, and Anselmi had shown that there is an increase 
in the excretion of a 5-HT metabolite, 5-hydroxyindole acetic acid, in the urine 
during the headache phase.61 This all fitted very, very nicely. So it came to me: 
‘Okay, we’ll record carotid blood flow in our animal experiment’; those were 
the early days of the electromagnetic blood flow meter. Not only that, we also 
recorded blood flow in the mesenteric artery, femoral artery, and many other 
blood vessels. To my surprise, in the very first experiment, I saw that when I 
gave ergotamine, I think 1 or 2μg per kg doses, nothing happened to blood flow 
in any of the other blood vessels, except that carotid artery blood flow decreased 
enormously. There was no, or very little, increase in blood pressure with those 
doses.62 So this was surprising; why was this happening? And it happened also 
with methysergide.63 It didn’t happen with pizotifen64 and unfortunately it didn’t 
happen with mianserin, which was an Organon compound.65 So I said to the 
management that mianserin was perhaps not a good compound for migraine. 
It turned out to be effective as an anti-depressive agent. In 1974, we published 
that methysergide was acting like 5-HT, so I compared it with 5-HT and it also 
decreased blood flow in the carotid artery and I said, ‘Why? This is interesting.’ 
So methysergide is in fact an antagonist at what we now call the 5-HT
2
 receptor, 
or the D receptor at that time, but an agonist at what I termed the atypical 
receptors in our publication of 1974.66 And so, this is where one should look for 
an anti-migraine drug. 
Around that time, the head of department of Organon pharmacology, Ivan 
Bonta, was appointed Professor of Pharmacology at Rotterdam and I thought, 
‘Oh, perhaps I want to be called a Professor’, which was very high sounding in 
those days. So I said: ‘Well, I’d like to go back to academia’ and I moved with 
him to Rotterdam. But I tried to persuade Organon that this was the line they 
should go down and this was where perhaps the future lay. 
60  Kimball, Freidman and Vallejo (1960). 
61  Sicuteri, Testi and Anselmi (1961). 
62  Saxena (1972). 
63  Saxena (1972, 1974).
64  Saxena (1972).
65  Saxena, van Houwelingen and Bonta (1971). 
66  Saxena (1974). 
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The next important thing was that I came here to London for the first time, to 
one of the Migraine Trust meetings; I think it was the second or third meeting 
in 1971/1972 or around that time. There I met Hartwig Heyck, and I think 
Michael O’Brien was saying, ‘Look, patients are pale when they are having a 
migraine attack’.67 I heard Hartwig Heyck, a neurologist at that time in Berlin, 
talk about so-called arteriovenous anastomoses. I had never heard of them. I 
thought: ‘What are these? I don’t know.’ But, he explained that these are the 
direct communication between arteries and vein. When they open up all the 
blood is shunted to the venous side, causing ‘dancing’ arteries.68 I said: ‘Well, 
that’s very fascinating. I’d like to have a model in animals so that we can record 
blood flow across arteriovenous anastomoses.’ So, with the help of our friend 
from San Francisco, Ralph Forsyth, who came to us for about a year and a 
half, I established the radioactive microsphere technique and we were able to 
show that 5-HT decreases arteriovenous shunting, but conspicuously increases 
blood flow in the skin.69 When I infused 5-HT on one side, half of the pig head 
turned red, but the arteriovenous shunting went down to nearly zero.70 Well, 
that’s very fascinating. Exactly the same thing was happening with ergotamine 
minus the dilation part, so no redness, no nothing.71 The same happened with 
methysergide.72 Later on, of course, more drugs were available to block the 
5-HT receptors, so we were able to say, ‘Okay, arteriovenous constriction is 
mediated by the atypical 5-HT receptor.’ With Pat Humphrey and others, 
we were able to classify and name the 5-HT receptors and we said, ‘Well, this 
atypical 5-HT receptor is 5-HT
1
-like’, later called 5-HT
1B
.73 If I remember 
correctly, it was at Pat’s insistence that we initially called it ‘5-HT
1
-like’; he 
wanted to be vague. 
67  See, for example, Lance and Anthony (1971). 
68  Heyck (1969). Professor Hartwig Heyck (1912–1982) was Chief Physician of the Neurological 
Department of Rudolf Virchow Hospital in Berlin.
69  Saxena and Verdouw (1982). 
70  Professor Pramod Saxena wrote: ‘By the way, infusion of 5-HT in the human brachial artery also 
decreases arteriovenous shunting and causes skin redness (Blauw et al. (1991)).’ Note on draft transcript, 
1 August 2013. 
71  Johnston and Saxena (1978). 
72  Forsyth and Saxena (1978). 
73  Bradley et al. (1986). 
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Humphrey:  I think people just need to realise this was in the pre-molecular 
era. These receptors hadn’t been cloned and I was very worried about being too 
dogmatic about what it was, so ‘5-HT
1
-like’ was right, I think, because in the 
end 5-HT
1B
 and 5-HT
1D
 are almost undifferentiable pharmacologically anyway, 
even molecularly they’re incredibly similar.
Saxena:  Absolutely correct. So the pharmacologists were ahead of the molecular 
biologists in this respect. And there were not many pharmacologists in 
those days – I think you could count them on one hand – I think four or 
five pharmacologists were working in the field of migraine. This was an area 
which was depleted. I thought, ‘Oh okay, not many people are following this.’ 
Later on, of course, with the discovery of sumatriptan everything changed. 
Just to round off: 5-HT and methysergide and ergotamine are very selective 
in constricting carotid blood vessels and this selectivity extends exclusively to 
arteriovenous anastomoses, emphasizing the work of Heyck. I was very excited 
and, I think, Pat, it was 1975 or 1976 that we met in London. I had been 
invited to give a talk at, I believe, a British Pharmacological Society meeting, 
and Pat happened to be there as well. He said: ‘Well, do visit us’ and ‘very nice 
meeting you’ etc. etc. I thought, ‘Well, this young man is very dashing’ but I 
didn’t know him at that time. So, I went to his office at Allen & Hanburys, 
if I recall correctly, at Ware. We had a talk and some years later, 1980/1981, 
before sumatriptan was synthesized, at least as far as I know, he came along 
with Wasyl Feniuk to Rotterdam with two compounds and tested them in our 
arteriovenous anastomoses model. I have the experiments somewhere still on 
my computer. They didn’t tell me, of course, what compounds they tested, but 
these were effective in decreasing arteriovenous shunting. Pat and Wasyl were 
very happy and they went back extremely satisfied. 
O’Brien:  I just wanted to comment on Heyck’s experiments. He published his 
paper in 1970 and the suggestion was there were shunts both in the scalp and 
in the brain and the shunts opened up in the brain, thereby causing cortical 
ischemia, which thereby caused the aura.74 That was his theory. And, in fact, 
although shunts do exist in the skin they’ve never been demonstrated in the 
brain. His experiments were basically to inject a tracer into the carotid artery 
and measure jugular venous concentrations and he found that migraine 
patients, when they didn’t have a headache, and control patients had the same 
arteriovenous difference. But the arteriovenous difference dropped considerably 
during the headache stage, suggesting shunt flow. Unfortunately, it doesn’t 
74  Heyck (1970). 
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really match with Elkind’s experiments in which he injected a tracer, sodium 
unfortunately, which is diffusion, not perfusion, dependent, and he showed an 
increased clearance which is not shunt flow because shunt flow is not perfusion 
dependent.75 So you wouldn’t measure it. And Elkind’s experiments, which were 
very elegant really at the time, showed faster clearance from the scalp, implying 
increased blood flow. 
Volans:  Could I add to the list of drugs that was in use for prevention? Clonidine. 
I can’t remember the exact mechanism of action but in contrast to its original 
use for treating hypertension it was thought to be quite different. The dose 
that was developed for migraine was very much lower than the one used to 
lower blood pressure and this avoided many of the side effects. It was marketed 
as something called Dixarit. But what happened to that? I don’t see it on any 
present-day lists of preventative treatments.
Peatfield:  There was very little evidence that it worked at all. I drafted a review 
for the Drug and Therapeutics Bulletin after Andrew Herxheimer and I hatched 
a plot to get rid of the stuff on the grounds that it didn’t work.76 [Laughter] My 
friend John Fozard said it had no pharmacological effect at the doses used in 
man in any animal model whatever.77
Olesen:  Just a last thing about ergotamine. It was actually a very effective drug 
but people didn’t quite know how to use it and there were very, very poor studies 
of the pharmacology of ergotamine available at that time. Actually my first PhD 
student was Peer Tfelt-Hansen and he studied the pharmacology of ergotamine. 
We wrote four or five papers about it because I thought that a compound that 
has no general analgesic effect but nevertheless works for migraine is a very 
interesting substance and might lead us on the way to understand migraine 
mechanisms.78 But it turned out that the drug was too dirty; it works on too 
many receptors and it wasn’t possible to use the mechanisms of the drug to 
understand migraine, and it was shown that bioavailability is very, very variable. 
The dose had to be titrated in every single patient and the dose needed can 
vary up to a factor of ten between patients. The route of administration was 
75  Elkind, Friedman and Grossman (1964).
76  [Peatfield] (1990). 
77  Peatfield, Fozard and Rose (1986). For biographical information on John Fozard see page 101.
78  Tfelt-Hansen, Eickhoff and Olesen (1980, 1982a, 1982b); Tfelt-Hansen and Olesen (1981).
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extremely important, oral bioavailability being very, very low. The rectal route 
was popular on the continent and still is and ergotamine is somewhat better 
absorbed rectally. Using the full potential of ergotamine would actually have 
made it a much better drug but it wasn’t really realised how to do that until the 
triptans came around.
Humphrey:  I just wanted to respond to Michael actually but having heard what 
Jes has just said, I think he’s brilliantly clear as usual. Listen to him. Because 
there is that amazing finding, as you said, that it’s not an analgesic and it works 
in migraine so there’s a clue there, a very important clue. But the dirtiness of the 
drug has to be recorded. We know it’s an alpha agonist, we know it’s a dopamine 
agonist, we know it interacts with a lot of the 5-HT receptors, so it’s not a clean 
drug. And in this day and age, 2013, we should be using cleaner and cleaner 
drugs. That should be the aim of all drug development. The triptans are actually 
selective and clean, we’ll come onto it at some stage, just activating the receptor 
through which ergotamine, and through which methysergide, were working, 
without activating all the other receptors. Can I just respond to Michael about 
the arteriovenous anastomoses? I think Heyck, a bit like I feel about Wolff ’s 
work, did work on arteriovenous anastomoses that was incredibly important 
and yet, nowadays, most don’t believe in them in regard to the aetiology of 
migraine, and possibly I don’t either, but it was again a very important way 
forward because we learnt so much about things that were going on in the 
head.79 The mere fact that he could measure these AV differences on the side of 
the headache means there’s some pathological event on the headache side that’s 
going on, possibly related to disruptions of cranial blood flow, which are very, 
very local. So if you’re talking about shunts we’re not talking about massive 
shunts, we’re talking about local shunts. I did actually find a paper, I don’t 
know how good it is and I have not seen the work reproduced, but the authors 
actually found evidence of dural shunts in the meninges.80 If we believe that 
that is where the vascular changes are taking place, then we should debate their 
significance if there are shunts there apparently.
Olesen:  I too really must say that there aren’t any functioning shunts in human 
beings and there aren’t any functioning shunts during migraine attacks. We 
have studied this many, many times with much, much better techniques than 
those which Heyck and others used in the old days, and the way I look at this is 
79  Heyck (1969). 
80  Kerber and Newton (1973).
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that sometimes a false positive finding can be extremely stimulating to science. 
Science moves on and later on you realise it was actually wrong but it was very 
productive. It set a lot of thought into motion and a lot of development and 
that’s how we should look at shunts today. They do not exist in the human 
situation, not even during a migraine attack, but the results at the time were 
extremely interesting. The model that Pramod Saxena developed was extremely 
good and extremely important in predicting efficacy of future migraine drugs, 
but not because it exists in humans.
Saxena:  Jes and I have been friends for, I don’t know, 45–50 years nearly, but 
this is one point which we have not been able to resolve. Pat said: ‘Well, I believe 
that the shunts are not important.’ There’s nothing to ‘believe’ in science; you 
either show it or put it on the shelf until somebody else proves it right or wrong. 
Whatever experiments Jes has done, which have been plenty and beautiful, it 
has not yet been ruled out whether the shunts are involved or not involved 
in migraine. It is not true that shunts are not there in humans. Going back 
many years, Rowbotham and Little and Kerber and Newton, I believe, showed 
very, very clearly that shunts are, of course, in the human skin but also in dura 
mater.81 So, we have got a challenge actually for the neurologists to take up 
experiments, which they can today. Peer Tfelt-Hansen did make an attempt, 
but he used normal volunteers. I challenge neurologists to have patients under 
attack and have a jugular venous catheter, which these days is not that difficult, 
and measure what Heyck did, all those years ago and prove him right or wrong. 
Do those same experiments first. And, Jes, saying that the science moves on. Yes, 
of course, in many cases it moves on, but I can give you examples where science 
comes back to the same old point. For example, Lauder Brunton proposed that 
amyl nitrite decreases the load on the heart by a vasodilator action and relieves 
angina pectoris attack. Again, more than a hundred years later we are back to 
the same theory.82 So that’s not the point that the science moves on; sometimes 
science comes back.
Olesen:  Pharmacological models can be extremely good and predictive even if 
they do not reflect the human situation, that’s the case with your model. I mean 
you have not studied human beings. I have studied human beings for 30 years, 
during and outside of migraine attacks, and when we inject radioactive xenon 
81  Rowbotham and Little (1965); Kerber and Newton (1973). 
82  Brunton (1867). Sir Thomas Lauder Brunton (1844–1916) was a physiologist and physician at 
Edinburgh Infirmary and later St Bartholomew’s Hospital, London, where he remained for 33 years. See 
also Fye (1986). 
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into carotid artery we could see clearly, for example in brain tumours, there was 
shunting because you see a peak in the clearance curve. But we’ve never seen 
anything like it in migraine during or outside of attacks. So I think it’s really a 
fruitless thing to continue to discuss. Those people who study it have not seen 
it; those people who don’t study it believe that it must be there because they 
have a very good animal model. 
Saxena:  Well, what do I say? [Laughter] I’ll shorten the debate and say, ‘Look, 
do the experiments that Heyck did at that time with the better techniques 
and better reliability in migraine patients under attack and prove us wrong.’ I 
wouldn’t care tuppence about it.
Weatherall:  I’m going to invoke the Chairman’s privilege to move on, if I 
may. I’m sure that you’ll be very happy to carry on that particular conversation 
afterwards. I’d like really to move on to talk about the triptans and maybe I 
could come back to Pat Humphrey. You’ve already told us a little bit about the 
circumstances in which you came to be asked to work on migraine. Take us 
back to that point and tell us about where you decided to take that particular 
request.
Humphrey:  Yes, okay. I was at St Mary’s Hospital Medical School where I was 
teaching physiology and had done a PhD in pharmacology there. I didn’t really 
want to remain a teacher, I wanted to discover a drug, so I was very delighted 
when David Jack asked me to come to Ware and start on a migraine project.83 
Why did he want somebody to work on a migraine project? Well, his daughter 
had migraine and he also believed in working on common diseases that were 
poorly treated, and, boy, was that the case. It is very common and it was very 
poorly treated, as Marcia Wilkinson, and other clinicians I went to talk to about 
it, made clear to me. So I thought it very important to start with the medical 
understanding first and I spent three months talking to people all over the world 
and reading all the medical literature. 
I think the seminal points were firstly, Wolff ’s work. I never knew Wolff, 
obviously he preceded me in years and everything else, but his papers were 
brilliant, they put me onto a vascular focus. Secondly, talking to clinicians, it 
was clear that ergotamine worked. Again, I think Jes has very elegantly made the 
point – it’s not an analgesic but it works in migraine; it’s doing something but 
where? Thirdly, Lance’s work was very instructive as well, seminal in the sense 
that methysergide seemed to be doing something the other 5-HT antagonists 
83  See page 21 and note 50.
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didn’t,84 and it turned out of course later we found out it’s an agonist at a novel 
previously unidentified receptor. Also, the whole 5-HT story that Lance had 
followed up on from other people, like Sicuteri, who showed indole acetic acid 
coming out in the urine during a migraine attack, so it looks as though 5-HT 
is depleted from platelets and then it comes out in the urine as its metabolite.85 
So, 5-HT is involved, ergotamine is a 5-HT agonist, and methysergide might 
have serotoninergic properties – at the time we didn’t know that it was a 5-HT 
agonist, but it was an ergot alkaloid type of molecule. We were looking at 
these concepts, which led to my view that we’ve got to find out what’s special 
about methysergide because why is it different to all the other 5-HT receptor 
antagonists but yet it’s doing something not dissimilar to ergotamine. I say that 
because, again, in talking to Lance in detail about his patients he told me, and 
this was the most seminal observation, that occasionally he gave methysergide 
to a patient in his office. They’d come in, they were having a terrible migraine 
attack and he would prescribe methysergide for prophylaxis but he said: ‘Take 
your first tablet now.’ And they took their first tablet in the office and it fixed 
the migraine in front of him. Now it didn’t happen very often but he was sharp 
enough to make the observation and tell me about it; that was the critical 
thing. So the whole thing was, what was unique about methysergide? Possibly 
an action shared with ergotamine, but that’s too dirty a drug to work out the 
amine receptor that might be involved because it activates so many different 
receptor types. 
Of course, the next seminal thing, the last bit of the jigsaw, was Pramod’s work 
because he was looking at carotid shunts. The thing about shunts that appealed 
to me was that they provided a hypothesis you could hang your hat on about 
what causes migraine. So the Heyck hypothesis around the pathophysiological 
role of shunts was the best we had at the time and there’s Pramod showing 
that the methysergide actively constricted these shunts whereas the other 5-HT 
antagonists didn’t. And so that was very appealing. Now that wasn’t how we got 
to sumatriptan specifically because, as Pramod has inferred, we’d already started 
looking at cranial blood vessels. We were trying to work out what was going on 
in terms of the receptors because at the time we only knew of two different 5-HT 
receptor types, the 5-HT
2
 receptor and the 5-HT
3
 receptor, which Gaddum 
called ‘D’ and ‘M’.86 We started looking at this and, funnily enough, one of the 
84  See, for example, Curran and Lance (1964); Lance, Anthony and Somerville (1970). 
85  Sicuteri, Testi and Anselmi (1961).
86  Gaddum and Picarelli (1957).
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preparations we used early on as a sort of marker for peripheral blood vessels was 
the canine saphenous vein. And it turns out that that was selectively constricted 
by methysergide. We couldn’t believe it; what’s happening here? That’s how 
we discovered sumatriptan really, by looking at blood vessels, looking at dog 
saphenous vein and suddenly finding out methysergide was an antagonist 
in every blood vessel we looked at except the dog saphenous vein, where it 
constricted.87 So then we went looking in cranial blood vessels and there we 
found some, but not all, cranial blood vessels would constrict to methysergide. 
We were really onto what we thought was a third 5-HT receptor type, and it 
eventually turned out to be the 5-HT
1B
 receptor. The other thing is we also 
found that the same or similar receptor was on sympathetic nerves innervating 
certain blood vessels where it was inhibitory, so that was probably the 5-HT
1D
 
receptor but at the time we weren’t sure. Every single compound we ever made 
activated both receptors so that’s why I was quite happy to lump them together 
for a very long time. But, having found a compound that was selective for the 
dog saphenous vein receptor, we wanted to go to Pramod’s laboratories and 
find out whether it constricted carotid shunts selectively, and it was brilliant on 
shunts. They were about the only vessels it constricted in vivo that you could 
measure. It didn’t affect cerebral blood flow or anything else, just constricted 
carotid shunt flow in an extraordinarily selective way and potently. 
Weatherall:  Can you just tell us a little bit about the process of how these 
molecules were made and constructed? 
Humphrey:  The other thing is that when I arrived at this empty lab and the 
Head of the department, Roy Brittain,88 said to me: ‘Well look, here are some 
lab notebooks of what we’ve been doing’ because apparently they’d had a project 
five years earlier and they had been synthesizing all these massive great ergot 
alkaloid molecules. One of the reasons ergotamine doesn’t work for lots of 
people is that it’s not absorbed. You know people who have taken it orally and 
it doesn’t even get into the blood stream, there’s virtually zero ergotamine in 
the blood. So I wasn’t going to make large molecules. Well, what would you 
make – 5-HT-like molecules. The 5-HT hypothesis was such that 5-HT was 
involved, so we were making very simple molecules, which were just simple 
indolic variants on 5-HT. Now I say that, I’m slightly embarrassed because I’ve 
87  Apperley et al. (1980). 
88  Dr Roy Brittain (1930–2013) was appointed Head of the Pharmacology Department at Allen & 
Hanburys Laboratories at Ware in 1962, becoming Research Director in 1979 and Head of Glaxo Group 
Research from 1983 until his retirement in 1992; see Drew and Humphrey (2013).
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got the chemist who made them all sitting next to me [Alec Oxford] and I say 
‘simple molecules’. Well, at that time making 5-HT analogues was not easy. 
There was quite a long run in period until we got going. But that’s what we did. 
We made simple analogues of 5-HT. 
Weatherall:  Maybe Alec Oxford, would you like to tell us a little bit about that 
side of things?  
Dr Alec Oxford:  Our target was an orally acting selective full agonist mediating 
contraction of the dog isolated saphenous vein. The strategy was to start with 
5-HT and identify the key features that gave the affinity and selectivity for this 
5-HT receptor. We assumed that the hydroxyl group would be very important 
and we spent a long time studying the properties of this substituent by replacing 
it with other groups such as a hydrogen atom, alkyl group, methoxy group or 
chlorine atom, usually with loss of activity and selectivity, but eventually we 
found that a carboxamide function gave rise to a potent agonist at this 5-HT 
receptor (AH21467, 5-CT). However, when this compound was injected into 
animals it caused a profound fall in blood pressure. This then led to the discovery 
that it was acting at a vasodilator receptor, now known as the 5-HT
7
 receptor, 
as well as the dog saphenous vein receptor. But we found that if we introduced 
another methylene group between the carboxamide and the indole ring we got 
rid of the activity at the vasodilator receptor, and this gave rise to a selective 
agonist at the 5-HT
1
 receptor on dog saphenous vein (AH22800). A more 
Figure 12: Dr Alec Oxford 
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potent and selective analogue (AH25086) was found to be an effective anti-
migraine agent but only by i.v. administration.89 Further analogues eventually 
gave rise to the orally acting compound sumatriptan only after several hundred 
tryptamine derivatives had been synthesized.90  
Humphrey:  Just to add to that, the whole hypothesis within the project which 
I was running at the time was to make a selective compound for this dog 
saphenous vein receptor and when we put it in vivo it should constrict the 
carotid shunts and it would not have any effect on blood pressure because it 
would not have any effect on any other blood vessels. When we put our lead 
compound (AH21467) into an anaesthetized dog, the blood pressure fell right 
down into its boots to everyone’s surprise and amazement. The project team 
was deflated and disappointed but I went to David Jack and said: ‘This has 
happened but I think we have probably found another 5-HT receptor, it’s the 
89  Doenicke et al. (1987). 
90  For an overview of the clinical studies with GR43175 see Perrin et al. (1989). For the development of 
sumatriptan see Humphrey et al. (1990); Humphrey (2001).
Figure 13: Chemical structure of some 5-HT agonists 
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only way I can explain it.’ He said: ‘Well, go away for 12 months and come back 
when you’ve proved it.’ That was the amazing thing because today that would 
never happen. It would be ‘hard luck, your hypothesis is wrong, go away.’ But 
he didn’t say that and luckily the chemists stuck with us too, because they were 
very disappointed that the hypothesis I had put together was possibly wrong. 
But they stuck through it and when we proved it, or had better evidence for it, 
we went away and started the chemistry again.
Blackburn:  I think this addresses my question earlier with regard to how 
important some of these agonists were in our early understanding of migraine. 
This is classic Sir Jim Black’s work, where he used agonists to tease out receptor 
function.91 That is what pharmacology is all about, developing 5-HT-like agonist 
compounds to understand receptor subtypes and their function.92
Saxena:  Absolutely. And Glaxo had experience in that because they had 
synthesized the anti-asthma drug salbutamol on the same basis, modifying 
the isoprenaline molecule to obtain a more selective compound.93 May I ask a 
question to Pat or Alec? Would they today reveal which were the compounds 
they tested at my lab in about 1981? They have never done it so perhaps today 
might be the day!
Humphrey:  Well, the problem is it’s so long ago I’ve forgotten, Pramod. [Pat 
smiling – laughter] 
Jones:  The fortunate thing about drug discovery and development is that if 
you’ve got pioneers like Pat and Alec, the ‘follower’ can actually benefit from 
all of their knowledge and experience – and that’s what happened in my time 
at Wellcome. By that time it was established that sumatriptan was effective, we 
91  Professor Sir James Black (1924–2010) was Professor of Analytical Pharmacology at King’s College 
Hospital Medical School, London, from 1984 to 1993. His work at ICI in the 1960s led to the development 
of the first beta blocker, propranolol. He was jointly awarded the 1988 Nobel Prize for Physiology or 
Medicine (with George Hitchings and Gertrude Elion) for ‘discoveries of important principles for drug 
treatment’. See the special issue of the British Journal of Pharmacology celebrating his life and work 
(McGrath, Bond and MacKie (eds) (2010)). 
92  For discussion on 5-HT receptor subtypes, see the Witness Seminar on drugs affecting 5-HT systems 
(Overy and Tansey (eds) (2013)).
93  The Allen & Hanburys research laboratories at Ware (absorbed into Glaxo in 1958) had developed the 
anti-asthma drug salbutamol in 1966, which was marketed in 1969 as the Ventolin inhaler; Sir David Jack 
(see page 21, note 50) discusses its development at the Witness Seminar on childhood asthma (Reynolds 
and Tansey E M. (eds) (2001)).
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knew its possible mode of action and, with very good medicinal chemistry, we 
decided to make the molecule more lipophilic so that we could get the drug into 
the central space – across the blood–brain barrier – because sumatriptan was 
relatively poor in that regard; in fact it probably doesn’t penetrate the blood–
brain barrier at all. So that led us to a rather simple, but very elegant, piece of 
medicinal chemistry that resulted in zolmitriptan. As you say, the word ‘simple’ 
is a comparative term and the absorption of zolmitriptan was 64 per cent against 
the 4 per cent of sumatriptan. 
Humphrey:  14-15 per cent of sumatriptan.
Jones:  Oh, I beg your pardon, 14–15 per cent. Interestingly, the Phase I study, 
as it was called in those days (nowadays we prefer to divide drug development 
into two steps, ‘Learn’ and ‘Confirm’), was conducted in a clinic in Amsterdam. 
I remember my Medical Director coming to my office and saying: ‘I think 
we’ve got a problem.’ The study was in a very small number of migraineur94 
volunteers, the statistical analysis of the results showed that the efficacy was 
equivocal. In fact, as we discovered, there was one patient who had just taken 
a dose of the experimental medicine and suddenly realised that her car was 
parked outside and she hadn’t paid the parking fee. She looked out the window 
to see it being towed away and flipped into a major migraine crisis. Analysis 
without that patient did show adequate significance and allowed us to carry on 
and do the next study in a broader population. Had we not known about that 
volunteer incident we probably would have killed the project! As it turned out 
the compound was never launched by Wellcome because we were then taken 
over by Glaxo who couldn’t take it on because of the monopoly potential with 
sumatriptan, so zolmitriptan became the property of Astra Zeneca.95 
MacGregor:  I was actually going to slightly change tack with the fact that 
the development of sumatriptan and the development of the IHS diagnostic 
criteria led to a complete change in the way that clinical trials for migraine were 
undertaken. I think that if we just had the classification and we hadn’t had the 
development of sumatriptan, or the other way around, then the development of 
clinical trial programmes in migraine and research would be very different. But 
having the two together meant that the whole way we approached clinical trials 
94  Dr Jeffrey Aronson wrote: ‘I can think of only two conditions whose sufferers are denoted by a French 
word in English: migraineurs and ticeurs (sufferers from Tourette’s syndrome).’ Note on draft transcript, 30 
July 2013.
95  Glaxo and the Wellcome Foundation merged in 1995 to form Glaxo Wellcome.
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at that time became much more rigid. The follow up with patients was much 
better and it led to a whole change in the way that we did research, not just the 
new drugs. Really incredible.
Blackburn:  One of the things we’ve discussed with Pat’s work and with 
sumatriptan was the focus on intervention therapy. I think it was you, Richard, 
and Tim Steiner, who worked with the ICI 5-HT receptor antagonists at the 
time, in particular ICI 169,369. It was around this time that ICI Pharmaceuticals 
were trying to develop a prophylactic treatment for migraine acting at the 5-HT
2
 
receptor as we knew it then. Interestingly, methysergide is also very potent at 
the 5-HT
2A
 receptor and we were trying to develop a selective 5-HT
2A
 receptor 
antagonist compound and we showed in a migraine study significant clinical 
efficacy. We also looked at it in anxiety, depression, and in schizophrenia. 
Unfortunately, the clinical signals in those studies were compromised by the 
clinical design and the number of patients, but ICI felt at that time that the 
prophylactic market was not a good market as we would be totally overwhelmed 
by Glaxo’s intervention therapy with sumatriptan.
Peatfield:  Weren’t we all?
Blackburn:  Yes, exactly. [Laughter] It even came to pass at one of the British 
Pharmacological Society meetings that there was some criticism of Glaxo in 
their marketing strategy and the way they went about it. But that’s by the by. It 
worked. It is an excellent drug. I also took part in a Migraine Trust meeting in 
London that Pat and I often talk about, where Barry Cox and I (ICI) presented 
the rationale for the prophylactic treatment of migraine with ICI 169,369 and 
Pat and Glaxo were marketing sumatriptan for intervention therapy and did a 
fantastic job! After which the ICI marketing boys said: ‘There’s no way that our 
prophylactic treatment would be useful in the treatment of migraine.’96 The ICI 
marketing boys won and the project was terminated. 
However, today prophylactic treatment is still of great interest. And, interestingly, 
at that time I worked with a young lady in Lund in Sweden (Inger Jansen, now 
Inger Olesen, whom I’m delighted is with us today) with Lars Edvinsson, where 
we looked at the compound on human temporal artery and pial artery. If I’m 
96  Dr Tom Blackburn wrote: ‘… although it showed efficacy in one study at Charing Cross with Richard 
Peatfield.’ Email to Ms Caroline Overy, 18 December 2013. Dr Richard Peatfield added that there was ‘a 
small open study (10 patients) of ICI 169,369 done by my Charing Cross colleagues Paul Davies and Tim 
Steiner (while I was away as Senior Registrar in Leeds). This speaks of “some beneficial effect”, though it was 
“not marked” (Davies and Steiner (1990))’. Email to Ms Caroline Overy, 22 January 2014.
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correct, we observed antagonist activity on temporal and pial vessels, which was 
unlike the findings with ketanserin or methysergide.97 ICI 169,369 was active 
on both vessels and the interesting thing we found out much later, was that 
ICI 169,369 had activity at the 5-HT
1C
 receptor subtype, which subsequently 
became known as the 5-HT
2C
 receptor, which is found in the choroid plexus 
and has been implicated in the pathophysiology of migraine. At this time, I was 
developing these ideas, but unfortunately the interest and CNS research moved 
over to the US and the programme was closed down.
Weatherall:  What happened to the compound?
Blackburn:  It never made it, it just lost its way. It died and some would argue 
that compounds die in drug development either due to toxicity, safety, drug 
metabolism and pharmacokinetics, or lack of efficacy. But, in this case, and as we 
know today, 33 per cent of the attrition rate associated with drug development 
is down to marketing or management prejudice. Unfortunately, that was the 
case with the ICI compounds.
Peatfield:  I should say as a little aside there was a Migraine Trust symposium, it 
must have been 1990, when I think there were a thousand delegates and I think 
900 of them were paid for by Glaxo. It was a magnificent sales propaganda 
exercise and it carried the day.98
Blackburn:  This was the Migraine Trust meeting I think I went to that the 
Patron Princess Margaret attended. I think it was the one where Princess 
Margaret came in with her entourage and, getting back to the comment about 
champagne,99 the first thing she was given as a migraineur was a large gin and 
tonic as she walked in. [Laughter] So whether that cured her migraine or not, 
I don’t know. 
Olesen:  You bring up a very important point. Many possibly effective 
prophylactic drugs are not developed because people feel that the triptans 
solve all problems. I meet with many drug companies with several interesting 
compounds showing promise of prophylactic activity in animal models but 
they all get killed because so-called marketing research – which actually has 
nothing to do with research, it’s just prejudice – also says there’s a very small 
97  Jansen et al. (1991).
98  Some of the papers from this meeting were published in a special issue of European Neurology, entitled 
Sumatriptan. From molecule to man (Anon (1991)).
99  See page 17. 
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prophylactic market. This is because all drugs are off-patent. Marketing people 
also think that the triptans can do everything we need. This, we know of course 
today, is far from true. Talking about the triptans, they were an enormous 
breakthrough, it was a change of paradigm of the whole scene for migraine and 
their importance cannot be over-emphasized.100 For many years we have known, 
however, that they are far from the final answer that we need to the migraine 
problem. We are now actually in a situation where their success is blocking 
further drug development.
Weatherall:  Thank you, Jes, I think that’s a very, very interesting point from 
a historical point of view. I’d like to just take the story back a little bit because 
we took it through with Pat Humphrey to the point at which they developed 
a compound and you trialled it in Pramod’s model and that it seemed to be 
effective. I just wondered if you could speak a little bit more about how that 
compound actually became the drug? 
Humphrey:  Obviously we got excited because we could then elucidate within 
the company, an idea of how this compound would work clinically. You know 
we had the carotid shunts hypothesis, this compound worked on the shunts. 
Obviously one of the more challenging points that was an issue for me was 
that we had a vasoconstrictor agent – what’s it going to do? We went on to do 
some extensive microsphere studies which we’d learnt in Pramod’s lab, and I’ll 
be eternally grateful to him for that, where we could show that this compound 
didn’t affect coronary blood flow, didn’t affect cerebral blood flow, it didn’t 
affect blood flow in the limbs, and it was very different to ergotamine in terms 
of its vascular profile. All it did was constrict these shunts. So we had Heyck’s 
carotid shunt hypothesis of the aetiology of migraine, we had a compound that 
worked on it, so let’s get in a clinic and find out. The problem was that nobody 
was very interested in the idea. You went to talk to clinicians about this idea but 
none was interested. I’m not going to name names, but they weren’t. We ended 
up having a couple of anaesthetists in Germany who were prepared to do the 
study and that paper was published in 1988.101 
The other problem, of course, is how do you do such a clinical study properly 
and this is why I was so excited by Jes Olesen’s work, his thinking, and his drive. 
But, to be fair, there was a lot of push from Glaxo in terms of wanting that done. I 
think there was quite a bit of funding, wasn’t there, Jes? Through Glaxo’s support 
100  See Humphrey, Ferrari and Olesen (eds) (2001). 
101  Doenicke, Brand and Perrin (1988).
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things got going internationally. And it was for the good of everybody. People 
knock the pharmaceutical industry and I’m not going to defend the marketing 
boys but at the end of the day this was a potentially exciting compound. If we 
could do the right studies and show it worked, we could then market it and we 
could go on and find other drugs. This drug, at the end of the day, didn’t need 
marketing because it worked. I’ve got a letter in my pocket (Figure 14), which 
is one of many that I still receive from women, saying, ‘You’ve changed my life’, 
which is extraordinary; 20 years on you still get letters like that.102  
So it must work. It didn’t necessarily need marketing but you do, in the modern 
era, need structured support and funding. When we started trying to develop 
sumatriptan in a new therapeutic area, without experience, we did not have 
an understanding of how to conduct proper clinical trials and unfortunately 
our German friends, who, though competent, were not proper neurologists. 
It needed people like Jes Olesen and Jim Lance and other people around the 
102  At a Witness Seminar on platinum salts, Robert Naylor, Professor of Pharmacology and 
Neuropharmacology at the University of Bradford (1998–2011), refers to receiving similar letters of thanks 
from patients, following the introduction of ondansetron as an antiemetic in cancer treatment. See Christie 
and Tansey (eds) (2007), page 59.
Figure 14: Letter to Dr Patrick Humphrey thanking him for his part in 
the development of sumatriptan 
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world to say: ‘This drug works’, before others would believe in it. When I heard 
people like Jes saying, ‘Yes, this is a good drug’, you knew it was a good drug 
that could benefit migraineurs. Then the issues really were more around the 
safety issues.
But I’ve probably gone off a little bit from what you asked me to talk about 
because the original compound worked really well in these German trials. We 
got very excited about it but for various reasons we didn’t want to develop it, 
there was an issue around oral bioavailability. Trevor’s already alluded to the 
bioavailability of sumatriptan,103 which was the follow-up compound from 
AH25086, but I was very happy with it because it actually was absorbed very 
well, because that 14 to 15 per cent was absolutely reliable, it wasn’t variable as 
you often get with a 15 per cent bioavailability compound.104 I didn’t want it to 
get in the brain. I still don’t think sumatriptan gets in the brain to any significant 
degree – a lot of the other triptans do, and they’re no better clinically.105 But at 
the time I thought: ‘This is going to be bad news if we get a compound like 
this into the brain, we don’t want it in the brain.’ So 14 per cent was great by 
me and sumatriptan was the development compound, and it was patented in 
1984. By then, all this work that Jes and all the international people he’d pulled 
in had done, had led us to be able to do some really good trials, and it all came 
together. Sumatriptan Trial 1, well it’s all out there in the literature, you can see 
it, but it was just literally amazing, particularly by the subcutaneous route.106 
But around the corner was the other issue about safety and we were initially 
using sumatriptan intravenously in our experimental trials. We did have one 
woman who had an ECG event but we argued that we were not going to use 
this drug intravenously; a great big bolus of any drug will create very high local 
concentrations. We knew it was safe in all the animal studies we had done. We 
had given it to animals for months; we had given it by every route you can 
think of. We argued that it was just a question of dose. But, as it turned out, we 
found that there were some 5-HT
1B
 receptors in human coronary arteries and 
that led to a lot of work looking at isolated coronary arteries and so on. In the 
end we concluded that this drug was safe providing you weren’t going to give 
103  See page 39. 
104  Fowler et al. (1988). 
105  Dr Patrick Humphrey wrote: ‘This refers to other triptans thereby making an important point about a 
predominantly peripheral action for them all, see Humphrey, Ferrari and Olesen (eds) (2001).’ Email to Ms 
Caroline Overy, 19 December 2013.
106  See, for example, the Sumatriptan Auto-Injector Study Group (1991). 
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it to people with severe arteriosclerosis, you weren’t going to give it to people 
who were in the middle of a stroke or other such cardiovascular risk scenarios.107 
Again, diagnosis is absolutely imperative. There’s a big story there but I won’t 
go on about it, but that was my biggest worry for a number of years, and I spent 
a lot of time talking to cardiovascular experts and trying to do studies to show 
this drug’s safe. Ironically, it’s now available over the counter in Britain – it’s just 
extraordinary. That was the biggest issue – if the marketeers had to do anything, 
it was to support efforts to evaluate safety issues to show people that it was safe, 
rather than it worked because it really did work, that was obvious.  
Weatherall:  I’d like to concentrate on one final issue, which is the reception of 
sumatriptan and the triptans in clinical practice. Jes, could I ask you for your 
recollections of where this compound first hit the radar and what the uptake 
was like and how that process happened?
Olesen:  We were, of course, part of the drug development programme and the 
classification was used actually before it was published, it was already used in 
the Glaxo trials. I just want to mention the first experience with intravenous 
107  See, for example, Brown et al. (1991). 
Figure 15: The sumatriptan discovery team c. 1984. Pictured left to right: Martin Owen,  
Helen Connor, Patrick Humphrey, Darko Butina, Wasyl Feniuk, Marion Perren,  
Alec Oxford, Pam Gaskin, Ian Coates  
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sumatriptan; it was just unbelievable. We said all along: ‘If this drug is going 
to work it’s going to change the whole field because it’s so selective.’ So far we 
never had something like that. But the odds that it was going to work were not 
that high. I still remember my PhD student who was treating patients with 
slow infusion of sumatriptan intravenously. She treated a couple of patients 
and came back to me and said; ‘This is unbelievable. As we are injecting this 
compound the patient says, “Now my headache stops throbbing,” and before I 
finish the injections the patient says, “Now my headache is gone.” It’s like giving 
glucose to a patient in hypoglycaemia when they wake up during your actual 
infusion.’ That was, of course, very, very convincing. So I don’t know which 
country registered first; Denmark registered this drug very early.
Humphrey:  I think Holland was earlier.
Olesen:  Holland was just a little bit before Denmark but was it 1991 or 
something like that?
Humphrey:  I could tell you in a minute, I’ve got a list (Table 3).  
Date Country Date Country
1991 June 17 Holland 1992 July 7 Venezuela
1991 August 1 New Zealand 1992 August 4 Mexico
1991 September 30 UK 1992 August 25 Malaysia
1991 November 1 Sweden 1992  October 1 Iceland
1991 November 11 Luxembourg 1992 October 5 Uruguay
1991 November 25 Portugal 1992 October 14 Poland
1992 January 10 Singapore 1992 October 14 Belgium
1992 January 13 Italy 1992 November Paraguay
1992 February 3 Canada 1992 November 11 Austria
1992 February 3 Denmark 1992 November 21 Chile
1992 February 18 Hong Kong 1993 February 1 Germany
1992 March 5 South Africa 1993 February Colombia
1992 March 31 Greece 1993 March Cyprus
1992 April 1 Israel 1993 March 8 Argentina
1992 May 18 Australia 1993 March 29 USA
1992 July 3 Finland
 
Table 3: Launch dates of sumatriptan. Information supplied by Dr Patrick Humphrey 
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Olesen:  I think it varied a lot how it was taken up because it had to do with 
the reimbursement in the different countries. People thought that this was 
outrageously expensive, to treat this disease, which was at that time really not 
recognized as anything other than more or less hysterical women who were 
psychologically out of balance or something – that was the general prevailing 
view of migraine before the advent of the triptans. It was far too expensive – £5 
to treat a migraine attack. It’s much better to lie in bed for two days and vomit. 
So that was the attitude in most countries – they were not willing to give good 
reimbursement of the drug up front – but in Holland and Denmark and other 
Scandinavian countries it gradually got the reimbursement. I think that was 
crucial for the take up of the drug.
Blackburn:  It still is today.
Olesen:  It spread very rapidly in those countries where it was reimbursed, for 
example in Denmark. A few years later and almost every patient was offered a 
triptan.
Peatfield:  I was going to make that very point that the price was always a major 
problem here, because of course there hadn’t been a budget for migraine. It’s easy 
in Britain to introduce a technique or a device if you’re saving money but in this 
situation the reverse applied. There was no perceived disease, so there was no 
clinical problem. Suddenly we were spending vast amounts of money on individual 
patients, which is why Glaxo had to market it in the aggressive way they did, and 
the marketing did work. But even now we tend to put this drug fairly far up a 
spectrum with aspirin and paracetamol and ibuprofen and you name it, albeit on 
separate attacks as a way of trying to keep costs down and only allow the patients 
who really are desperate for it to take it, simply because it still costs a lot of money.
Saxena:  I do remember sumatriptan was marketed in 1991 in Holland and, as 
the laws were at that time, there was no reimbursement for the tablets because 
they were grouped together with ergotamine and then you’ll only get little back. 
Patients then learnt to inject themselves. So everybody was injecting in Holland. 
By the way, I remember I was sitting next to Pat and I happened to remark: 
‘Look, this drug is very, very costly; it is more costly than gold, platinum and 
diamond taken together.’ The marketing boys didn’t take me very kindly. 
Blackburn:  I think addressing your point, Jes, with regard to price reimbursement, 
we’re still faced with the same issues and challenges 22 years later. Migraine is not seen 
as a life-threatening disorder, like anxiety and depression, yet price reimbursement is 
still a major concern for any new medication being launched today. 
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Jones:  That’s very true. Allergan’s most recent migraine drug is Botox.108 You 
will understand that the cost of Botox is high but if you think about how much 
it cost to actually invest in the kind of research that Pat and Alec did, and we 
did in Wellcome, and at Allergan, how many years it takes and, nowadays, the 
increased burden of the regulatory numbers of patients that you have to include 
– and then double that to get enough data for health technology assessment, 
not to prove safety and efficacy but to convince pricing bodies about its cost-
effectiveness – then you can understand why the cost is high. The one thing 
that Allergan have managed to do with Botox in that context is to show payers 
the economic gain that they get in terms of ‘back to work’ or reducing ‘carer 
cost’, etc.   
Mrs Wendy Thomas:  I’m Chief Executive of the Migraine Trust and I was on the 
NICE guidelines development group on headache, which published guidelines 
last September.109 It’s interesting about cost because what was discovered in terms 
of cost-effectiveness, which is why the advice now to GPs in upping treatment, 
is that when a patient with migraine goes to see a doctor they are offered an 
NSAID and a triptan. That was actually cheaper than any other particular way 
108  For the use of the botulinum toxin in the treatment of migraine, see, for example, Becker and Amirlak 
(2012); Rapoport (2012); Frampton (2012); Durham and Cady (2011). See further comments by Professor 
Trevor Jones on page 57. 
109  NICE (2012).
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of treatment. The other thing that astonished all the health professionals around 
the table was that the evidence showed that an antiemetic was as good on its 
own as with other treatments. So, though cost is obviously terribly important, 
the business of the NSAID and the triptan turned out to be the cheapest and 
most effective option, which of course keeps NICE very happy indeed. Also 
the point being made about Botox and other things is absolutely right. We 
forget how many people suffer from migraine; there are 25 million days a year 
of work and education in this country lost through migraine, and that is part 
of the problem when you do the economic costs. Tim Steiner has done some 
excellent work on the epidemiology and the economic cost of migraine, which 
the government has taken on board for figures.110 But that’s what we’ve got to 
keep pushing at, given that the reason why migraine doesn’t get funding, and 
I’m sure we’ll talk about this afterwards, of course, it doesn’t actually kill you. 
Aronson:  Can I give a patient’s view?
Weatherall:  Please do.  
Aronson:  I have migraine, at least I have what I call migraine. It sounds sexier 
than cluster headache or tension headache or any other syndromic abnormality 
that you might describe. But I’ll tell you my story and you’ll decide whether I have 
migraine, and I’ve had it pretty much all my life. Certainly I remember as a child 
at the age of seven or so suffering sick headaches, what my mother called bilious 
110  See, for example, Steiner (2010); see also Steiner et al. (2003).
Figure 17:  Dr Jeffrey Aronson and Dr Richard Peatfield 
Migraine: Diagnosis, Treatment and Understanding c.1960–2010
50
attacks. Headache, severe; a few hours later vomiting; going to bed; waking up, 
feeling as if your brain has been scrambled. It’s debilitating. I had it until I was in 
my early or mid-teens and then not again for 20 to 30 years, when it came back. 
These attacks are very severe. In me, they start with a pain in the neck about an 
inch behind the mastoid process. They then spread up over the right side of the 
head into the forehead. Occasionally I get a dull aching on the left side but the 
usual way of it is as I’ve just described, on the right. It gets worse over a few hours 
and I vomit, the intensity of the vomiting being proportional to the intensity of 
the headache. During this time I have sought a darkened room but photophobia 
is not a major aspect, nor is hyperacusis or any other local symptoms, tenderness, 
or whatever; just the headache and the vomiting. After the vomiting, I sleep and 
I wake up the next morning, as I said, feeling as if my brain has been put in a 
liquidizer and poured back into my skull and I am mentally pretty much out of 
it for that day. So this is a 24–36-hour disease as far as I’m concerned, and it is 
incapacitating. I have tried everything: aspirin, paracetamol, prochlorperazine as 
an antiemetic sublingually or buccally rather than orally. I haven’t tried ergotamine 
or methysergide, I certainly haven’t tried clonidine. Nothing worked. 
I was visiting my friend and colleague Robin Ferner in Birmingham one day; 111 
 we were writing a paper. It was a sunny day; dehydration brings it on, not in 
my case chocolate, but wine brings it on. Any alcohol actually, more than one 
unit, except the day after an attack after a triptan when I’m refractory and can 
drink, which is another benefit of the triptans. So I got a migraine during that 
day. It was a beautiful spring bank holiday and Robin said: ‘What do you do 
about it?’ I said: ‘Nothing works.’ I said: ‘The only thing that works is exercise, 
half an hour on the bicycle up the Banbury Road, down the Woodstock Road 
to St. Giles, back up to Summertown, that relieves the headache. But I’m not 
in Summertown and I don’t have my bicycle. What am I going to do?’ He said: 
‘We’ll go to the chemist and get you a triptan.’ Now at that time there was this 
caution about being aged over 45 and a risk of myocardial infarction because 
of coronary vasoconstriction, and I had avoided triptans because of that. But 
he said: ‘Oh no, don’t worry about that, forget it.’ I said: ‘Fine, let’s go and 
get it.’ So we went to the pharmacist’s and he only had naratriptan in stock – 
Naratriptan Melts.112 So I bought a tablet at a vast cost; Robin wrote a private 
111  Professor Robin Ferner is a Consultant Physician and Clinical Pharmacologist at Birmingham City 
Hospital and Honorary Professor of Clinical Pharmacology at the University of Birmingham.
112  Naratriptan, marketed as Naramig, was launched by GlaxoSmithKline in 1997. See comments by 
Dr Patrick Humphrey on pages 63–4. 
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prescription. We walked back to his house and I put it under my tongue. Now 
I thought, nitrates under the tongue act very rapidly. So I thought that this 
melt under the tongue would act very rapidly. So I let the tablet melt under 
my tongue, and suddenly [snaps fingers] – nothing happened. Well, the saliva 
accumulated under the tongue until I had to swallow it and I thought: ‘Well, 
that was a waste of ten quid or whatever.’ I went on writing the paper, because 
I knew nothing would affect the migraine and I thought I’d better get as much 
work done as I could before I conked out. One and a half hours almost to the 
minute after putting that melt into my mouth the headache switched off – just 
like that. If you’d told me that that would happen I would not have believed you. 
It was like a switch and the headache disappeared instantaneously. It’s happened 
once to me before in other circumstances113 but I would not have believed it. 
Since then I’ve taken naratriptan regularly. I take it orally, and it works within 
about an hour and a half to two hours. And the other thing that I’ve noticed, as 
the last part of this story, is that having been taking it now for about ten years 
I suppose, and the frequency of my attacks has increased, but the severity is 
aborted by taking a tablet of naratriptan as soon as I feel the headache coming 
on. Occasionally I wake with it and then it’s sometimes too late and I have to 
take two tablets, and even then sometimes that doesn’t help, but that is rare. 
Weatherall:  Speaking on behalf of the clinicians in the audience, you have 
migraine, and an effective treatment which is thanks to Pat and to Alec and 
Pramod and all the others who worked on the triptans. 
I’d like to move on to one other aspect really of the 5-HT story and then take 
that into the scientific impact of the triptans. One thing that I think that Pat 
may have briefly alluded to and rang some bells with me in terms of what 
Richard Peatfield, I believe, found himself doing in the early days in Clifford 
Rose’s group was the platelet story.114 There are bits and pieces of migraine 
113  Dr Jeffrey Aronson wrote: ‘On that occasion I was down to give an after-dinner speech at a dinner hosted 
by the erstwhile magazine The Listener, at the Café Royal, and my migraine came on during the dinner. I 
went to the toilet to vomit and the chairman for the evening found me there. I said that I didn’t think that 
I could give the speech and he persuaded me just to give the toast. When the time came he introduced me, 
and as I got to my feet the headache switched off instantaneously. I gave the whole speech, sat down, and 
the headache flooded back. Could it have been an effect of endorphins?’ Note on draft transcript, 30 July 
2013.
114  See also the discussion in the Witness Seminar on drugs affecting 5-HT systems (Overy and Tansey (eds) 
(2013)). 
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research from a historian’s point of view that rise and fall and this is something 
that was quite prominent in the 1960s, 1970s, and 1980s but has fallen out of 
view. Richard, what can you recall?
Peatfield:  I had five minutes’ notice of this question and I would need a few 
days to reread all the material because it has slightly faded from memory. I was 
appointed by Frank Clifford Rose115 to work at Charing Cross in 1979 on a 
fellowship supported by the Migraine Trust, so there was a bit of an obligation 
to do some sort of headache-oriented research. It soon became clear that I 
needed a source of wise guidance, which was kindly given to me by Merton 
Sandler who is now sitting in front of me. So Marek Gawel and I trailed off to 
Merton Sandler’s lab at Queen Charlotte’s and we worked out what we could 
do.116 As with most science it’s all based partly on the availability of patients and 
partly where the technology had got to, and this was the era of platelet function 
and platelet testing for monoamine oxidase. Merton, as you know, is a world 
authority on monoamine oxidase and had spent a long time chasing monamine 
oxidase in platelets.117 He had a number of research fellows, PhD students, 
who were biochemists and pharmacologists who did much of the technical 
work and I was just responsible for recruiting the patients, taking the blood 
samples, and making quite sure that someone else centrifuged them rather more 
skilfully than I was able to.118 That became very clear very early but Merton 
was very sweet about my utter inability to actually stand in the laboratory all 
afternoon when I had outpatient letters to dictate. So basically the vogue at 
the time was that platelets were hyperactive in migraine and really nothing has 
happened to gainsay that view, it’s just that technology has moved on, and 
particularly pharmacology has moved on. They have bigger and bigger scanning 
machines and cleverer and cleverer algorithms for working with them and so 
the cutting edge has moved elsewhere but that doesn’t mean that the platelets 
have forgotten about migraine, though we may have forgotten about platelets. 
I’m sure that somewhere in the heart of the pathogenesis of migraine, platelets 
are still there and are still somehow acting as blotting paper between attacks and 
115  Dr Frank Clifford Rose (1926–2012) was a Consultant Neurologist at Charing Cross Hospital from 
1965 to 1991 and Chairman of the Migraine Trust from 1987 to 1995. See further biographical details on 
pages 106–7. 
116  Dr Marek Gawel is a Neurologist at the Sunnybrook Health Sciences Centre, Toronto, where he runs the 
Headache Research Unit, and is Associate Professor of the Division of Neurology, University of Toronto.
117  Collins and Sandler (1971). See also Sandler (2004).
118  See, for example, Littlewood et al. (1984).
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discharging some kind of noxious small molecule, almost certainly 5-HT or 
something closely related to it, during the attack. Probably they’re filtered out 
in the lungs, which is probably the reason why patients with persistent patent 
foramen ovale have rather worse migraine, because they can bypass the lungs. 
This would explain why patients with hereditary haemorrhagic telangiectasia, 
the disease with the large arteriovenous malformations within the lungs, also 
have extremely bad headache.119 So there’s probably more to platelets than 
meets the eye but the technology has moved on and the whole thing has rather 
shrunk from public viewing. But when somebody in 150 years’ time writes a 
comprehensive textbook of the pathogenesis of migraine (I look forward to 
reading it if I’m still around), I’m sure that platelets will be somewhere in there 
as a contributory factor.  
Sandler:  I just wanted to say that Richard wasn’t such an idiot as he makes out; 
he was really quick on the uptake for a clinician. [Laughter] I’m an ex-clinician 
myself when I say that. What he’s trying to tell you is, I think, that platelets 
contain only monoamine oxidase B, they don’t contain any A at all. But in 
migraine we found a transitory decrease in monoamine oxidase B during the 
period of the attack of migraine. Why or how I have no clue, but that’s just 
another chance finding and we put it on record, we wrote a paper to Nature on 
all that.120
119  See Nightingale and Ray (2010).
120  Sandler, Youdim and Hanington (1974).
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Blackburn:  Just following on from Richard’s comment, like Merton I followed 
this work with great interest and I was pleased to share a train going up to 
Manchester with Merton on many occasions. However, I published a paper 
in 1990 in a book entitled Cardiovascular Pharmacology of Serotonin edited by 
Pramod Saxena and David Wallis, where data was presented on another ICI 
compound, ICI 170,809, a selective 5-HT
2A
 receptor antagonist, showing an 
inhibition of human platelet aggregation in vitro and ex vivo.121 It was a double 
blind randomized study which showed that the compound was extremely potent 
at 0.1mg/kg p.o. (per oral) and at the time I felt this was extremely important 
in understanding the pathogenesis of migraine and trying to link the platelet 
with either vascular or the neurogenic events. And, I’d love to hear Pat talk a 
bit later about some of the discussions he had with John Fozard at the time 
where the Sandoz group were coming from the neurogenic approach, where 
modulation of dorsal raphé and other raphé nuclei could well be important in 
the pathogenesis of migraine. And, there was often some great debate between 
Pat and John and Brian Richardson. At that time in the 1980s and 1990s we 
all were trying to piece together the vascular events, with platelet events and 
the control of these raphé cell bodies, what they were actually doing and the 
neurogenic consequences of migraine.
Weatherall:  I’m going to ask Pat to come to that point in a minute but can I just 
mention another aspect of the problem that was happening around the same 
time, that is some of the studies that you Jes, Martin Lauritzen, and your group, 
were doing on regional cerebral blood flow in aura. I wondered if you might just 
tell us a little bit about that please?
Olesen:  As I mentioned, I did my thesis on the physiology and pharmacology 
of brain blood flow in humans using the intracarotid injection of radioactive 
xenon technique developed primarily in Copenhagen by Professor Niels Lassen, 
who was my mentor. Having finished the thesis I thought, ‘Migraine is an 
interesting disease to study with brain blood flow’ because there had been some 
studies; Michael O’Brien did the first study with not very precise methods but 
it was really pioneering work.122 Then my neurological mentor, Skinhøj, studied 
a few patients with intracarotid xenon, showing decreased blood flow during 
the aura.123 So that’s why I decided to focus studies on this and we worked 
121  Blackburn et al. (1990). 
122  O’Brien (1967); see page 5. 
123  See, for example, Skinhøj and Paulson (1969). 
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on this for some 10–15 years because it’s very, very difficult to get patients in 
during an attack and study the brain blood flow. The first years of study were 
done in the days before the CT scanner came around, where patients who had 
perhaps migraine aura, perhaps transient ischemic attack, were angiogrammed. 
We actually proved that the injection of saline or the puncture or the injection 
of contrast medium would elicit a migraine aura at a lag time of about one hour. 
We worked closely with radiologists so we could take patients after an angiogram 
to the flow laboratory and when they were in there we had time to take a resting 
state measurement and then they got the aura. Therefore we could follow the 
development of the aura with repeated brain blood flow measurement and we 
could show the slow spread of reduced blood flow, which was very similar to 
spreading depression. We could also show lack of functional activation in the 
area affected by the aura. And there was preserved autoregulation and abolished 
or decreased response to CO
2
, many things that were similar to the animal 
experiment model of cortical spreading depression. But at the same time we 
saw that in migraine without aura there were no changes in brain blood flow.124 
I followed up on the City of London Migraine Clinic and created a similar 
clinic in Copenhagen in order to get access to lots of patients during acute 
attack and, with Martin Lauritzen, we studied a large number of spontaneous 
attacks. At that time with single photon computerized tomography and xenon 
inhalation, which was atraumatic, we could show that blood flow was perfectly 
normal during migraine attacks without aura but quite abnormal during the 
migraine aura.125 That was actually the basis for a distinction between migraine 
with and without aura in the first edition of the International Headache 
Classification in 1988.126 We could also demonstrate that the original simple 
idea of vasoconstriction followed by hyperaemia was not explaining the 
migraine attack, because people got headache while blood flow was still low and 
sometimes blood flow stayed high long after their migraine attack had gone. So 
there was no good association between blood flow and migraine pain. Clearly 
the Wolff hypothesis of vasoconstriction was not right; it was cortical spreading 
depression and this has later been substantiated by PET studies and fMRI 
studies and so on. But the enigma after that was really: (a) why does cortical 
spreading depression cause headache? And (b) why do patients without aura get 
a headache? What’s the basis of their attacks?
124  See, for example, Olesen (1978). 
125  See, for example, Lauritzen and Olesen (1984).
126  See pages 14–15 and note 29.
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Weatherall:  Thank you. So we have a situation in the late 1980s and early 
1990s where we have a very effective new drug developed out of work on 5-HT. 
We have a breaking down of the biphasic view of migraine pathogenesis that 
Michael O’Brien mentioned right at the beginning. But Pat Humphrey, can I 
turn to you and ask: in that context were people discussing and debating how 
your drug actually worked?
Humphrey:  Well, can I just slightly precede that because if we’re still in the early 
1990s then we were discussing platelets and whether they were relevant and, 
yes, John [Fozard] and I did have a number of debates on this. I think he was a 
little bit more positive than I was, but at the end of the day I think we probably 
got to a similar space because we both wrote reviews and mine was written in 
the Journal of Neurology in 1991 where I sort of debunked the belief in platelets 
and migraine because it just didn’t really seem to hang together.127 I think there’s 
some question about how reliably it happens in every patient. Clearly in some 
patients you can get the metabolite of 5-HT, 5-hydroxyindole acetic acid, in 
the urine. You get a substantial drop of 5-HT, about 40 per cent, in platelets, 
so clearly something’s happening in many of these patients. In fact, it was quite 
interesting that Lance thought that maybe when people were sick that there 
was some sort of physiological mechanism whereby, by being sick, you released 
5-HT from enterochromaffin cells in the gut and then this replenished the 
5-HT in the platelets. But he actually made all the measurements, thankfully, 
and disproved his own hypothesis because there’s not enough 5-HT coming 
out of the gut to replenish what was lost from the platelets.128 There are a lot 
of reasons for thinking it’s difficult to put anything into a pathophysiological 
scenario. However, what causes the 5-HT to be released from platelets? It does 
beg the question: is there some humoral agent circulating that may be intimately 
involved in the pathophysiology that we still haven’t found out about? That’s 
worth a PhD research study without a doubt. I’m not sure whether John and 
I both agreed on it, but certainly in my review of the platelets I said: ‘Well, 
okay, the platelets may not be important but maybe this release mechanism is 
happening somewhere else too, i.e. in the brain.’ That’s when you start to think, 
is 5-HT involved in control of trigeminal neurons and central pain pathways? 
But if you’re talking about the early 1990s, sumatriptan was only released in 
127  Humphrey (1991). See also Fozard and Kalkman (1992). 
128  See, for example, Anthony, Hinterberger and Lance (1969). 
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1991; yes, there was a lot of interest in mode of action, and there were a lot of 
people saying, ‘No, it can’t possibly be a vasoconstrictor mechanism, it must 
be something else.’ It did set off a whole lot of research but I think that went 
over that whole decade and beyond, and I think a lot of people will want to 
contribute to that discussion. 
Jones:  I’m fascinated by the discussion we’ve had many times this afternoon 
about chasing the mechanism of action of drugs.129 Of course, we all want 
to understand more how drugs work so that we can determine possible side 
effects or develop improved drugs, but the complexities are huge and I have 
said on many occasions there are virtually no ‘magic bullets’, they’re all ‘magic 
shotgun pellets’ and they work on all sorts of receptors. That’s especially true 
of botulinum toxin (Botox). We really don’t understand all the mechanisms of 
how Botox is working in this condition. We know how it is effective in patients 
who’ve had more than 15 days of migraine problems a month and what we are 
now doing is teasing the molecule apart – it’s a very complex piece of biology – 
and looking at segments of it, to find those elements that are effective in pain.130 
We believe that this will open up, I hope, another generation of products which 
will be more specific in action and reaction.
MacGregor:  Going back to the way research was being done in the 1980s, 
particularly to the comment I made about how much of it may have included 
aura and not included without aura, is that the potential reason why we’re seeing 
different things?131 So, for example, could the platelet hypothesis be more related 
to migraine with aura rather than migraine without aura – which leads into the 
wonderful debates during the 1980s: are migraine without aura and migraine 
with aura two different disorders?132 Nowadays we’ve shifted onto ‘Tension type 
headache is a mild version of migraine’ and this new disease of chronic migraine. 
We’re beginning to muddy the waters as to what we’re actually researching. But 
if we’re bringing in these heterogeneous conditions under our label of migraine 
129  The mechanism of the action of drugs has been discussed in various Witness Seminars; see, for example, 
the Witness Seminars on clinical pharmacology (Reynolds and Tansey (eds) (2008a and b)).
130  See page 48 and note 108.
131  See pages 10–11. 
132  See, for example, Ziegler (1985); Dalessio (1985); Hachinski (1985); Wilkinson and Blau (1985); 
Olesen (1985). 
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when we have such a clear classification that we could be using, we are going 
to get things that don’t match up – we don’t know if people are looking at a 
condition that isn’t as heterogeneous as perhaps we now like to think it is?133 
Saxena:  I have a question actually to clinicians mostly. I have a conviction: I 
do not have any proof of it, but my conviction is that migraine is a syndrome 
rather than a disease. I’d like to know whether this classification which Jes has 
done can explain whether or not it’s a syndrome or what views people have. And 
if it is a syndrome then, of course, there are going to be different mechanisms 
and different treatments and that may also say why triptans are not effective in 
some patients.
Volans:  One of the things that may be muddying the waters and which we need 
to consider in more detail, is the importance of what we call drug-induced 
headaches. This appears to be a problem for almost every class of drugs that 
are used in migraine. I was very convinced about drug-induced headaches with 
ergotamine but beyond that I can’t really claim any clinical experience.
Sandler:  There was something we haven’t talked about at all. In about the 1990s 
there was a rash of papers indicating that patients with a right to left cardiac 
shunt tended to get migraine pain and that this was confirmed at a number 
of different centres at the time.134 This was the actual migraine pain, not the 
spreading depression that we’re talking about. This was one of the reasons that I 
said before that I always think of the Leão’s spreading depression as nothing but 
another trigger of migraine pain.135 
Olesen:  To answer Pramod’s question about syndrome: because migraine is a 
heterogeneous syndrome and it’s illustrated very well by the rare variant familial 
hemiplegic migraine where there are already three different genes involved 
and the mutations in these genes have different mechanisms136 But there is 
probably a final common pathway in the mechanisms. We have to look at 
biochemical pathways somehow. It’s clear that migraine can have many, many 
133  Professor Anne MacGregor clarified this: ‘… the classification of migraine seems to be expanding to 
incorporate an increasing number of headaches labelled as migraine. Research into the true nature of the 
condition becomes difficult as the classification includes more heterogeneous disorders under this label.’ 
Email to Ms Caroline Overy, 19 December 2013. 
134  For a more recent discussion of cardiac shunts, see, for example, Bussone (2006).
135  See page 5. 
136  See, for example, Ferrari (2008). 
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different initiating mechanisms but somewhere down the line there is a final 
common pathway, and sumatriptan and the other triptans have actually helped 
us understand that, because when they are given as injection they are effective 
in 80 per cent of the patients. By the way, that’s also an external validation of 
the clinical diagnostic criteria that we made for migraine in the mid-1980s. We 
were able, from purely clinical symptoms, to identify a disease that has 80 per 
cent response to a very selective kind of drug. So it works both ways but what 
people are really looking for now, of course, is to hit the final common pathway 
because if you go out and try to hit all the individual initiating mechanisms 
there may be a hundred different mechanisms and we would never be able to 
have a drug that could work for more than a small percentage of patients. But 
down the pathway is the hot spot that we all want to identify.
Aronson:  I look at this nosographically the other way around. Instead of 
thinking that 80 per cent of all migraineurs respond to triptans, and I’ve used 
triptans for a lot of patients with migraine-like headaches, I think of them as 
triptan-responsive headaches. I don’t think that’s necessarily nosographically 
very useful, but it’s very useful clinically that there are headaches that respond 
to triptans. I don’t know whether they’re migraine or what the mechanism is, 
maybe they’re heterogeneous with multiple mechanisms, but they respond to 
triptans and that’s my diagnostic category.
Olesen:  In classification you cannot use drug response. When we did the first 
edition of the International Headache Classification that was before the triptans 
and there were actually several members of the committee who wanted to 
include response to ergotamine as a diagnostic criterion for migraine and I was 
able to fight that. There were also other people who wanted to include a positive 
family history as a diagnostic criterion of migraine. But if you include that in 
the criteria you can’t study genetics and migraine. If you include response to a 
drug in the criteria you are stuck there, how are you going to test new drugs 
that may work and so therefore you cannot do it like that. Now that has been 
said, when you have cases where it is difficult to distinguish between tension-
type headache and migraine, you don’t really know what precisely is this in your 
clinical practice, it is obviously perfectly fine to try to give them a triptan. If 
they respond to a triptan you think this is probably more migraine-like. If they 
don’t respond but have a better response to aspirin you think this is probably 
more like a tension headache.
Migraine: Diagnosis, Treatment and Understanding c.1960–2010
60
Aronson:  No, I don’t go that far. I agree entirely with what you’ve said 
nosographically. That’s absolutely right. But clinically I think it’s useful to label 
the headache in that way. I don’t then say it’s migraine because it responds to a 
triptan, I just say: ‘it’s triptan-responsive; aren’t you lucky?’ [Laughter]
Weatherall:  There is an absolutely fundamental issue here of how you define 
what you’re dealing with and how you differentiate different types of headaches. 
Of course, there is a philosophical point whether one is a lumper or a splitter 
in terms of trying to define what one’s dealing with from the clinician/historian 
point of view. One of the great successes, I think, of the first edition of the 
International Headache Society (IHS) criteria is that it allowed a definition of 
a coherent group for clinical trial purposes. I think those of us who look after 
patients would recognize that not everybody has read the IHS criteria, and 
not all their headaches fulfil them, even though we feel quite comfortable as 
clinicians labelling them as migraine. I’d like to move on really briefly to bring 
us back to the business of the impact of the triptans on the science of migraine. 
Humphrey:  Perhaps I could start off with something interesting from the 
history point of view, that for me one of the major excitements of sumatriptan, 
other than the major one, which was obviously to find a drug to treat patients, 
was the stimulus that it gave to trying to understand the aetiology of migraine 
better. It was kicked off beautifully by a meeting that Merton Sandler organized 
at Leeds Castle in 1988. I’ve got the book here and it’s called, a brilliant title, I 
don’t know whether you came up with it, Merton, A Spectrum of Ideas.137 There 
are a lot of people who I wish were here, like John Fozard and other people that 
were talking. John was talking about evidence from 5-HT receptor antagonists 
for a neural aetiology. He was trying to push something very different to what 
I was trying to push in terms of an idea, it was 5-HT
3
 antagonists for migraine. 
As it turned out they didn’t work but it nevertheless stimulated a huge amount 
of debate and a lot of experimentation, which led to other ideas. Even Richard 
Peatfield was there talking about the role of platelets in migraine with a personal 
perspective. This was all before sumatriptan was actually marketed but the story 
was out, and everybody wanted to know how it worked. That was a tremendous 
meeting. It was also a tremendous meeting because we had the privilege of 
having dinner with Princess Margaret, who was then the patron of the Migraine 
Trust, and we had a jolly good evening and I think she did as well. But what was 
137  This volume, Migraine: A spectrum of ideas, contains the papers presented by the 25 participants at the 
Migraine Workshop in 1988 (Sandler and Collins (eds) (1990)).
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interesting was that we had a very interesting menu and one of the things on this 
multi-course menu was lettuce soup and I was really looking forward to lettuce 
soup because I’d never had it before and I thought: ‘That will be interesting to 
taste.’ Anyway, there was so much wine flowing, I don’t think anybody noticed 
the lettuce soup didn’t come except me and I was muttering. It turned out that 
Princess Margaret didn’t want lettuce soup so it was all poured down the sink. 
And the maddest person of all in the whole castle was the chef who had to put 
five gallons of his best lettuce soup down the sink. [Laughter]
Sandler:  This is absolutely true. 
Humphrey:  I think that really did set the scene and I’ll pass over to other people, 
but my own reflection of that next decade was wanting to know: is sumatriptan 
acting as a vasoconstrictor or is it acting neuronally? There was a huge amount 
of experimentation focused on this. Just suffice to say, another exciting point 
was that I was put in a debate with Peter Goadsby, again another person who 
really should be here, who contributed a massive amount to understanding 
the mechanism of action of the triptans.138 I was put in a debate with him in 
Whistler in Canada so it was very appropriate, apart from the fact that it was 
my 25th wedding anniversary and that was a bit of a difficult one to pull off. 
‘Go and give a lecture in Whistler’, I was told, so I took my wife. Anyway, it 
was like a prize fight, I was in the ring with Peter Goadsby and it was very 
exciting. I thought I won on the vasoconstrictor story while still alluding to 
the fact that sumatriptan will inhibit neurons and maybe there’s partially an 
involvement via that. Peter Goadsby, of course, thought he won and he refused 
to talk about the vasoconstrictor side of things even though he knows very well 
that it’s quite important. At the end of the day they had a vote and the whole 
audience were neurologists and migrainologists and I think they were all very 
diplomatic and they agreed it was a draw (Figure 19). [Laughter] Again, there 
was a very interesting article associated with the debate that still stands. I read 
it for the first time nearly 20 years or something later, and it still is quite a good 
read.139 But things have moved on since then. 
138  Peter Goadsby is Professor of Neurology in the Department of Neurology, University of California, San 
Francisco, and Director of the UCSF Headache Center. He became Director of the Wellcome Trust Clinical 
Research Facility at King’s College London in 2013. For his research on the mechanism of actions of the 
triptans, see, for example, Ferrari et al. (2002); Goadsby, Lipton and Ferrari (2002); Goadsby (2007).
139  The debate was held at the second International Sumatriptan Symposium, a satellite symposium to the 
World Congress of Neurology, on 11 September 1993. See Humphrey and Goadsby (1994).
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Weatherall:  Yes, it’s a shame that Peter couldn’t be with us today because 
I would have liked to really ask him about the work that he did with Lars 
Edvinsson using sumatriptan essentially as a tool to try to unpick which of the 
neuropeptides, calcitonin gene related peptide (CGRP), Substance P, and so on, 
are actually relevant in migraine pathogenesis.140 Jes, do you want just to say a 
little bit about that side of things?
Olesen:  We must not forget Michael Moskowitz’s important work.141 One of 
the ways in which it stimulated research was that his neurogenic inflammation 
model for some time looked like an important model that could predict the 
efficacy of anti-migraine drugs, but then was proven to be unspecific because 
many drugs worked in this model but did not work in migraine.142 On the 
other hand it may still be a sensitive model because all effective drugs inhibit 
neurogenic inflammation. So maybe all drugs that work in migraine have to 
140  See Edvinsson and Goadsby (1994).
141  Dr Michael Moskowitz is Professor of Neurology at the Neuroscience Center at Massachusetts General 
Hospital. His laboratory’s research has focused on cerebral blood vessel function and translational studies of 
stroke, migraine, and traumatic brain injury. 
142  See, for example, Moskowitz (1993); Buzzi and Moskowitz (2005). 
Figure 19: Dr Goadsby and Professor Humphrey after their debate at the 2nd International 
Sumatriptan Symposium, in September 1993 at Whistler, BC, Canada  
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also work in this model, we don’t know yet. Mike and others too showed that 
triptans bind to the peripheral sensory nerve endings and hyperpolarize them. 
So stabilizing peripheral nerve endings was one mechanism. Later on, also in 
Boston, Rami Burstein has done wonderful work showing that the triptans also 
work pre-synaptically in the brain stem to inhibit the transmission of impulse in 
the first synapse of the trigeminal system.143 So there are at least two neurogenic 
mechanisms that may or may not be important – we still don’t quite know – 
together with vasoconstriction. I favour that the triptans are effective because 
they work at three different sites at the same time, not one mechanism. 
Humphrey:  Can I just add to what Jes has said. I think the Moskowitz data 
was really interesting and we knew before that triptans would inhibit neuronal 
transmission so that wasn’t unique, but there are two things against the 
Moskowitz concept. One of them is some drugs didn’t work in migraine even 
though they worked in his model, that’s a killer for a start. I pointed out right 
from the start that 5-HT doesn’t work in his model, yet we know 5-HT can 
relieve the symptoms of a migraine attack, so there’s that issue. The final point 
for me is that we designed sumatriptan not to get into the brain, hence the poor 
bioavailability that Trevor has referred to,144 and I believe it does barely get in 
the brain. In fact, even Peter Goadsby’s got data to show that it doesn’t get in 
the brain in animal models and yet the newer triptans are all very lipophilic, 
they get into the brain, so does naratriptan by the way, and they’re no better 
clinically.
Jones:  Just briefly, about the lipophilicity of zolmitriptan. We knew that the 
onset of activity of sumatriptan was about an hour or more. The marketing 
team said to us, ‘If you can get something which is faster acting then that will be 
an advantage over sumatriptan.’ So that was why we tried to increase absorption.
Humphrey:  But, as I was saying to Jeff, we already had a much more lipophilic 
compound than any of them and that was naratriptan. And, funnily enough, 
what happened was they got one or two triptan-like side effects in a very early 
study and so they went to a much lower dose. So that negated any side effects 
(indiscernible from placebo) and in fact naratriptan is a very interesting triptan 
because you can’t get any triptan-like side effects with that drug at all. And yet, 
because it’s a lower dose, it may not be as effective for some people, but Jeff says 
143  For a general review, see for example, Burstein, Jakubowski and Rauch (2011). 
144  See page 39.
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he still uses it and it’s very good for prophylaxis around menstrual migraine and 
so on, so it’s got a place. But if you’re talking about who’s got the best lipophilic 
compound, naratriptan beats the lot.145 
Saxena:  To add to what Jes and Pat have said, is that you’ve got to ask two 
other questions, namely there are 5-HT
1D 
receptor agonists, there are 5-HT
1F 
receptor agonists and they were being promoted as anti-migraine agents. Well, 
this is fine; the notion was that they will be effective in migraine because they 
work on the neurons and not on blood vessels. It turned out that these types of 
compound are completely inactive. Some people still say that they are active. 
I don’t believe in it because the drug companies are not stupid, they are very 
clever. If there was any chance of developing a 5-HT
1F
 or 5-HT
1D
 compound 
they would have done it by now. So, that’s a response to Peter Goadsby. 
Weatherall:  For once he’s not here to defend himself. [Laughter]
Blackburn:  Just talking on the 5-HT
1F
. I went across to join my first biotech 
company in the States in 1999, Synaptic Pharmaceuticals, and Dr Terry 
Branchek was working alongside Eli Lilly at that time. I think I arrived on the 
Monday and the project died on the Thursday. That was a sad day with regard 
to the 5-HT
1F
 receptor theory and migraine.
Saxena:  So they don’t want to look further.
Weatherall:  I’d like to take the discussion in a slightly different direction. One 
of the things that’s really struck me, listening to what’s been said about the way 
that research was done in the 1960s, 1970s, and 1980s, is the importance of 
being able to recruit patients relatively easily and straightforwardly from walk-
in clinics. We’ve obviously got the City of London Migraine Clinic; Jes, you’ve 
mentioned purposely copying that pattern, presumably to treat patients as well 
as to recruit people for research. I just wondered about the issue of studying 
patients with an episodic condition and the limitations that would put and how 
people would try to counter those limitations. 
Olesen:  Yes, we had a problem when we wanted to study brain blood flow 
during migraine attacks. It’s very difficult to recruit patients to actually come in 
during a spontaneous migraine attack. They are nauseated, they may vomit in a 
taxi. Even if you pay for a taxi for them they want to stay in bed at home and so 
on. So our experience has been that you need to recruit at least 10 times more 
145  For a review of naratriptan, see Mathew (1999). See also comments by Dr Jeffrey Aronson on 
pages 50–1. 
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patients than you end up studying, maybe 20 times more patients than you 
end up studying. There are some really formidable problems there and today 
we see the same problem in magnetic resonance (MR) studies, for example. We 
have managed to study 19 patients during spontaneous attacks, which we just 
published in the Lancet Neurology.146 But others have only managed to study one 
patient. We could do it because we have a huge flow of patients and we have an 
inpatient unit also, it’s very difficult.
Weatherall:  Do you still run a clinic where people can just walk in?
Olesen:  No, we did away with that years ago because it’s quite resource-
demanding. You have to have doctors on duty and if you have the normal 
Neurology Resident responsible for a walk-in clinic, they really have other 
problems they consider to be more important, so the patient can lie there and 
wait for the Junior Registrar to come and treat them. It’s very difficult to make 
it work.
MacGregor:  I was going to say that sumatriptan, with its brilliance, killed off 
research on acute patients. When I first started working at the City of London 
Migraine Clinic towards the end of the 1980s, we were still getting one or two 
people in a month for acute treatment of migraine. I think when Glyn Volans had 
been working there, there was no problem getting patients coming in because 
they weren’t being treated effectively by their GPs. As soon as sumatriptan came 
on the market there was something that people could take that enabled them 
to carry about their usual daily business. So why on earth would they want to 
not take their triptan, to come along, and be involved in clinical trials when 
they would then be throwing up in a taxi on the way there? However much you 
pay them, however much you organize it for them, you can now not get acute 
patients to come along to a clinic for treatment.
Volans:  I tried to provoke migraine and failed miserably in a small number of 
volunteers who were fed whatever they said caused their migraine attacks and it 
never worked. Has anybody any better experience than me? 
O’Brien:  In my original series I had seven patients measured in the prodrome 
and all seven worked at Guys. The equipment was all set up to run and these 
people were asked to come straight to the lab as soon as they’d had the first 
inkling of a migraine attack. But from outside the hospital it would have been 
impossible.
146  Amin et al. (2013). 
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Peatfield:  I think we ought to pay tribute to Mike Cutrer at this point; he was 
one of the authors in many of Mike Moskowitz’s papers and is actually the brain 
you see on the published scan because he could quite literally elbow people out 
the way and get himself scanned within minutes of his own migraine starting.147 
There are a lot of his own scans in print. There aren’t many people like him.
Olesen:  To add a couple of things here also, almost by definition it’s impossible 
to study spontaneous migraine attacks at the time when you most want to study 
them – that is at the very initiating moment of the attack. It’s not possible 
because patients have to go to the clinic, there has to be something done either 
to draw blood or to put them in a scanner and so on. So it’s almost by definition 
impossible to study attacks until after one to two hours into the attack and so 
you cannot measure the initiating mechanisms. That was one reason why I 
switched over, around 1990, to study provoked migraine attacks because there 
you can provoke the attack with nitroglycerin and CGRP and many other 
substances that we have studied and you can study the patients before and just 
as they are developing attacks and so on. The problem is, of course, are these 
induced attacks identical to spontaneous attacks? 
Weatherall:  The City of London Migraine Clinic, to my understanding, was 
set up initially as a treatment exercise and was pretty much the first migraine 
clinic of its type. I think that Macdonald Critchley ran a clinic from somewhat 
earlier. And obviously the Danish had a centre that dates back 30 years or so 
at this stage. I wonder whether I could ask about the importance of specialist 
headache clinics in terms of not only the research but also actually building and 
promoting knowledge about headaches more generally. Richard, you’ve been 
actively working in the clinic that bears Princess Margaret’s name for over 30 
years.
Peatfield:  One point I think I should make. I started working for Frank Clifford 
Rose in 1979 and I was effectively second down from Princess Margaret. The 
patients weren’t sent to Princess Margaret, they weren’t sent to Frank Rose, they 
were sent to me. And I have to say my therapeutic effect was far greater when 
I was Princess Margaret down two notches than when I went to Leeds as a 
Senior Registrar. There I had actually much more status and was paid more but 
I was clearly a trainee whereas before, I was God minus two. [Laughter] A lot 
147  See Cutrer et al. (1988). Fred Michael Cutrer is Associate Professor of Neurology at the Mayo Clinic, 
Rochester, MN. 
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of migraine clinic work is actually giving the impression you know what you’re 
doing, actually getting the real problem out of a patient, not wasting time doing 
unnecessary investigations, and not starting them on a treatment they’ve already 
tried, especially ones that they themselves had bought at the chemist, but trying 
something different, something that only I had some expertise about. As well, 
of course, as using them as material to collect blood samples for this, that, and 
the other research project. So specialist clinics did have a major role and I think 
they still have a major role. I think now that neurology is breaking up into more 
and more special interest clinics, it’s vitally important that every major centre 
should have a clinic specifically for migraine patients.
Olesen:  And other headaches please.
Peatfield:  Oh yes.
Weatherall:  Anne MacGregor, much of your working life is based in and around 
the City of London Clinic. What role do you think that that clinic has played in 
the life of migraine in this city, in this country?
MacGregor:  It started off as the City Migraine Clinic originally, with a little 
ambulance that was supposed to pick people up from their place of work. 
Marcia then opened the City of London Migraine Clinic in 1980, when the 
Princess Margaret Migraine Clinic was moved to Charing Cross Hospital.148 
It was interesting to see the difference between NHS-based and charity-based 
clinics. In the charity setting, you could meet the needs of the patient rather 
than necessarily meet the needs of a manager, which can sometimes make 
the organization a little bit more complicated. But I think the main thing we 
gave patients was time. Patients wanted somebody who understood what they 
were talking about, who would let them speak, and who would help them to 
understand what they were experiencing. This was very different from what 
they were experiencing in general practice, which was: ‘You’ve got a condition, 
you’ve got migraine.’ Some of it was: ‘well, just go off and deal with it because 
148  The City Migraine Clinic was opened by Princess Margaret in 1970 in Little Britain near St Bartholomew’s 
Hospital, it then moved in 1973 to Charterhouse Square and larger premises on a six-year lease. The 
Migraine Trust ceased funding the clinic in 1979 to focus spending on research rather than patient care, 
and in 1980 the City of London Migraine Clinic (now the National Migraine Centre) was founded as a 
registered charity by Dr Nat Blau and Dr Marcia Wilkinson. The name of the Princess Margaret Migraine 
Clinic transferred to a new clinic at the Charing Cross Hospital. For a history of the Migraine Trust, 
including the migraine clinics, see Rose (2006). 
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that’s what you should expect.’ Otherwise it was just get the prescription pad 
out and write a prescription for something that wasn’t necessarily effective – be 
it a preventative treatment or a symptomatic treatment. But the patient never 
knew how it was going to end. So with a lifelong condition, they would get 
a drug but still be left wondering how else to cope with their lives. Or they 
were given a brain scan and told: ‘It’s okay, your brain is quite normal; it’s just 
migraine. Go away and live with it.’ There was an awful lot of ‘just deal with 
it, it’s migraine.’ I think migraine clinics gave the condition credibility. Then 
going back to sumatriptan, a drug which was specifically for a condition gave 
the condition credibility. I totally agree with the need to open more migraine 
clinics but perhaps more multidisciplinary clinics, with ophthalmologists, 
gynaecologists, and psychiatrists – not just neurology.
Professor Brian Hurwitz:  I was a GP for 30 years on the border of Islington, 
Hackney, and the City of London. I would just like to say that, in my experience 
as a GP, the City of London Clinic was a much better option to send patients 
to for the very reasons that we’ve just heard. Holistic care was on offer there 
with continuity of follow up from which people benefited. If you contrast that 
with the headache clinic at, for example, Queen Square, the thing that really 
struck me – and I eventually gave up referring patients to that clinic – was they 
were staffed with numerous clinical research fellows on short tours of duty in 
the headache clinic with very little continuity of care. Patients had a pretty 
Figure 20: Dr Mark Weatherall, Professor Brian Hurwitz and Dr Michael O’Brien 
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poor outpatients’ experience, the fellows were constantly saying the same things 
to quite different people, and, as I generally only ever referred complex-to-
manage patients, in my experience they frequently gained little from the clinic. 
So while some specialist NHS clinics might be helpful in terms of gaining 
research subjects, in my experience over a 30-year period, they’re not very good 
therapeutically.  
Weatherall:  Jes, do you have a comment specifically on that? 
Olesen:  Well, it’s wonderful we have this meeting about migraine, we’re talking 
about migraine clinics, but it’s really important to say headache clinics because 
we now know that, even if migraine is the most important headache disorder, 
what about cluster headache? What about trigeminal neuralgia? What about 
chronic tension-type headache? What about medication overuse headache, 
which is now a huge problem?149 What about all the many other primary 
headaches that we have identified and defined in the headache classification?150 
So really we should move away from the idea of migraine clinics. That is one 
thing. The other thing is that there are different kinds of clinics and people 
don’t always understand that. The original concept in the City of London 
Migraine Clinic and my own clinic originally in Copenhagen and a few other 
places was to let people come in with an acute attack, get treatment, and send 
them home. Of course, at the time this was good because patients got no other 
service but today it’s a useless exercise. In Denmark, we have identified three 
tiers of service: the first level, which takes care of the great majority of patients, 
are the GPs. The next level in Denmark is a practising neurologist or a non-
specialized department of neurology. The third tier is the highly specialized, 
multidisciplinary headache centre that we now have in Copenhagen, which 
covers the whole country, which is only five million people, but we only get 
patients who have seen a neurologist before they come to us. That brings up an 
important thing: the knowledge about headache has escalated enormously – just 
look at our big textbook called The Headaches, 1100 pages.151 There is so much 
knowledge about this that a general practitioner has no chance of knowing it all. 
Even a non-specialized neurologist has no chance of knowing it all. If you really 
want to utilize all the available knowledge about headache today there must be 
149  For discussions of chronic medication overuse headache and migraine, see, for example, Negro and 
Martelletti (2011); Sun-Edelstein, Bigal and Rapoport (2009). 
150  For a summary of the primary headache classification, see Appendix 2.
151  Olesen et al. (eds) (2006). 
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specialized centres, and the conclusion is that, even if patients have been seen 
by a neurologist, we can still help the majority of them. That’s simply because 
there is so much knowledge available that can only be handled appropriately by 
persons who have specialized in headache.
Weatherall:  Mary Ayres, could you talk about the role of patient groups in this 
process?  
Mrs Mary Ayres:  First of all I’m going to say the specialist clinic has played 
a large part in the lives of many of the members of the British Migraine 
Association (now Migraine Action). Whenever volunteers were needed for a 
piece of research at the City of London Migraine Clinic they came in their 
hundreds, and it was a lifeline for many people. Anne was talking about having 
time to talk. My first visit to the clinic was with my small daughter to see Dr 
Blau152 and he said to me: ‘Mum, sit there, be quiet. I’m talking to daughter,’ 
which he did, and she was able to tell him how unwell she was. I have seen the 
success of the Specialist Nurse service linked to Migraine Action. This has been 
a great help to a lot of our members and to non-members of the Association. 
I’m sure a lot of people come self-diagnosed and need reassuring or because 
their doctor doesn’t understand and only has ten minutes. So you do need time. 
I think clinics are vital.
152  Dr Joseph Norman (Nat) Blau (1928–2010) was a Consultant Neurologist and Clinical Director at the 
City of London Migraine Clinic from its opening in 1980 until his retirement shortly before his death. He 
was Honorary Medical Adviser to the British Migraine Association (Migraine Action) from 1980 to 2007.
Figure 21: Professor Tilli Tansey and Mrs Mary Ayres 
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Thomas:  I totally agree with Mary and also with Anne, it is about time. I think 
there are some good models that we’re aware of at the Migraine Trust for patients 
going to headache centres, and I totally agree with Jes, yes, they should be 
headache centres. What we know is that there are around eight million people 
with migraine in the UK, an awful lot of people. It’s a pity they don’t all put a 
pound in every year then we might have £8 million to do some decent research. 
[Laughter] That’s another story, which hopefully we’ll get on to near the end 
but we know that about 50 per cent of people don’t actually go to their GP – we 
need more GP education, more GP training. Again Jes is right, obviously they’re 
not going to know everything, but there’s a lack of interest and there’s a lack of 
interest within neurology as well. I know a lot of people who get sent on to a 
neurologist because their GP is fed up with them coming back, they send them 
to a neurologist who isn’t interested in headache (obviously a good GP over 
there [i.e. Brian Hurwitz] who sent them to the right person), and then they go 
and they’re even more frustrated. Most of the time they don’t go because perhaps 
their parents have had migraine and they’ve said: ‘Oh, you know, nothing can 
be done, go and lie down.’ There are some very good models where you have a 
neurologist and a headache nurse who carries on doing the follow ups. 
Weatherall:  Vicky, do you want to talk a little bit about the role of the headache 
nurse and what potentially you have to offer? 
Mrs Vicky Quarshie:  I’m the Headache Specialist Nurse working in Hull with 
Dr Fayyaz Ahmed.153 I’ve been in post for seven years now, and even in the 
short space of time that I’ve been working in headache as a specialty, there 
have been significant advances in the understanding and treatment of migraine, 
considering how long it is since triptans were first introduced to the market. 
My background is neurology and initially I worked on the neurology ward. The 
first time the concept of medication overuse was brought to our attention on 
the ward it was like a revelation and it does make you reflect upon your own 
practice.154 
153  Dr Fayyaz Ahmed is a Consultant Neurologist at the Headache Service Hull and East Yorkshire Hospitals 
NHS Trust. For an account of the role of the Headache Specialist Nurse, see Appendix 3.
154  Mrs Vicky Quarshie wrote: ‘The realization that possibly many patients who have been treated for 
headache in the neurology ward often admitted for another neurological condition, have possibly had a co-
existing medication overuse headache complicating the underlying headache phenotype, often migraine.’ 
Note on draft transcript, 23 October 2013.
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Patients would inform nursing staff and say: ‘Oh, I’ve got a headache.’ The 
nurses would ask: ‘What do you usually take when you have headache?’ The 
patient would respond with: ‘I take paracetamol or co-codamol.’155 The nurse 
would look at the drug card and inform the patient they were not written up for 
it and the doctor would need to prescribe it or if the patient was written up for it 
the nurse would administer it to the patient and possibly unwittingly contribute 
by compounding the medication overuse headache cycle.156 
My personal goal is to inform every nurse and medic within our trust about 
medication overuse headache and encourage them to stop and think before 
they add paracetamol or opiate derivatives to the drug card ‘When Required’ or 
to simply ask the patient about their headaches – whether they have a formal 
diagnosis, the frequency of the headaches, and acute analgesic use. 
155  Mrs Vicky Quarshie added: ‘Generally this would be something that the patient would have bought over 
the counter or with their weekly groceries and therefore it would not be prescribed on the hospital drug card 
or reflected on the repeat GP prescription readout.’ Note on draft transcript, 23 October 2013.
156  Mrs Vicky Quarshie wrote: With the knowledge of medication overuse headache, the actions of nurses 
and medical staff would be different. Rather than prescribing the medication, questions would be asked: 
why does this patient have headaches? Have they been given a formal diagnosis for the headaches they 
experience and what treatment have they tried previously? Most importantly, the question should be how 
often do they have headaches and how often do they take medication particularly analgesics and triptans 
which can quite easily elicit the possibility of medication overuse contributing to the overall headache 
profile. It is difficult to believe in these enlightened times with the knowledge about medication overuse that 
this scenario would happen. However, medication overuse is still a significant problem for many patients 
attending neurology clinics, GP surgeries and many people within the community who do not even consult 
their GP or a healthcare professional.’ Note on draft transcript, 23 October 2013.
Figure 22: Mrs Vicky Quarshie 
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If this scenario was implemented within every healthcare setting, by how many 
people would it be possible to reduce the incidence of medication overuse and 
then address the underlying headache phenotype with a more effective strategy 
with benefits to patients and the overall healthcare budget?
Within our clinic in Hull we have probably around 28 to 30 new referrals a 
week into the headache clinic and they’re seen by Dr Ahmed and the registrars. 
A large majority of patients are given a management plan and are discharged 
back to the GP. However, all patients are given my contact details where they 
can be given rapid access back within the service if required.157
Sometimes when patients come to me they’ve had quite a bad experience through 
the healthcare system via the GP or unfortunately through secondary care 
providers, and they can be quite negative and angry when they come to clinic.158 
I do agree that generally what I have is more time to sit down with patients 
to listen to what they actually want. When you listen to patients, it’s not a 
prescription that they want, they want somebody to know and somebody 
who understands exactly what is going on for them. Quite often patients are 
surprised when I say: ‘Well, how about we start taking away some of those 
treatments and then see what exactly is going on before we start giving you 
another medication to try; let’s take something away.’ Often patients are quite 
receptive to that because they’ve come in quite angry about: ‘Oh, you just want 
to give me another tablet’, and I’ve said, ‘No, let’s just stop and think about this 
and take everything away if it isn’t working; let’s strip it back.’ 
I do provide education sessions for patients, public, and other healthcare 
professionals, often in association with Migraine Trust, Migraine Action, British 
Association for the Study of Headache (BASH), within the hospital trust where 
I work, community healthcare setting, and the pharmaceutical industry, which 
I do see as an essential part of my role. 
One of my interests is migraine in children. Although we don’t see young children 
in clinic, we do see adolescents and that’s something that I think is an area that 
really needs to be addressed because children and teenagers with migraine grow 
157  Mrs Vicky Quarshie added: ‘following a telephone call which can be initiated by the patient in addition 
to their GP or other healthcare professional.’ Note on draft transcript, 23 October 2013.
158  Mrs Vicky Quarshie wrote: ‘Often this is because the patient does not feel that they have been listened 
to or that the healthcare professionals previously involved within their care have failed to understand what 
it is that they as an individual experience as a result of their condition or during their headache episodes.’ 
Note on draft transcript, 23 October 2013.
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up into adults with, what we have all agreed, is a lifelong condition. Children 
from a young age can experience primary headache disorders, therefore we have 
to think about the way that we educate about the treatments and effective safe 
medication use.
The whole issue of medication can start off with Calpol being given to a child 
as a baby. Then they get a bit older and they can have half a paracetamol and 
then they get a bit older and are given a full tablet, then eventually allowed two 
paracetamol tablets and eventually they become teenagers who will reach for the 
paracetamol just in case they get a headache because they’re going out and don’t 
want headache to spoil their time with friends. 
We’ve got to start thinking about educating and addressing this scenario a lot 
earlier, which is why I go into schools to do awareness sessions. I can’t do it on 
my own; it feels like I am sometimes and I am looking at trying to get other 
healthcare professionals involved within school nursing. I think the support 
groups do an absolutely fantastic job because they really do take a lot of heat off 
me, particularly with the written information they provide, because trying to 
get good evidence-based papers written through clinical governance in a timely 
fashion would take a lot more time away that I can spend with patients. 
Jones:  I wonder, could I just indulge you with a little story about Calpol 
which you mentioned? The Wellcome Foundation bought a company in the 
North of England called Calmic. They had a formulation of paracetamol and 
called it Calpol. This proved to be very much more palatable than the British 
Pharmacopoeia solution of paracetamol, which was very, very bitter. What 
Calmic did was to use a very traditional mucilage of tragacanth and acacia 
(which has been used for centuries in pharmacy) to suspend the paracetamol 
rather than it being dissolved. Well, I was sitting in my office one day and a man 
knocked at the door. He said, ‘Boss, can you phone the chairman and tell him 
we can’t make any more Calpol.’ And I said, ‘Why is that?’ He said, ‘Because 
the Bedouin have moved south.’ ‘Excuse me? The Bedouin have moved south?’ 
‘Yes.’ Now, you see, tragacanth is a natural gum abstracted from some plants in 
North Africa by the Bedouin as they tend their goats. That year the weather in 
the region where the tragacanth grows was bad so they decided to up camp and 
move south, so no tragacanth. [Laughter] So that’s why the man said to me, 
‘Well, could you phone the chairman, mate, and tell him that we can’t make any 
more Calpol.’ I said, ‘What’s this picture behind me on the wall?’ He said, ‘Oh, 
it’s a picture of the earth taken from the moon.’ I said, ‘Well, the man who took 
that picture got back!’ He said, ‘What?’ and I replied: ‘So it’s not the end of the 
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world because the Bedouin have moved south.’ Firstly we chose a chemically 
modified starch as the replacement to tragacanth, and then used an amount that 
would make the density of the suspension equivalent to that of paracetamol so 
it wouldn’t settle and the bitter taste of paracetamol doesn’t get to the tongue. 
Also, we adjusted the rheology of the formulation so that it doesn’t slip off the 
spoon so easily – so you can chase the kids around the room when you are 
trying to give them a dose! I thought you might like to know a bit of Calpol 
history. [Laughter] I can’t remember the exact date, but it was probably about 
20 years ago. 
Weatherall:  There’s a whole Witness Seminar in agriculture and pharmacology 
with the ergots and everything else, isn’t there? I want to come back to this 
question because I asked it right at the very beginning when we were talking 
about the migraine field in the 1960s and 1970s, and I asked whether neurologists 
were really interested in migraine and I think Michael O’Brien said that they 
were. But everything we hear is that actually nobody is very interested in it. GPs 
aren’t interested in it, neurologists aren’t interested in it. Why not?
Blackburn:  It’s not life threatening.
Weatherall:  But there are a lot of things that aren’t life threatening that people 
are interested in.
Blackburn:  Yes, I worked in anxiety and depression for a long time with a number 
of companies, in particular SmithKline Beecham, and I worked on Seroxat/Paxil 
for ten years. We ‘downstreamed’ the drug into the anxiety-type disorders/stress 
and migraine, as you know migraine is linked with stress/anxiety. But anxiety and 
depression weren’t seen as life threatening and it was one of the biggest hurdles to 
try and get over with regard to the clinical, regulatory, and marketing prejudices. 
However, the drug still became a multibillion dollar product at the end of it all! 
It’s the same in migraine, it’s very difficult to get that message across, you can do 
all of the stats concerning quality of life and lost productivity with regard to the 
economic consequences of migraine, but government reimbursement policies 
today will dictate you to prescribe a ‘generic’ non-steroidal, an ergotamine-
like compound or over-the-counter sumatriptan. So the future treatment of 
migraine, I think, is going to be very difficult for young start-up companies or 
big pharmaceutical companies to bring new products forward because it’s already 
well treated according to government price control agencies.159
159  Dr Tom Blackburn wrote: ‘Unless there is significant differentiation on safety and efficacy and it is an 
“innovative” therapy.’ Note on draft transcript, 14 July 2013. 
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Thomas:  Just very briefly, I think part of it is that migraine is very much a 
hidden condition and it has been treated as a hidden condition. People have 
been stigmatized, they don’t like to say they’ve got it when they get a job because 
they’re afraid they will be seen as unreliable, and you try and get anybody to 
stand up and say: ‘I’ve got migraine’, be it Ryan Giggs, who has migraine, and a 
few other celebrities who just don’t want to back it up. But as well as that, and 
though I’m sure you’re undoubtedly right, and I know what governments are like 
on this, what is changing today is social media. We’ve now got a lot of younger 
people who are on Facebook and Twitter and all those things saying: ‘Yes, I’ve 
got migraine. I’m not putting up with this; what are you doing about it?’ And 
it’s very easy. We have our e-bulletins and we do get patients for research. But 
actually there are people standing up saying, ‘I’ve got it and I’m proud,’ as it were.
MacGregor:  The lack of funding is because migraine is not taken seriously. 
With three charities, Migraine Trust, Migraine Action, and, when I was at the 
City of London Migraine Clinic, you could never get funding to run the clinic, 
to get support, or to do research. There’s just no money there. People would 
donate while they had a problem but they very rarely leave anything in their 
wills. It will go to the donkeys, the horses, the cancer societies, whatever it is, 
that is much more important to them at that time when they are writing their 
wills. Unless we can get more money into migraine, we’re all going to be beating 
ourselves with sticks.
Quarshie:  In the UK there are only 12 specialist headache nurses.160 When you 
consider the incidence of migraine compared to asthma and diabetes alone, 
the number of specialist nurses that you have to deal with and address those 
conditions, and, of course, there is also the financial incentive to address such 
conditions as the primary care physicians are paid for effective outcomes.161 
There’s a tariff for treating diabetes, for treating heart disease. I think once 
the NICE quality outcomes are implemented and a tariff attached to them 
then you’d see an improvement in how migraine is managed and other primary 
headache disorders.
160  Mrs Vicky Quarshie wrote: ‘Since the Witness Seminar in May 2013, the number of Headache Specialist 
Nurse posts within the UK have now increased from 12 to 17 which is almost a 33.3% increase and additional 
posts are in the planning stages which is very welcome news.’ Email to Ms Caroline Overy, 3 March 2014.
161  There are 8 million sufferers of migraine in the UK (www.migrainetrust.org/key-statistics (visited 21 
January 2014)); 5.4 million sufferers of Asthma in the UK (www.asthma.org.uk/asthma-facts-and-statistics 
(visited 21 January 2014)); 2.9 million suffers of diabetes (www.diabetes.co.uk/diabetes-prevalence.html) 
(visited 21 January 2014)).
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Humphrey:  You asked specifically why clinicians aren’t interested; well, it’s a 
transient condition and if you wait long enough it goes away, and people aren’t 
going to die of it. I was going to make a more particular point, which is that it’s 
a female condition and you know probably a lot more doctors are men possibly, 
or is it 50/50 now, but it’s still weighted in the wrong direction. And I think 
unless you’ve had migraine or you’ve got migraine, you’re not sympathetic. So 
you find a doctor who’s got migraine himself, he’s much, much better at dealing 
with his patients. So that’s an important point as well. But again, sorry about 
going on about anecdotes, but my wife has for years and years never believed 
she has migraine but did have a headache at menses. So I used to say: ‘Well, take 
a paracetamol, dear’ and that was the end of it. Well, anyway, a friend of mine 
came, a very famous person who many of you will know, Steve Peroutka, who 
is a neurologist and pharmacologist,162 and he said: ‘Pat, Mary’s got menstrual 
migraine.’ I said: ‘No, no such thing.’ Anyway, at the time sumatriptan was not 
freely available, it was just in the very early 1990s so Steve sent sumatriptan 
from America, saying: ‘This is like sending coals to Newcastle.’ [Laughter] My 
wife took one sumatriptan, boom! Headache’s gone. She said to me: ‘You’re 
supposed to know all about migraine.’ And I said: ‘But you never told me the 
headache didn’t go away when you took the paracetamol!’ So you’ve got to 
know about it, you’ve got to understand it.
Dr Katherine Foxhall:  I’m a historian and I’ve been looking at the history of 
migraine from the seventeenth, eighteenth, and nineteenth centuries and one 
of the questions that’s most interested me is why, in the twentieth century, does 
migraine come to be assumed to be a female disorder by many people? When 
you look at the end of the nineteenth century, the point at which migraine was 
historically taken most seriously by the medical profession, you get a number 
of men of science discussing what had previously been seen as a kind of bilious 
disorder associated with the stomach and with the humours. In the 1870s 
migraine becomes associated with aura through the philosophical discussions 
of men like John Herschel and David Brewster; these were very prominent men 
of science interested in the stars and in vision. And it’s in the 1870s you get 
people like Liveing and Latham publishing their monographs and articles on 
what Liveing called ‘nerve storms’ and that kind of thing.163 Then suddenly, in 
162  Dr Stephen Peroutka is now an independent consultant to pharmaceutical and biotechnology companies 
in the USA; he has been Chief Medical Officer of Semnur Pharmaceuticals Inc. since October 2013. 
163  Liveing (1873).
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the 1880s and 1890s, you get all of these physicians writing to the American 
medical journals and the Lancet saying: ‘Oh, I have this aura too.’ So it’s at that 
point that migraine becomes taken very, very seriously. What’s very interesting 
is how then, in the twentieth century, that declines and you get a lot more 
different kinds of theory. In the early twentieth century, migraine theories break 
up. You have theories about allergy, you have ideas about hormones, so migraine 
becomes associated much more with women and I wonder whether that is really 
part of the problem. Lots of the comments of this afternoon have also been that 
many people assume that migraine is just a women’s disorder and that it’s about 
neurotic women or things like that. So I think that’s part of the problem but it’s 
a very interesting historical shift that is actually quite recent.  
Aronson:  Pat’s comment about menstrual migraine makes me want to go back 
to our first session and ask about oestrogens in the mechanism, because I don’t 
think we discussed them. Can anyone say anything about the roles of oral 
contraceptives, changes during pregnancy, menstruation? 
Weatherall:  Anne, I’m sure you’d love to comment? 
MacGregor:  Richard examined me on my MD thesis so perhaps he should 
comment?164 My comment is just that Barnes Wallis might have wished that 
164  Professor Anne MacGregor’s MD thesis explored the role of oestrogen in migraine (MacGregor (2008)).
Figure 23: Professor Anne MacGregor, Dr Katherine Foxhall and Mrs Mary Ayres 
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he had sumatriptan available because he apparently knew every ditch between 
London and Oxford because of his migraines.165
Hurwitz:  I just wanted to say something about the idea that a condition that’s 
not life threatening is inherently uninteresting: that strikes me as a highly 
questionable proposition. If true it would make a great deal of neurology 
decidedly uninteresting, would it not? It also implies 90 per cent of medicine 
is uninteresting. And it doesn’t explain why conditions go through such clear 
phases, of fading interest and then growing interest. You take a condition 
like diabetes, which in the 1940s and 1950s was not seen as an ‘interesting 
condition’. It didn’t have much clinical work going on, there was very little 
research happening. Clinics were often not consultant-led but run by non-
clinical biochemists and nurses. But it’s now an enormous industry, a discipline 
in its own right that’s highly prestigious. Mortality has fallen because of 
treatment, and, as mortality has fallen, interest and prestige have risen. 
Humphrey:  I was just going to ask from some of those who know around the 
table for some clarification on the female disease or not? As far as I am concerned 
the literature is full of data that says that three times more women than men 
have migraine and five times more men than women have cluster headache. Is 
that true or not true?166
Peatfield:  Yes.
Humphrey:  That’s what I thought. 
Weatherall:  Although modern epidemiology shows that to be the case, there 
is a difference between information that you get from epidemiological studies 
and the perception of a disease, which is what Katherine was talking about. So, 
for example, if you go back to the end of the nineteenth century you find that 
migraine is perceived as a disease of educated, nervous undergraduate types, who 
are stressed out about their exams; it is not perceived as a disease predominantly 
of the working classes. Whereas if you look at modern epidemiology, everybody 
gets migraine; it’s not class-specific. So there are very interesting questions about 
the way that diseases are perceived and the impact that that has on funding 
decisions and so on. 
165  i.e. stopping to be sick. Sir Barnes Wallis (1887–1979) was an aeronautical designer and engineer who 
is best known for his ‘bouncing bomb’ and the air raid on the dams of the Ruhr in Germany during World 
War II.
166  See, for example, Russell et al. (1995); Evans and Bahra (2004). 
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Humphrey:  Well, I was certainly told by an eminent professor of neurology in 
Japan that ‘we don’t have migraine here’; this was about 15 years ago or more. 
And another professor, a younger one who had actually trained in America, 
took me aside later and said: ‘That’s not true, it’s just that the women aren’t 
allowed to complain.’ [Laughter]
O’Brien:  You asked the question as to why there wasn’t the interest but in fact 
most headache and most migraine was dealt with by GPs and they simply 
don’t have the time to sit for half an hour or 40 minutes, which is what 
many of these patients need. The more complicated ones are then referred 
to hospital. There was a time, going back a generation, when neurology was 
largely an inpatient speciality and the consultant went round and performed 
in front of a whole lot of people, at Queen Square for example. The junior 
consultants and registrars fed the system from outpatients. So there wasn’t 
anybody at senior level who was necessarily particularly interested in it. I 
think there are many doctors who like to roll up their sleeves and sink their 
arms into gore, you know, to the elbows and others who don’t. You have to 
be interested in the people and be interested in taking detailed histories, and 
if you aren’t interested in that then migraine has less to offer. Also, I think, 
because there were not the opportunities for MDs and PhDs in migraine as 
there were in many other subjects, there weren’t the departments that could 
support that sort of activity and so the thing just rolls on like that. You get 
fewer people involved. I think now that neurology is mostly an outpatient 
speciality and not an inpatient speciality is one of the reasons why the interest 
in migraine has flourished.
Thomas:  Can I just go back to funding briefly, insofar as it is trying to get 
younger researchers and clinicians interested in headache and seeing that they 
might have some sort of career and some sort of funding to go on for training. 
We’ve just managed to get a Migraine Trust fellowship awarded at the Migraine 
Trust meeting (which is now called the European Headache and Migraine 
Trust International Congress), which was held last September.167 It’s the first 
time we’ve been able to do that for a while and it is about funding. But there’s 
the All-Party Parliamentary Group on Primary Headache Disorders, which 
167  The 3rd joint biennial congress of the Migraine Trust and the European Headache Federation was 
held in London, 20–23 September 2012. The 2012 Migraine Trust Fellowship was awarded to Dr Anna 
Andreou to investigate ‘hypothalamic–thalamic interactions in migraine pathophysiology’ at Imperial 
College London for three years.
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is funded by Headache UK, of which Migraine Trust is the major funder in 
fact.168 We did have a session on research about three years ago, and various 
important institutions were asked to come and say what they were funding, 
what headache research they were funding. Neither the Medical Research 
Council nor the National Institute for Health Research (NIHR) nor the 
Wellcome Trust came. They all just would not come.169 Stephen O’Brien,170 
who was then the Chair of the All-Party Parliamentary Group, wrote to them 
privately and asked them if they would come and have a private discussion 
with me, because I was chair of Headache UK, and him. We did have two 
people come from the Wellcome Trust. The Medical Research Council and the 
NIHR just didn’t bother to reply.
Olesen:  It’s very true that the area is grossly underfunded. We did a 
large European-wide study called Resource Allocation to Brain Research 
focusing on all brain disorders, including both psychiatric and neurological 
disorders.171 We’ve also done another study about the cost of brain disorders 
and, when we looked at the research funding compared to the societal cost 
of the disorders, headache research came as the absolute lowest funded of all 
the brain diseases.172 
168  The All-Party Parliamentary Group on Primary Headache Disorders was relaunched in 2008, comprising 
a cross-party group of MPs and members of the House of Lords, the aim of which is to ‘highlight and raise 
awareness amongst parliamentarians of the key issues affecting sufferers of primary headache disorders, their 
families, carers and health professionals working in the field. By discussing these issues in parliament the 
group aims to influence policy and legislation to improve the lives of those affected by primary headache 
disorders.’ See the Headache UK website at http://headacheuk.org/appgphd/appgphd.html (visited 26 
November 2013). Headache UK is the umbrella group for migraine and headache organizations, which 
includes the Migraine Trust, Ouch (UK), BASH (British Association for the Study of Headache), Trigeminal 
Neuralgia Association UK, and Migraine Action.
169  The first report of the Group ‘Headache Disorders – not respected, not resourced’ (2010) is available 
online at www.migrainetrust.org/assets/x/50147 (visited 26 November 2013); see the chapter on company 
research (Hargreaves (2010)) and the conclusion (Goadsby (2010)). 
170  Stephen O’Brien has been Conservative MP for Eddisbury since 1999. He was Shadow Minister for 
Health and Social Care from 2005 to 2010.
171  Sobocki et al. (2006).
172  A study commissioned by the European Brain Council: Gustavsson et al. (2011). See also Olesen et al. 
(2007). For the economic cost of migraine in Britain, see Steiner (2010) and Steiner et al. (2003). 
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In America they have done some studies of NIH funding and, again, headache 
and migraine research comes at the very bottom. Compared, for example, to 
epilepsy, headache disorders have about three times higher cost but epilepsy 
research has about ten times to fifteen times more funding than headache 
research.173 So the underfunding is not just there, it’s outrageous, it’s terrible. 
When the study in America, for example, asked the NIH: ‘why don’t you fund 
headache research more when it’s such a prevalent disease?’ the answer was: 
‘Because the applications aren’t good enough’. So it’s a catch 22 situation. When 
the field is underdeveloped and remains underdeveloped, how can you pull it 
up? You need funding to do good enough applications. So it’s a really difficult 
situation but I have good hopes because we are now looking at signalling 
molecules, receptors, and the specific drugs like triptans, not only that but 
calcitonin gene related peptide (CGRP) receptor antagonists and so on. This 
will bring headache much more into the neurobiology realm and I think that 
will support both the esteem of the condition and the funding.
Jones:  I just wonder whether we could have some comments from the patient 
organizations and the medical groups, nursing and so on, about whether, shall 
we say, you ‘have your act together.’ I know Jes is part of the European Brain 
Council and that brings together a cluster of people involved in brain conditions. 
When I was Director General of the Association of the British Pharmaceutical 
Industry, I found that when we were in discussions with patient organizations, 
like in cancer, that there might be three or four competing groups, and they just 
fought each other, instead of saying, ‘Look, we all have a common agenda here.’ 
So, is one of the problems that you are not getting the ‘share a voice’ because 
your messages are just too dispersed? And the second question relates to how 
successful you are in persuading the pharmaceutical industry to put up the 
money for practice nurses, like Mary Baker did so successfully for Parkinson’s 
disease nurses,174 because it’s in their mutual interest. 
173  In 2007 the NIH funding of migraine per person was estimated at $0.36, while for epilepsy the figure 
was $35. See Schwedt and Shapiro (2009), page 166.
174  Mary Baker MBE is President of the European Brain Council. She worked for 18 years for Parkinson’s 
Disease UK of which she was Chief Executive until 2001; she was President of the European Parkinson’s 
Disease Association (EPDA) from its formation in 1992 until 2006; and President of the European 
Federation of the Neurological Associations (EFNA).
Migraine: Diagnosis, Treatment and Understanding c.1960–2010
83
Ayres:  We’re all in this together. I was just looking at my little list here: we’ve 
got the Migraine Trust, Migraine Action, Spectrum Alliance, Pain UK, Ouch, 
and the Irish Migraine Association.175 
Jones:  Do you speak with one voice?
Thomas:  I would say we have a different way of doing things but essentially 
we’re still putting the person with migraine at the centre of it; it’s perhaps 
just doing it slightly differently. I think you’re right, one shouldn’t be fighting 
each other and I don’t think we are, but I think that today’s patient goes onto 
the internet and expects to see more than one organization. In fact, we have 
scientific trustees, including Mark, on our trustee board and Peter Goadsby and 
others. We have a slightly different way of doing evidence-based stuff but the 
fact is it’s important to, we’re a bit of a hybrid, but we are there. I’m sure that a 
lot of the people who look at our website and who are supporters, are the same 
people who look at Migraine Action and it’s a pick and mix. You’ve got to give 
people some choices.176
Jones:  I’m thinking about funding.
Thomas:  Actually, if you look at any of the evidence on organizations getting 
together, there’s very rarely any money saved. There’s very clear evidence on that 
from mainly the charity governance groups.177 Funding is a problem.
175  The Migraine Trust, founded in 1965, is the health and medical research charity for migraine; see http://
www.migrainetrust.org/ (visited 27 November 2013). Migraine Action (formerly the British Migraine 
Association) is a national charity founded in 1958, for people affected by migraine; see www.migraine.org.
uk (visited 26 November 2013). Spectrum Alliance UK was founded in 2007, representing various charities 
and support groups for people who suffer adverse health effects from modern low energy lighting; see www.
spectrumalliance.co.uk/ (visited 27 November 2013). Pain UK was founded in 2011 as an organization to 
help people in pain and support charities dealing with pain; see www.painuk.org/ (visited 27 November 
2013). Ouch (UK) is an organization established in 2001 for the understanding and raising awareness of 
cluster headache; see, http://ouchuk.org/ (visited 27 November 2013). The Migraine Association of Ireland 
is a charity set up in 1994 to support and provide information to people with migraine and other headache 
disorders; see http://www.migraine.ie/ (visited 27 November 2013).
176  Mrs Wendy Thomas wrote: ‘The Migraine Trust is a research charity that responded to patients wanting 
evidence based information and the other patient groups tended to use forums etc.’ Email to Ms Caroline 
Overy, 18 November 2013.
177  See La Piana and Harrington (2010). Mrs Wendy Thomas wrote: ‘[This publication] showed that 
charities which merged didn’t actually have cheaper costs. Mergers rarely happen but takeovers do.’ Email 
to Ms Caroline Overy, 18 November 2013. 
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Jones:  Would it attract more funding for research and nurses and so on if you 
had just one organization?
Thomas:  Nobody’s interested in funding.
Quarshie:  When I first came into post seven years ago my post was funded 
through sponsorship from a drug company and our Headache Research Fund. 
After two years there was a real uncertainty around whether the NHS Trust I 
am employed by would actually continue funding the post, or whether I would 
become redundant and return to the neurology ward and the service would 
discontinue. Due to the current economic climate there is a real problem within 
healthcare trusts in that, if you can get funding and demonstrate that there is a 
need for that service, then there should be a commitment from the NHS trust 
to take over and continue funding at the end of the initial two-year period. 
Sandler:  I think the answer to funding is ‘bring on the stars’. I was just about to 
say that there can’t be many of us left who remember the board of the Migraine 
Trust in round about the early 1960s. And there we had total glamour. There 
was C P Snow and his bad tempered wife.178
Ayres:  Sorry to disagree, but C P Snow was one of my predecessors as President. 
Indeed, that was very glamorous.179 
Sandler:  Well, the British Migraine Association had more than C P Snow. They 
had, as they say, his bad tempered wife, Pamela Hansford Johnson. She was 
terrible. [Laughter] There was also Cyril Kleinwort.180 They all gathered in a 
little cabal beforehand in a meeting room and then all streamed in; when I say 
‘all’ there were other big names in this collection. And in the meeting room 
Princess Margaret suddenly came in, if there was a lecture by somebody or 
other, some eminent American visitor and then everybody sat down. She came 
178  The writer and scientific administrator, Charles Percy Snow (1905–1980), Baron Snow of the city of 
Leicester from 1964; his wife was the writer and playwright, Pamela Helen Hansford Johnson (1912–1981). 
179  Mrs Mary Ayres clarified this: ‘1962–1974, Lady Snow (Pamela Hansford Johnson) was President of the 
British Migraine Association; 1964–1975, Lord Snow was one of several Vice Presidents of the Association. 
He retired when he was elevated to the Peerage.’ Email to Ms Caroline Overy, 26 March 2014. For a 
history of the British Migraine Association see see A Brief History of Migraine Action available online at 
www.migraine.org.uk/js/plugins/filemanager/files/downloads/History_of_Migraine_Action.pdf (visited 31 
March 2014)
180  Sir Cyril Kleinwort (1905–1980), a partner in the private bank Kleinwort Benson, suffered from 
migraine and was Honorary Treasurer of the Migraine Trust, donating £10 000 a year until his death.
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in late, took her gloves off, sat down gently, put her head down, slept during the 
whole lecture, and then sort of streamed out again. The Migraine Trust never 
seemed to be short of money at that time. 
Thomas:  It wasn’t because of Princess Margaret though.
Ayres:  Princess Margaret was not associated with the British Migraine 
Association except insofar as they were the cause of the Migraine Trust becoming 
the Migraine Trust and they were very proud of that. So I think our founder 
just went for as many people with double-barrelled names as he could for his 
first set of members of the committee. [Laughter] And there were about 17 for 
many years.
Weatherall:  I’m just going to say a few things to close. Firstly I’m going to thank 
you all very much indeed for your attendance and your contributions to the 
Witness Seminar. It’s always difficult to know how these things will go because 
I could sit down and grill any one of you one-to-one and get a huge amount 
of interesting and exciting stuff out of you; but one of the things that we look 
for is an emergent collective voice on this, and I think we’ve been reasonably 
successful in getting that today. So many thanks for all your contributions. 
I’d like just to say a couple of things with my historian’s hat on that arise out 
of what Katherine was saying about the situation 100–120 years ago. When 
migraine first does become an area of interest, there were people like the rather 
strange, and otherwise completely obscure, Cambridge pair of Edward Liveing, 
who published his work on nerve storms, which is the sort of archetypal neural 
theory, and Peter Latham, who published his lectures where he outlines an 
embryonic version of the biphasic theory, which Michael O’Brien mentioned at 
the beginning of the seminar, that is vasoconstriction followed by vasodilation.181 
My view on this, which may or may not be historically correct, is that actually 
they were blown apart by no less a luminary than William Gowers, who, of 
course, was the leading British exponent of neurology.182 And Gowers, as he was 
wont to do, picked apart both Liveing’s and Latham’s theories on the basis that 
they did not explain the phenomena that he saw in his patients. Unfortunately, 
that left a bit of a gap in terms of theories of migraine pathogenesis; that was 
181  Liveing (1873); Latham (1873). See also Weatherall (2012a).
182  Sir William Gowers (1845–1915) was Consulting Physician and Professor of Clinical Medicine at 
University College Hospital. His Manual of Diseases of the Nervous System was internationally recognized 
(Gowers (1886–8)).
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the gap into which not only Harold Wolff walked in the 1930s (looking at 
pain both as a function of pain-sensitive structures within the scalp, particularly 
the dura and the blood vessels, and also as a function of changes in the blood 
vessels using ergotamine as the very powerful research tool), but also the gap 
into which psychoanalytic and psychological theories of migraine pathogenesis 
fitted. One of the things that we didn’t get a chance to explore fully today is 
how powerful those psychological concepts of migraine have been, and of the 
fact that it’s incredibly pervasive that headache is not an important problem, 
leading to the strange situation that headache is either incredibly dangerous 
because it means you’ve got a brain tumour, or it’s not at all dangerous, and in 
fact your complaining of headache means you are either morally deficient or 
you’re swinging the lead, trying to get out of what you’re supposed to be doing. 
These polarities are very entrenched from a cultural point of view. All the work 
that we’ve talked about today still has yet to shift those very deeply entrenched 
views of what headache is about. The great thing about all the work that we 
talked about, especially the triptan story, is that of course it has materially led 
to improvement in the lives of people with headaches, which is what all of us 
who are clinically and scientifically interested in the subject want to promote. 
And, of course, the discussions that we’ve had at the end show that we are really 
still struggling to take that forward in the future, to continue to translate the 
scientific interest into benefits for patients, which is still very much there in the 
work that Jes and his group, and Mike Moskowitz and Rami Burstein and all 
the scientists that we’ve talked about have done. So thank you very much indeed 
for coming today. I hope you enjoyed it as much as I did; I hope you found it 
interesting and valuable. 
Tansey:  May I also add my thanks to Mark and to all of you for coming and 
contributing so much. It’s been a very thought-provoking afternoon. I’m 
particularly impressed by Trevor Jones’ knowledge of the birthplace of British 
pop stars. [Laughter] You have hidden talents, Trevor, you really do. I would 
also like to add my particular thanks to Mark Weatherall, an ideal chairman. 
There are not many neurologists with a PhD in the history of medicine even 
if you did have a very generous external examiner, Mark. [Laughter] No, he 
very well deserved his PhD. He’s a great loss to the subject so I’m very pleased 
that he’s coming back into history of medicine because it’s very important that 
practitioners, scientists, and clinicians do engage with contemporary history of 
medicine. So, thank you very much indeed, Mark.  
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Appendix 1
Theories of migraine 1900–1960: a brief background to the  
Wellcome Witness Seminar
Mark Weatherall
Migraine is found in the medical and lay literature throughout recorded 
history. By 1900 scientific theories of migraine fell into two broad camps: 
neural theories, as epitomized by the theory of ‘nerve-storms’ expounded in the 
monograph On Megrim, published in 1873 by the English physician Edward 
Liveing; and vascular theories such as those put forward by du Bois Reymond, 
Mollendorf, and Peter Wallwork Latham. Liveing’s work was regarded by the 
great English neurologist William Gowers as the best work on the subject, and 
in recent decades, through the advocacy of Oliver Sacks and John Pearce, it 
has become regarded as a masterpiece of the genre. It did not, however, lead to 
changes in the understanding or treatment of migraine at the time, and it is the 
vascular theories that provide the main background for the understanding of 
migraine between 1900 and 1960, not least because of the gradual introduction 
of an effective medication with clear vascular effects: ergotamine.
During the 1920s and 1930s several reports attested to the effectiveness of 
ergotamine in treating migraine. At the same time advances in neurosurgical 
technique allowed increasingly sophisticated attempts to localize brain function, 
including pain. These two strands were brought together in the 1930s by the 
American neurologist Harold Wolff in classic papers published in 1938 and 
1940.183 In the first of these he investigated the effect of ergotamine upon the 
extracranial arteries during attacks of migraine, showing that it reduced pulse 
amplitude as it diminished the intensity of the headache; in the second he 
demonstrated that pain could be evoked by stimulation of dural blood vessels 
and sinuses, and of the large intracerebral arteries, the painful sensations being 
localized to the ophthalmic branch of the trigeminal nerve, where migraine 
typically manifests. These observations were central to Wolff ’s landmark 1948 
monograph Headache and Other Head Pain, which immediately became the 
standard work on the subject.184
183  Graham and Wolff (1938); Ray and Wolff (1940).
184  Wolff (1948).
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Wolff himself was cautious about extrapolating his findings in the extracranial 
arteries to those of the intracranial arteries, but nonetheless a simple vascular 
theory – that aura was due to constriction of cerebral vessels, and headache to 
vasodilation – was distilled from his monograph into countless student lectures 
and textbooks. The problem with this simple theory was – as Gowers and others 
after him pointed out – that it did not explain the phenomena, particularly those 
of visual aura, the gold standard clinical description of which was published by the 
visual physiologist Karl Lashley in 1941.185 Lashley studied his own visual auras 
meticulously, noting that they always started at or near the centre of fixation, 
spreading laterally and never impinging upon the midline. Some of his auras had 
scintillating zig-zag edges; others were exclusively negative. He mapped these 
phenomena onto the known anatomy of the occipital cortex, postulating that a 
wave of inhibition (sometimes preceded by intense excitation) must propagate 
away from the occipital pole at a speed of approximately 3 mm/min.
This concept was initially difficult to reconcile with the prevailing orthodoxy, 
but in 1958 the Canadian neurologist PM Milner pointed out that a potential 
alternative physiological mechanism might be cortical spreading depression, 
first demonstrated in 1944 by the Brazilian physiologist Aristedes Leão.186 When 
Leão tried to induce experimental seizures by electrical stimulation of the cortex 
of rabbits, he found instead an orderly and progressive flattening of cortical 
electrical activity, spreading away from the point of stimulation, followed some 
time afterwards by recovery of function in the same pattern; the speed at which 
this wave crossed the cortex was – tantalizingly – 3 mm/min.
Wolff himself believed that migraine pathogenesis involved not only 
vasodilation, but also the release of perivascular nociceptive factors that damaged 
local tissues, and increased sensitivity to pain in migraine attacks, thought 
possibly to have an allergic basis. Various candidate substances were studied 
during the 1940s and 1950s, including histamine, acetylcholine, bradykinin, 
and 5-HT. The most powerful known 5-HT antagonist, lysergic acid (LSD), 
was not clinically useful because of its hallucinogenic effects. In 1959, however, 
the Italian neurologist Federigo Sicuteri published a study demonstrating that 
1-methyl-D-lysergic acid butanolamide (methysergide), a more powerful 5-HT 
antagonist than LSD but not a vasodilator, was a safe and effective prophylactic 
185  Lashley (1941).
186  Milner (1958); Leão (1944).
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treatment for headache.187 A spate of further studies followed, including the 
first well-conducted randomized controlled trial in headache, published by 
Southwell et al. in the Lancet in 1964.188 Sicuteri showed that increased levels 
of 5-HIAA (the main metabolite of 5-HT) could be found in the urine during 
migraine attacks, and a series of papers from Jim Lance’s group in Sydney began 
to delineate the role of platelet dysfunction in migraine (platelets being the 
main repository of 5-HT in the body). A second 5-HT antagonist, pizotifen, 
was developed as a migraine prophylactic by Sandoz in the 1960s, appearing at 
around the time that reports of methysergide-induced retroperitoneal, cardiac, 
and pulmonary fibrosis began to appear.
Harold Wolff ’s final service to migraine was to sit on an Ad Hoc Committee 
of the US National Institutes of Health on the Classification of Headache.189 In 
1962, the year that Wolff died from a stroke at the age of 63, the Committee 
produced a diagnostic classification that was influential throughout the 1960s 
and 1970s. The basis of this classification was clinical, heavily influenced by 
extensive patient case series such as that published by Selby and Lance in 
1960.190 At the period at which this Witness Seminar commences, therefore, 
there was a relatively recently proposed classification system for headaches 
(including migraine), various prevailing theories (predominantly with a vascular 
basis) regarding migraine pathogenesis, and a series of established and novel 
treatments for migraine, including ergotamine and methysergide.191
187  Sicuteri (1959).
188  Southwell, Williams and Mackenzie (1964).
189  Ad Hoc Committee on Classification of Headache (1962).
190  Selby and Lance (1960).
191  For secondary sources, see Tfelt-Hansen (2010); Tfelt-Hansen and Koehler (2011); Weatherall (2012b).
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Appendix 2
Summary of the classification of primary headaches192 
1. Migraine
1.1 Migraine without aura 
1.2 Migraine with aura 
1.3 Chronic migraine 
1.4 Complications of migraine 
1.5 Probable migraine 
1.6 Episodic syndromes that may be associated with migraine
2. Tension-type headache (TTH)
2.1 Infrequent episodic tension-type headache
2.2 Frequent episodic tension-type headache
2.3 Chronic tension-type headache
2.4 Probable tension-type headache
3. Trigeminal autonomic cephalalgias (TACs)
3.1 Cluster headache
3.2 Paroxysmal hemicrania
3.3 Short-lasting unilateral neuralgiform headache attacks
3.4 Hemicrania continua
3.5 Probable trigeminal autonomic cephalalgia
4. Other primary headache disorders
4.1 Primary cough headache
4.2 Primary exercise headache
4.3 Primary headache associated with sexual activity
4.4 Primary thunderclap headache
4.5 Cold-stimulus headache
4.6 External-pressure headache
4.7 Primary stabbing headache
4.8 Nummular headache
4.9 Hypnic headache
4.10 New daily persistent headache (NDPH)
192 Adapted from the Headache Classification Committee of the International Headache Society 
(IHS) (2013), 636–37.
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Appendix 3
The Role of the UK Specialist Nurse in Headache
Ria Bhola and Victoria Quarshie, Headache Nurse Specialists
The role of the specialist nurse has developed rapidly across specialties over 
recent years. This has been facilitated by several factors in the UK: reforms in 
nurse education and guidelines created for role expansion, government targets 
for health outcomes, reduction in junior doctors’ hours, patient demands for 
greater choice and accessibility, and the development of headache services. 
Currently in the UK there are just 12–14 headache nurses and many are 
members of the British Association for the Study of Headache (BASH).193 The 
numbers may increase as new services develop and the impact of the role is 
recognized as a crucial, cost-effective component of these services. 
Within the UK group there is an awareness of the diversity in each 
other’s practice and the variation in skills, knowledge, and experience. 
This diversity in practice is often discussed at the annual nurse 
meetings where knowledge and experience is shared within the group. 
Role components
While it is accepted that there is diversity in the way that individual nurses 
practise there are some elements of the role that are generic and remain the core 
of practice: 
• Professional
 Maintaining professional registration by reviewing and maintaining own 
professional education, knowledge, and practice, and complying with the 
Nursing and Midwifery Council (NMC) Code of Professional Conduct at 
all times is essential, as is participation in professional interest groups and 
bodies by sharing experiences as this aids in the process of identifying and 
promoting best practice.
• Clinical expert
 By understanding and delivering care to individuals with a diagnosis 
of primary headache disorder from diagnosis and throughout their 
193  See note 160 on page 76.
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periods of need, the nurse will be involved with the ongoing assessment, 
planning, reviewing, and evaluation of an individual’s care and ensuring 
all documentation complies with the NMC Guidelines. In possessing the 
ability to acknowledge their own boundaries in expertise, experience, and 
knowledge and that of professional colleagues in doing so, the nurse is able 
to ensure that the most appropriate member of the multidisciplinary team 
is consulted for specific management issues. 
 The majority of the nurses operate a telephone clinic or an advice-line where 
patients, their carers, and others involved within their care can contact the 
nurse between hospital appointments for advice, support, information, 
and review. The contact with the specialist nurse is not intended to replace 
the general practitioner’s (GP) role. It rather assists and compliments their 
practice, highlighting the specialist needs of the patient. 
 Many headache specialist nurses will be involved in the development of 
care pathways for patients presenting with primary headache disorders, 
and many nurses develop and run their own nurse-led clinics, working as 
autonomous practitioners within their own scope of competence. 
• Consultation and leadership
 Other healthcare professionals can also utilize the specialist nurse as a 
resource to inform their own practice. Essential parts of the role are to liaise 
with primary care groups/Trusts and foster these relationships by offering 
advice, education, and support, while being aware of the boundaries of 
one’s own role and knowledge. For the care of headache patients to develop 
and improve it is essential that the nurses share their specialist knowledge, 
experience, and research with their colleagues, providing leadership and 
support to nursing colleagues and peer groups in the management of 
patients with primary headache disorders. 
• Educator 
 The specialist nurse operates as educator to patients and colleagues. Some are 
actively involved in the development of educational programmes for other 
healthcare professionals and patient groups, within both the primary and 
acute Trusts locally. Often nurses are invited to participate in educational 
programmes for other professional bodies, national support groups, private 
organizations, and members of the public. As an educator, it is essential 
that the nurse is able to promote the needs of this patient group and enable 
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greater understanding of primary headache disorders and the optimistic 
outlook for patients. Enabling patients to manage their condition better is 
crucial in long-term disorders.
 Patient education is at the core of the headache specialist nurse role. 
Providing patients with the information they require to understand their 
condition and make informed choices about their headache management 
makes them better equipped to become active managers and responsible for 
their own healthcare and well-being. 
 Also, when management strategies do not deliver the desired outcome, 
the specialist nurse is often the first point of contact when problems are 
encountered and it is at this stage the nurse is required to re-evaluate 
the symptoms and planned care, offer support and alternative treatment 
options, and address inappropriate or unrealistic expectations of treatment. 
The nursing philosophy and patient education strategies employed by the 
headache specialist nurses are generally based on health promotion models, 
with the focus being on adding quality to life when living with a lifelong 
condition.
• Research 
 The nurse’s role in research requires that they are able to develop their own 
critical appraisal skills and are thereby able to identify and utilize good 
quality, research-based evidence to underpin and inform their nursing 
practice. Frequently the specialist nurse will be involved in the audit of 
services delivered; this is essential for monitoring the quality and identifying 
areas that require improvement. Audit is also essential for providing evidence 
that the specialist nurse role is a viable option for delivering high-quality, 
cost-effective care to service users. 
 Often the research role will require the specialist nurse to be involved in 
clinical trials, and it is imperative that the nurse remains objective, adhering 
strictly to study protocols and ensuring that meticulous detail is given 
to the documentation of data to ensure that the trial does not become 
compromised; this is particularly important as research findings shape and 
inform future patient management and care.
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Developing and refining the role
It is acknowledged that specialist nurses go through a role development process 
to acquire skill and competence to function with maximum effectiveness. Stages 
of the role development process have been identified which facilitate the process:
 
Increasing competence through individual direct patient care 
↓
Direct care or care planning for this patient group
↓
Working with the staff to change the care provided for the patient group as appropriate
↓
Conducting or participating in research and audit
↓
Planning for changes in patient care delivery based on experience and research
↓
Increasing input into the higher levels of healthcare delivery system
↓
Integrating all role components with confidence
 
 
Common activities for headache nurses
Individual headache services will vary in the degree to which the nursing role 
covers these components, but the main activities undertaken will include:
• Telephone consultations
 To monitor patient progress at intervals such as follow up from a clinic 
consultation or inpatient episode, to monitor drug efficacy and tolerability, 
and to support patients with treatment changes or to address patient queries.
• Outpatient clinic role
 To take a headache history, assess level of disability, provide and assess 
headache diaries, and to provide support and advice (on lifestyle issues, 
use of medication, change of medication, analgesia withdrawal, and deliver 
treatment procedures, e.g. nerve blocks). 
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• Inpatient care (where applicable)
 To assess patient needs and ensure they understand the plan of care in 
hospital, to monitor progress of treatment, and optimize care and ensure 
effective discharge planning.
• Organizational activities
 Working with relevant areas of the organization to negotiate and improve 
service delivery and developments. 
• Research and education
 Monitor future developments and stay apprised of new and emerging 
therapies. Input into research and audit to improve patient and service 
outcomes. 
 
Conclusion
The specialist nurse is a non-traditional nurse with expanded boundaries. These 
roles have a valuable contribution to make in the global effort to reduce the 
burden of headache and meeting the vision of the World Health Organization 
to the benefit of headache sufferers. 
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Biographical notes*
* Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources.
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Since 2002 he has been Professor 
of Medicine and the Arts at King’s 
College London, where he directs 
the Centre for the Humanities 
and Health, which is funded by 
the Wellcome Trust (see: www.
kcl.ac.uk/innovation/groups/chh/
index.aspx) and hosts MSc, PhD, 
and postdoctoral programmes. 
Based in the Department of English 
at King’s, his research interests 
include narrative studies in relation 
to medical practice, ethics, law, and 
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the literary shape of eighteenth- 
to twentieth-century clinical 
case reports. He has co-authored 
and edited 120 peer-reviewed 
papers, 40 book chapters, and 
several books. He holds honorary 
professorships in the Centre for 
Value, Ethics, Law and Medicine 
at the Faculty of Medicine, 
University of Sydney, the Schools 
of Humanities and Medicine at 
Hong Kong University, and at the 
Institute of Neurology, Queen 
Square, University College London. 
Prior to his current position he 
was Professor of Primary Health 
and General Practice at Imperial 
College London. 
Sir David Jack
Kt CBE PhD FRS FRSE 
(1924–2011) studied pharmacy 
and pharmacology at Glasgow 
University where he became 
Assistant Lecturer before National 
Service. After working in the 
pharmacy research department 
at Glaxo (Greenford) and at the 
pharmaceutical company Menley 
and James (later part of Smith Kline 
and French), completing a part-
time PhD at London University, he 
was appointed Head of Research 
at Glaxo (Allen & Hanburys) 
at Ware in 1961, becoming 
Research and Development 
Director from 1978 to 1987 when 
he retired. He pioneered major 
developments in the treatment 
of asthma (salbutamol), gastric 
ulcers (ranitidine), migraine 
(sumatriptan), and cancer therapy-
induced emesis (ondansetron). 
He was awarded the CBE in 1982 
and knighted in 1993. For further 
details, see Watts (2012); Barnes 
and Breckenridge (2012).
Professor Trevor Jones 
CBE PhD HonDSc  FRSC 
FRSM FKC HonFRCP FFPM 
FBPharmacolS FCPP (b. 1942) 
graduated in pharmacy and 
chemistry. After teaching at 
Nottingham University he joined 
the Boots Company where he 
was Head of Pharmaceutical 
Development and then moved to 
the Wellcome Foundation, firstly as 
Head of Technical Development, 
then succeeded Professor Sir John 
Vane as Group R&D Director. 
For ten years he was Director 
General of ABPI and is now a 
member of the Boards of Directors 
of a number of pharmaceutical 
companies in the USA and EU, 
including Allergan Inc. (California). 
He is a founder member of the 
Geneva-based, public-private 
partnership, Medicines for Malaria 
Venture (MMV) and in 2004 was 
appointed to the World Health 
Organization (WHO) Commission 
on Intellectual Property Rights, 
Innovation and Public Health 
(CIPIH). He was for 12 years a 
member of the UK Government 
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regulatory agency – the Medicines 
Commission – and Chair of the UK 
Government Advisory Group on 
Genetics research. He is currently 
on the Research Board of the EU 
Commission Innovative Medicines 
Commission (IMI) and the Board 
of the UK Stem Cell Foundation 
(UKSCF). He is a visiting professor 
at King’s College, London and 
holds honorary degrees and Gold 
Medals from six universities. 
Professor Anne MacGregor 
MD FFSRH MICR DIPM 
(b. 1960) is a specialist in Headache 
and Women’s Health. She works 
at Barts Sexual Health Centre, St 
Bartholomew’s Hospital, London 
and is Honorary Professor, 
Centre for Neuroscience and 
Trauma, Blizard Institute of 
Cell and Molecular Science at 
Barts and the London School of 
Medicine and Dentistry. She is 
Vice Chair and CRQ Convenor 
of the Examination Committee 
of the Faculty of Sexual and 
Reproductive Healthcare and is 
joint Faculty Deanery Advisor for 
NE Thames. She has published 
over 180 research papers and book 
chapters, five single author books, 
five co-authored books, and has 
co-edited three books. She was 
an expert advisor for the NICE 
headache guidelines and is co-
author of the BASH guidelines for 
the diagnosis and management of 
migraine, tension-type, cluster, and 
medication overused headache, now 
in their third edition. Her research 
crosses the fields of neurology and 
reproductive healthcare, with her 
MD thesis exploring the role of 
oestrogen in migraine. 
Dr Michael O’Brien 
MD FRCP (b. 1938) qualified 
from Guy’s Hospital Medical 
School in 1962 and trained in 
neurology at Guy’s Hospital, the 
National Hospital for Neurology 
and Neurosurgery, and at the 
Regional Neurological Centre in 
Newcastle. His MD thesis (1973) 
was on ‘Cerebral Cortex Perfusion 
Rates in Migraine’. He has held 
three MRC research posts: at Guy’s 
Hospital 1965–1966, in Newcastle 
1969–1970, and at the University 
of Minnesota in Minneapolis 
1971–1972. He was Consultant 
Neurologist at Guy’s Hospital 
from 1978 until his retirement in 
2003. His special interests include 
cerebrovascular haemodynamics 
and pathophysiology, 
mononeuropathies, and women 
with epilepsy. He has held 
Civil Aeronautics Authority 
(CAA) and Federal Aviation 
Administration (FAA) private 
pilot’s licences since 1982 and 
became Consultant Advisor in 
Neurology to the UK CAA in 
2001. He is a past President of 
the Harveian Society, the Clinical 
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Neurosciences Section of the 
Royal Society of Medicine and the 
South of England Neurosciences 
Association. He lectures for the 
National Association of Decorative 
& Fine Arts Societies (NADFAS) 
and at the School for Oriental and 
African Studies on Khmer Art and 
Architecture and on Hindu Temple 
Art, Architecture and Mythology.
Professor Jes Olesen
MD DMSc DHonC (b. 1941) 
received his MD in 1967 and his 
doctorate degree in Medical Science 
in 1974 from the University of 
Copenhagen. Since 1985 he has 
been Professor of Neurology at 
the University of Copenhagen 
(Assistant Professor 1975–1985), 
and is Founder and co-Chair of 
the Danish Headache Center, 
Department of Neurology, 
Glostrup Hospital in Copenhagen. 
He has published 33 books and 
over 600 scientific articles and book 
chapters. He is one of the founders 
of the European Federation of 
Neurological Societies and of 
the European Brain Council. He 
has received several Danish and 
International awards, including the 
Niels A Lassen award, the Mogens 
Fog award, the Mångberg prize, 
the Great Nordic Research prize 
of the Lundbeck Foundation, and 
he is honorary member of many 
societies, including the Association 
of British Neurologists, the German 
Neurological Association and the 
French Neurological Association. 
He is an honorary doctor of La 
Sapienza University of Rome. 
He has given many invited/
named lectures throughout the 
world. His research interests are 
focused on migraine and other 
headaches, and span from clinical 
studies and classification over 
human pathophysiological studies 
involving particularly brain blood 
flow and MR all the way to basic 
research into neural and vascular 
signalling mechanisms.
Dr Alec Oxford
MA DPhil (b.1940) read chemistry 
at St Catherine’s College, Oxford. 
He joined Allen & Hanburys in 
1967 as a senior research chemist, 
subsequently progressing to senior 
research leader in 1977. Then for 
14 years, from 1979, he directed 
teams of synthetic organic chemists 
identifying agents that interact 
with 5-HT receptors leading to the 
discovery of the anti-migraine drug 
sumatriptan and the antiemetic 
agent ondansetron. From 1996 
to 2007 he was an independent 
consultant on medicinal chemistry.
Dr Richard Peatfield
MA MD FRCP (b.1949) qualified 
from Queens College Cambridge 
and the Middlesex Hospital 
in 1973. After general medical 
training he was appointed Migraine 
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Trust Research Fellow at Charing 
Cross Hospital in 1979, completing 
a Cambridge MD thesis in 1982 
(examined by Marcia Wilkinson 
and Merton Sandler). He then 
moved to be Senior Registrar in 
Neurology in Leeds, returning to 
Charing Cross as a Consultant 
Neurologist in 1989. Until he was 
joined by Dr Mark Weatherall in 
2007, he was the only neurologist 
with an interest in headache at 
Charing Cross. He was Chairman 
of the British Association for the 
Study of Headache from 2007 to 
2010. He maintains a research 
interest in possible triggers for 
migraine.
Mrs Vicky Quarshie
Dip HE Adult Nursing (b.1972) 
is a Headache Specialist Nurse 
and works within the Headache 
Service based at Hull and East 
Yorkshire Hospitals NHS Trust. 
She has held this post for the past 
eight years, prior to this she worked 
as a staff nurse in the general 
neurology ward since completing 
her Diploma in Adult Nursing in 
2000. She is a council member 
of the British Association for 
the Study of Headaches (BASH) 
and also a member of both the 
British and European Headache 
Specialist Nursing Forums. 
She has given presentations 
on headache management and 
treatments to patient groups, 
healthcare professionals, and the 
pharmaceutical industry at local, 
national, and European level, 
and is committed to increasing 
awareness of headache disorders 
and providing quality, effective, 
evidenced-based care for headache 
sufferers. She has also recently 
written a chapter for the second 
edition of the textbook Childhood 
Headache, ‘Drawing as an 
expression of migraine symptoms 
in Children; can a picture really 
paint a thousand words?’ (Quarshie 
(2013)), and contributed to clinical 
research regarding the use of 
Botox in the treatment of chronic 
migraine.
Dr Frank Clifford Rose
MBBS MRCS FRCP (1926–
2012) qualified in medicine at 
King’s College, London and the 
Westminster Hospital in 1949. 
Following posts at the National 
Hospital, Queen Square and St 
George’s Hospital, in 1965 he was 
appointed Consultant Neurologist 
at Charing Cross Hospital where he 
established his specialist migraine 
clinic in 1974, which became the 
Princess Margaret Migraine Clinic 
in 1980. He was active in the 
World Federation of Neurology 
and was Chairman of the Research 
group on Migraine and Headache 
from 1980 to 1995; he was a 
founding member of the European 
and International Headache 
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Societies and was Chairman of the 
Migraine Trust from 1987 to 1995. 
See Goadsby, Evers and Peatfield 
(2012).
Professor Merton Sandler 
MD FRCP FRCPath FRCPsych 
(b. 1926) graduated in medicine 
at Manchester University, and 
held various house and registrar 
jobs leading to a lectureship in 
Chemical Pathology at the Royal 
Free Hospital Medical School. 
He was Professor of Chemical 
Pathology, University of London 
from 1973 to 1991. He was 
President of the British Association 
for Psychopharmacology 
(1980–1982). He has received 
various international honours 
and awards, including the CINP 
Lifetime Award for contribution 
to monoamine studies in human 
health and disease. For an interview 
with Merton Sandler, see Healy D. 
(1996), pages 381–400.
Professor Pramod Saxena
MBBS MD (b. 1939) studied 
medicine and went on to receive 
his MD in pharmacology from 
King George’s Medical College, 
Lucknow, India in 1965. After 
working in pharmacology and 
as a family physician he joined 
the Pharmacology Department 
of Organon, the Netherlands, 
where his research focused on the 
development of muscle relaxant and 
antidepressant drugs. In 1970 he 
became Professor of Pharmacology 
in the new Medical Faculty at 
Rotterdam; he was Chairman from 
1990 to 2004. There he continued 
his research into migraine and 
5-HT. In 1998 he set up Erasmus 
Pharma and was Managing 
Director until 2005. He has a large 
number of scientific publications, 
which have been extensively cited; 
he has organized many national 
and international meetings and 
has been on the editorial board of 
several scientific journals. He was 
awarded the Harold G. Wolff Prize 
(1973) and John Graham Senior 
Clinician Award (1996) by the 
American Headache Association, 
and the Dutch Headache Society 
instituted a ‘Prof. Dr. P. R. Saxena 
prize’ awarded annually to the 
author of the best scientific paper 
in the headache field, published in 
an international journal. 
Professor Tilli Tansey
OBE PhD PhD DSc HonFRCP 
FMedSci (b. 1953) graduated in 
zoology from the University of 
Sheffield in 1974, and obtained her 
PhD in Octopus neurochemistry 
in 1978. She worked as a 
neuroscientist in the Stazione 
Zoologica Naples, the Marine 
Laboratory in Plymouth, the MRC 
Brain Metabolism Unit, Edinburgh, 
and was a Multiple Sclerosis Society 
Research Fellow at St Thomas’ 
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Hospital, London (1983–1986). 
After a short sabbatical break at 
the Wellcome Institute for the 
History of Medicine (WIHM), 
she took a second PhD in medical 
history on the career of Sir Henry 
Dale, and became a member of the 
academic staff of the WIHM, later 
the Wellcome Trust Centre for the 
History of Medicine at UCL. She 
became Professor of the History 
of Modern Medical Sciences 
at UCL in 2007 and moved to 
Queen Mary, University of London 
(QMUL), with the same title, in 
2010. With the late Sir Christopher 
Booth she created the History 
of Twentieth Century Medicine 
Group in the early 1990s, now the 
History of Modern Biomedicine 
Research Group at QMUL.
Mrs Wendy Thomas
BSc (b. 1949) has spent over 
30 years in the voluntary sector, 
mainly in sexual health, in the UK 
and in the developing world. She 
has spent the past 25 years in the 
Chief Executive role, and been 
Chief Executive of The Migraine 
Trust since 2006.
Dr Glyn Volans
BSc MD FRCP (b. 1943) 
read medicine and gained an 
intercalated BSc in physiology and 
biochemistry at the University 
of Newcastle upon Tyne. After 
gaining his MRCP he moved to 
St Bartholomew’s Hospital in 
London and the Princess Margaret 
Migraine Clinic where he was 
funded by the Migraine Trust 
(1972). He undertook the research 
for his MD on drug absorption 
during migraine. In 1975 he was 
appointed Consultant Clinical 
Pharmacologist at the Guy’s 
Hospital Poisons Unit and became 
Director of the Unit in 1980. 
Since that time he has not been 
directly associated with migraine 
research but has maintained an 
interest in the safety of analgesic 
drugs, including over-the-counter 
preparations. He retired from 
clinical practice in 2009 but 
remains an Emeritus Consultant 
in the Department of Clinical 
Pharmacology, Kings College 
London (STH).
Dr Mark Weatherall
MB BC FRCPEdin PhD  
(b. 1968) is a Consultant 
Neurologist at Charing Cross and 
Ealing Hospitals, council member 
of the British Association for the 
Study of Headache, a Trustee of 
the Migraine Trust, and a Fellow 
of the Royal College of Physicians 
of Edinburgh. Before studying 
clinical medicine at Cambridge, 
he was a historian of medicine 
with interests in the development 
of the medical sciences and 
medical education between 1800 
and 1950. He lectures on the 
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emergence of modern medicine at 
Imperial College, London, and is 
currently researching the meanings 
of headache in the journals of 
Dorothy Wordsworth and the 
novels of Wilkie Collins.
Dr Marcia Wilkinson
MA FRCP DM (1919–2013) 
qualified in medicine at Oxford 
in 1943 and trained in neurology 
at the Royal London Hospital. In 
1953 she was appointed Consultant 
Neurologist at the Elizabeth 
Garrett Anderson Hospital where 
she remained until 1984. There in 
1963 she started a migraine clinic 
for the treatment of patients and 
research into migraine. She was 
appointed Medical Director of 
the City Migraine Clinic when it 
opened in 1970 and, together with 
Dr Nat Blau, established the City 
of London Migraine Clinic as an 
independent charity in 1980. She 
was a founding member of the 
International Headache Society and 
was President from 1985 to 1987. 
See MacGregor (2013).
Professor Harold Wolff
(1898–1962) received his MD 
at Harvard in 1923. Following 
training in neurology and 
psychiatry with posts at Cornell 
and Johns Hopkins, and periods 
in Russia and Austria, he was 
appointed Chief of the Neurology 
Division at Cornell’s new Medical 
Center at New York Hospital in 
1932. In addition to this post, 
he was Professor of Neurology 
and Director of the Neurological 
Division at Bellevue Hospital, New 
York. He became the first Anne 
Parrish Titzel Professor of Medicine 
at Cornell in 1958. His research 
focused on cerebral circulation and 
made major contributions to the 
understanding of the mechanisms 
of migraine and other vascular 
headaches. He was the author of 
over 500 papers and 14 textbooks, 
including Headache and other Head 
Pain (1948, 2nd edn 1963). See 
Blau (2004) and Wolf (1962). 
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